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Safa F. Mohamad 
THE ROLE OF OSTEOMACS IN REGULATING STEM CELL FUNCTION AND THE 
HEMATOPOIETIC NICHE 
 
 
Maintenance of hematopoietic stem cell (HSC) function is an orchestrated event requiring 
the participation of multiple cell types within the hematopoietic niche. Among the key 
cellular components of the niche are a group of specialized bone-resident macrophages 
known as osteomacs (OM). Reported here is a detailed characterization of OM and 
description of discriminating phenotypic and functional properties that clearly distinguish 
OM from bone marrow-derived macrophages (BM Mφ). Furthermore, it was established 
that OM support hematopoiesis enhancing activity of osteoblasts and that this activity was 
augmented by megakaryocytes. Serial transplantation demonstrated that HSC 
repopulating potential was best maintained by in vitro cultures containing OM, osteoblasts 
and megakaryocytes. Interestingly, BM Mφ were unable to mediate the same 
hematopoiesis enhancing activity regardless of whether megakaryocytes were present in 
co-culture or not. Subsequently, to understand the importance of networking between the 
residents of the niche, 3D tissue cytometry was performed on fixed and stained 
unperturbed bone marrow sections. This approach identified the spatial relationships 
between OM, osteoblasts, megakaryocytes and HSC within the niche and defined 
parameters, under which these cell types coexist in undamaged bone marrow. In addition, 
single cell mRNAseq and CyTOF was performed to assess genetic and proteomic 
expression changes in OM following their interaction with megakaryocytes. These studies 
revealed the upregulation of CD166 and embigin on OM via osteoblast and 
megakaryocyte interactions. Clonogenic assays were conducted to examine the impact of 
these molecules in hematopoietic function. When these assays were initiated with CD166 
vii 
KO OM or shRNA-mediated embigin knockdown OM, it was established that loss of these 
surface molecules on OM caused a decline in the normal OM-mediated hematopoietic 
enhancing activity. Conversely, recombinant CD166 and embigin partially substituted for 
OM activity thus identifying potential mediators through which OM maintain hematopoietic 
function. This data, for the first time, reveal intimate spatial interactions between OM, 
osteoblasts, megakaryocytes and HSC in the hematopoietic niche. They also illustrate the 
importance of crosstalk between OM, osteoblasts and megakaryocytes and reveal novel 
mediators such as CD166 and embigin that cooperate with other elements of the niche to 
support HSC function. 
Edward F. Srour, Ph.D., Chair 
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CHAPTER ONE: Introduction 
 
 
Every day, the human body produces >1011 blood cells through a process called 
hematopoiesis (Catlin, Busque et al. 2011), derived from the Greek word Haima or 
haimatos meaning blood and poiesis meaning to make. The main protagonist in this 
process is the hematopoietic stem cell (HSC) which has the capability to self-renew, as 
well as differentiate into myeloid, erythroid and lymphoid lineages (Till and Mc 1961). 
Hematopoiesis occurs in the bone marrow which is encapsulated within the bone and 
interconnected with a complex vasculature. This leads to the formation of a highly enriched 
bone marrow microenvironment called the niche. The concept of a niche where HSC 
reside was first introduced by Schofield in 1978. He stated, “the cellular environment which 
retains the stem cell is called a stem cell ‘niche’”. He also proposed that, “the stem cell is 
seen in association with other cells that determine its behavior”. His findings concluded 
that the location of a stem cell is important for it to retain its stemness. Within the niche, 
HSC maintain their quiescent behavior. However, they leave the niche as mature 
differentiated cells at the cost of their immortality (Schofield 1978). 
Schofield’s revelation caused the expansion of the field of hematopoiesis and led to the 
identification of several niche components. However, even before Schofield introduced 
the concept of a niche, in 1977, Dexter et al. described the importance of stromal cells in 
maintaining the proliferation of HSC and granulopoiesis. He demonstrated that “feeding” 
HSC cultures at regular intervals with stromal cells is essential to increase HSC numbers 
(Dexter, Allen et al. 1977). Next, in 1994, human osteoblasts were identified as supporters 
of hematopoiesis through the production of granulocyte-colony stimulating factor (G-CSF) 
(Taichman and Emerson 1994, Taichman, Reilly et al. 1996). G-CSF also known as colony 
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stimulating factor-3 (CSF3) is a cytokine that controls the production, differentiation and 
function of granulocytes. Following this discovery, the role of murine osteoblasts in the 
hematopoietic niche was further validated in the early 2000’s by two independent groups 
who demonstrated the importance of parathyroid hormone (PTH) and bone 
morphogenetic protein (BMP) signaling in HSC maintenance (Calvi, Adams et al. 2003, 
Zhang, Niu et al. 2003). Next, in 2009, Dominici et al. introduced megakaryocytes as an 
imperative niche resident. They demonstrated the importance of megakaryocytes in the 
restoration of the HSC niche post radioablation (Dominici, Rasini et al. 2009). In 2010, 
Winkler et al. introduced a subset of macrophages called osteomacs (OM) as important 
players of the niche. They established that depletion of these osteomacs caused 
hematopoietic stem and progenitor cell (HSPC) mobilization to the peripheral blood 
(Winkler, Sims et al. 2010). 
Besides the residents mentioned above, several other cellular and soluble elements which 
participate in the niche have been identified. These participants include hematopoietic 
cells such as neutrophils and osteoclasts, neuronal and glial cells, mesenchymal stem 
cells, endothelial and perivascular cells and adipocytes. It is believed that HSC 
maintenance (quiescence, self-renewal, engraftment, mobilization and differentiation) in 
the hematopoietic niche is mediated by intimate interactions between cellular and soluble 
elements of the niche and stem cells. Discussed below are some of these cellular 
components and their role in the maintenance of hematopoiesis. Also detailed, is the 
importance of the anatomical location of these cell types in relation to HSC within the 
niche. 
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1.1 Ontogeny of murine hematopoiesis 
Studies of adult hematopoiesis postulate that all myeloid, erythroid and lymphoid cells 
emerge from HSC. However, where do HSC originate from? This question can be 
answered by characterizing the ontogeny of murine hematopoiesis which, in the 
mammalian system occurs over two waves. The first wave involves primitive 
hematopoiesis which is responsible for generating primitive erythrocytes and certain 
myeloid cells such as macrophages and megakaryocyte progenitors; and definitive 
hematopoiesis which involves the origin of myeloid, lymphoid and erythroid cells from the 
definitive HSC (Dieterlen-Lievre 1975, Orkin and Zon 2008, Medvinsky, Rybtsov et al. 
2011). Primitive hematopoiesis which occurs in the yolk sac (extra-embryonic mesoderm 
ingresses into the posterior primitive streak) paradoxically in the absence of definitive HSC 
marks the onset of hematopoiesis. Maturing erythroid cells can be seen in the yolk sac as 
early as embryonic day 7.5 (E7.5) and macrophage and megakaryocyte progenitors by 
E9.0 (Silver and Palis 1997). Interestingly, these fetal-derived macrophage progenitors 
are responsible for maintaining and replenishing several tissue resident macrophages in 
adult hematopoiesis (Schulz, Perdiguero et al. 2012, Yona, Kim et al. 2013). 
Definitive hematopoiesis begins in the aorta gonad mesonephros (AGM) where functional 
HSC with engrafting activity are observed by E10.5 (Müller, Medvinsky et al. 1994, 
Medvinsky and Dzierzak 1996). It was proposed that hemangioblasts are formed in the 
yolk sac during primitive hematopoiesis. These hemangioblasts are tripotent cells that can 
differentiate into hematopoietic and endothelial cells; and are capable of forming murine 
smooth muscle cells in vitro (Choi, Kennedy et al. 1998, Ema and Rossant 2003). In the 
AGM, hemangioblasts act as precursors for hemogenic endothelial cells which form on 
the ventral wall of the aorta and bud off HSC (North, De Bruijn et al. 2002, Lancrin, 
Sroczynska et al. 2009, Boisset and Robin 2010). This leads to the hypothesis that 
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hemangioblasts from the yolk sac are precursors for the hemogenic endothelial cells 
formed in the AGM. However, fate-mapping studies indicate that the yolk sac and AGM 
derive independently at different times of development (Turpen, Kelley et al. 1997). Since 
HSC are first observed on E8.5 in the AGM, before the onset of circulation; there is a low 
possibility of cells being circulated from the yolk sac into the AGM before this time. Also, 
even though HSC are observed in the AGM at E8.5, HSC-like activity is observed in the 
yolk sac by E9.0 and functional activity of AGM HSC occur by E11. It is possible that cells 
from the yolk sac colonize the AGM through circulation between E8.5 and E11 to activate 
HSC function (Palis, Chan et al. 2001). From this point on, HSC migrate to the fetal liver 
by E12.5, which becomes the major source of hematopoiesis prior to birth. After birth, 
HSC home primarily to the bone marrow which is the main location of the hematopoietic 
niche (Medvinsky and Dzierzak 1996, Orkin and Zon 2008, Medvinsky, Rybtsov et al. 
2011). 
1.2 Endosteal bone marrow niche vs Vascular bone marrow niche 
The anatomic localization of HSC is dynamic making it very difficult to pinpoint their exact 
location via imaging, especially since they are very rare and extremely difficult to precisely 
identify phenotypically. Furthermore, definitive HSC are classified into two sub-types: long 
term-HSC (LT-HSC) which are capable of contributing to hematopoiesis for potentially a 
lifetime; and short term-HSC (ST-HSC) whose reconstitution capabilities are limited to 
several weeks (Christensen and Weissman 2001). Each of these sub-types are 
phenotypically different, further adding to imaging difficulties. While HSC are known to 
circulate and reside in multiple locations, their primary site of localization is the bone 
marrow. Within the bone marrow, two main HSC niches have been described: the 
endosteal niche and the vascular niche (Kiel and Morrison 2008). Several studies have 
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identified cellular and soluble elements within these niches and have probed for the 
contribution of each of these elements towards HSC maintenance and function. 
The endosteal niche consists of the endosteal surface which is primarily lined by 
osteoblasts and surrounded by hematopoietic cells. This suggests reciprocal 
communication between osteoblasts and hematopoietic cells including HSC. This notion 
is supported by many groups which have documented several factors secreted by 
osteoblasts that regulate hematopoiesis. These include hepatocyte growth factor which is 
important for the survival of hematopoietic progenitors (Taichman, Reilly et al. 2001); and 
angiopoietin and thrombopoietin (TPO) which are implicated in maintaining HSC 
quiescence (Arai, Hirao et al. 2004, Yoshihara, Arai et al. 2007). In fact, increasing 
evidence suggests that HSC residing next to the endosteal surface are quiescent and 
produce progenitors which migrate to the center of the bone marrow towards the blood 
vessels as they mature and differentiate (Nilsson, Johnston et al. 2001). Other studies in 
support of the endosteal niche demonstrate that post transplantation, HSC have a 
tendency to home to N-cadherin+ osteoblasts predominantly located in the trabecular 
bone (Nilsson, Johnston et al. 2001, Zhang, Niu et al. 2003, Xie, Yin et al. 2009). This 
tendency to home to the trabecular bone could be due to the increased production of C-
X-C Motif Chemokine Ligand 12 (CXCL12) at this site post irradiation (Xie, Yin et al. 2009). 
CXCL12 also known as stromal derived factor-1 (SDF1) is a chemoattractant primarily 
secreted by stromal cells (Aiuti, Webb et al. 1997, Lapidot, Dar et al. 2005, Sugiyama, 
Kohara et al. 2006) mainly endothelial and perivascular cells (Ding, Saunders et al. 2012, 
Ding and Morrison 2013, Greenbaum, Hsu et al. 2013). This ligand binds to C-X-C Motif 
Chemokine Receptor 4 (CXCR4) also known as fusin/CD184 which is a surface protein 
expressed on HSC (Mohle, Bautz et al. 1998, Zou, Kottmann et al. 1998, Aiuti, Tavian et 
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al. 1999, Sugiyama, Kohara et al. 2006). It is a known fact that CXCR4-CXCL12 
chemokine signaling is important for the maintenance of the HSC pool (Aiuti, Webb et al. 
1997, Zou, Kottmann et al. 1998, Sugiyama, Kohara et al. 2006, Xie, Yin et al. 2009) and 
that CXCL-12 abundant reticular (CAR) cells express high amounts of CXCL12 
(Sugiyama, Kohara et al. 2006). CAR cells are an important part of the HSC niche and are 
located near sinusoidal endothelial cells as well as near the endosteum making it 
important for both vascular and endosteal niches (Sugiyama, Kohara et al. 2006). 
Supporting the concept of a vascular niche, Kiel et al. revealed that HSC identified via the 
SLAM (signaling lymphocyte activation molecules) markers localized adjacent to the 
sinusoidal endothelium in the bone marrow (Kiel, Yilmaz et al. 2005). Adding to this, 
several factors including fibroblast growth factor-4 (FGF-4) and SDF1 are secreted within 
the vascular niche which support hematopoiesis (Avecilla, Hattori et al. 2004). It has also 
been demonstrated that disruption of this vascular niche by in vivo ablation of endothelial 
cells led to failure of hematopoiesis, in particular, thrombopoiesis (Avecilla, Hattori et al. 
2004). 
Since the bone is highly interconnected with vasculature, it is very difficult to differentiate 
between an endosteal and vascular niche. Nombela-Arrieta et. al combined both these 
niche concepts; and using laser scanning cytometry demonstrated that HSPC localize 
near the endosteum which is in close contact with bone marrow (BM) micro vessels 
(Nombela-Arrieta, Pivarnik et al. 2013). Furthermore, quiescent HSC associate with small 
arterioles ensheathed with NG2+ pericytes near the endosteal region; whereas HSC that 
have entered the cell cycle redistribute to leptin receptor (LEPR)+ perisinusoidal sites 
(Kunisaki, Bruns et al. 2013). Strangely, most of these localization studies are limited to 
the position of HSC relative to either the endosteum or the vasculature (Aiuti, Webb et al. 
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1997, Nilsson, Johnston et al. 2001, Zhang, Niu et al. 2003, Kiel, Yilmaz et al. 2005, 
Sugiyama, Kohara et al. 2006, Xie, Yin et al. 2009, Kunisaki, Bruns et al. 2013, Nombela-
Arrieta, Pivarnik et al. 2013). Missing from these data are other cellular elements involved 
in HSC regulation within the niche. More comprehensive multi-dimensional imaging 
studies combining existing data with additional niche participants are warranted. 
1.3 Cellular components participating in the hematopoietic niche 
Several cellular niche components have been identified and examined for their role in the 
regulation of hematopoiesis. Some of them are mentioned below. 
1.3.1 Osteoblasts 
It is already established that HSC have a tendency to home towards the endosteum which 
is lined by osteoblasts (Nilsson, Johnston et al. 2001, Zhang, Niu et al. 2003, Xie, Yin et 
al. 2009, Kunisaki, Bruns et al. 2013, Nombela-Arrieta, Pivarnik et al. 2013). Due to the 
proximity of the bone and bone marrow, osteoblasts were one of the first stromal cells 
discovered as an important part of the hematopoietic niche. Early work on the role of 
osteoblasts in hematopoiesis established that these cells support human cord blood 
isolated CD34+ cells in vitro (Taichman and Emerson 1994, Taichman, Reilly et al. 1996). 
In fact, depletion of these osteoblasts in mice resulted in the loss of myeloid, lymphoid and 
erythroid progenitors in addition to the decrease in the number of HSC (Visnjic, Kalajzic 
et al. 2004). Since then, several researchers have worked to identify the molecular 
mediators through which these cells maintain hematopoietic function. One such group 
demonstrated that osteoblasts secrete hepatocyte growth factor which is important for the 
survival of hematopoietic progenitors (Taichman, Reilly et al. 2001). Another, administered 
the activation of parathyroid hormone (PTH) and its receptor (PTH1R) in vivo which 
resulted in increased bone anabolism and augmented HSC numbers (Calvi, Adams et al. 
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2003). Another group, conditionally depleted bone morphogenetic protein receptor 1A 
(BMPR1A) to demonstrate the importance of BMP signaling in regulating HSC numbers 
(Zhang, Niu et al. 2003). However, increase in HSC numbers does not necessarily 
correlate with increase in function (Lymperi, Horwood et al. 2007, Calvi, Bromberg et al. 
2012, Yu and Scadden 2016). Functional transplantation studies used to determine 
whether HSC can engraft, that is reconstitute the entire bone marrow are required. This 
was demonstrated via specific depletion of osteocalcin expressing mature osteoblasts. 
This depletion led to the increase in HSPC numbers with no change in engraftment as 
demonstrated via primary and secondary transplantations (Yu, Saez et al. 2015). Another 
group used strontium to increase the numbers of a subgroup of osteoblasts but failed to 
record an increase in HSC numbers (Lymperi, Horwood et al. 2007). They hypothesized 
that this discrepancy was due to the failure to increase the number of N-cadherin+ 
osteoblasts indicating that certain groups of osteoblasts support hematopoietic function 
better than others (Zhang, Niu et al. 2003, Lymperi, Horwood et al. 2007). 
In 2010, Chitteti et al. corroborated the importance of osteoblasts in the hematopoietic 
niche. Furthermore, this activity was dependent on Notch signaling and was suppressed 
by adipocytes (Chitteti, Cheng et al. 2010). On analyzing the maturational status of these 
osteoblasts; it was demonstrated that immature osteoblasts expressing high levels of 
Runx2 (Chitteti, Cheng et al. 2010) maintain the most robust hematopoietic enhancing 
activity (Chitteti, Cheng et al. 2010, Cheng, Chitteti et al. 2011). Phenotypically, these cells 
also expressed ALCAM (Activated Leukocyte Cell Adhesion Molecule) or CD166 which 
has been used during the last 10 years to identify immature osteoblasts. It was also 
demonstrated that CD166 knock out mice have decreased hematopoietic activity (Chitteti, 
Bethel et al. 2013, Chitteti, Cheng et al. 2013, Chitteti, Kobayashi et al. 2014). Conversely, 
mature osteoblasts which are Runx2low and osteocalcin+ do not express CD166 (Chitteti, 
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Cheng et al. 2013). Interestingly, constitutive activation of PTH1R on terminally 
differentiated osteocytes caused an increase in bone mass but a decrease in HSC function 
(Calvi, Bromberg et al. 2012) further indicating the importance of immature osteoblasts in 
the hematopoietic niche. 
Mature osteoblasts may not play a major role in HSC function, but they do have a role in 
hematopoiesis. Of note, depletion of osteocalcin expressing mature osteoblasts in mice 
causes a marked reduction in lymphopoiesis (Yu, Saez et al. 2015). This correlates with 
the fact that osteoblast lineage cells secrete CXCL12; and depletion of this chemokine 
causes a decrease in lymphoid progenitors (Greenbaum, Hsu et al. 2013). The same 
osteocalcin depleted mice even demonstrate compromised G-CSF induced HSPC 
mobilization (Ferraro, Lymperi et al. 2011). Overall, the maturational status of an 
osteoblast is important to determine its specific function in hematopoiesis. 
Osteoblasts also secrete osteopontin which negatively regulates stem cell numbers and 
is important to maintain a quiescent stem cell pool. Osteopontin null mice show increased 
expression of stromal jagged-1 and angiopoietin-1 which elevates HSC numbers and 
reduces apoptosis (Stier, Ko et al. 2005). Osteoblasts even secrete TPO (Yoshihara, Arai 
et al. 2007) and angiopoietin (Arai, Hirao et al. 2004) which are important for HSC 
regulation. LT-HSC possess the thrombopoietin receptor and the Tie2 receptor which 
binds to TPO and angiopoietin, respectively. The signaling pathways thus activated 
maintain stem cell quiescence in the osteoblastic niche (Arai, Hirao et al. 2004, Yoshihara, 
Arai et al. 2007). 
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1.3.2 Megakaryocytes 
Megakaryocytes are responsible for thrombopoiesis (Wright 1910), the process by which 
they form platelets which are responsible for the clotting of blood. However, in the early 
2000s, megakaryocytes were found to have another important function. They are involved 
in osteoblast proliferation and suppression of osteoblast differentiation (Kacena, 
Shivdasani et al. 2004, Kacena, Gundberg et al. 2005, Ciovacco, Goldberg et al. 2009, 
Bethel, Srour et al. 2011, Cheng, Hooker et al. 2013, Cheng, Streicher et al. 2015, Alvarez, 
Xu et al. 2018). This was demonstrated by targeting GATA-1 and NF-E2 transcription 
factors which are involved in megakaryocyte differentiation. GATA-1 knockdown and NF-
E2 deficient mice have increased megakaryocyte numbers and portray increased bone 
anabolism (Kacena, Shivdasani et al. 2004, Kacena, Gundberg et al. 2005). Since then 
the signaling pathways involved in this megakaryocyte function became an active area of 
investigation (Cheng, Hooker et al. 2013, Cheng, Streicher et al. 2015, Meijome, 
Baughman et al. 2016, Alvarez, Xu et al. 2018). By increasing osteoblast numbers, 
megakaryocytes are indirectly involved in regulating hematopoiesis. Furthermore, 
megakaryocytes tend to migrate to the endosteum post total bone marrow radioablation 
(Dominici, Rasini et al. 2009). This migration is based on thrombopoietin signaling as well 
as CD41 integrin-based cell adhesion (Olson, Caselli et al. 2013). Once they reach the 
endosteum, they participate in osteoblast proliferation through the increased expression 
of growth factors such as platelet derived growth factor-β (PDGF-β) and fibroblast growth 
factor-2 (FGF2). This proliferation of osteoblasts is important for HSC engraftment and to 
revert back to homeostatic conditions (Dominici, Rasini et al. 2009, Olson, Caselli et al. 
2013). 
Other mechanisms through which megakaryocytes directly support HSC maintenance 
have also been reported. Whole mount imaging demonstrated that HSC have a tendency 
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to localize adjacent to megakaryocytes in a non-random manner (Heazlewood, Neaves et 
al. 2013, Bruns, Lucas et al. 2014). Megakaryocytes also release several cytokines which 
are known to regulate hematopoiesis. Heazlewood et. al demonstrated that 
megakaryocytes secrete insulin growth factor-1 (IGF1) which in turn is important in 
increasing HSC numbers (Heazlewood, Neaves et al. 2013). They also release Platelet 
Factor-4 (PF4/CXCL4) (Bruns, Lucas et al. 2014, Norozi, Shahrabi et al. 2016), TPO 
(Nakamura-Ishizu, Takubo et al. 2014) and TGF-β (Zhao, Perry et al. 2014) all of which 
have been implicated in HSC quiescence. 
Megakaryocytes, being the progeny of HSPC can also regulate hematopoiesis via self-
regulation of their own proliferation. These cells release microparticles (different from 
exosomes) which can be endocytosed or directly fused into HSPC. Once fused, the RNA 
present in these microparticles can reprogram HSPC to specifically differentiate into 
functional megakaryocytes (Jiang, Kao et al. 2017). Through all the mechanisms 
mentioned above, megakaryocytes play an important role in maintaining the 
hematopoietic stem cell niche. 
1.3.3 Macrophages 
Macrophages are phagocytic immune cells known for their heterogeneity amongst 
different tissues (Cannon and Swanson 1992). Apart from the cartilage, resident 
macrophages in almost every tissue of the body are phenotypically identified (Davies and 
Taylor 2015). Amongst these tissue resident macrophages are three subsets that normally 
reside in close proximity in the bone marrow microenvironment called erythroblastic island 
macrophages (EIM), OM and bone marrow derived macrophages (BM Mφ) (Kaur, Raggatt 
et al. 2017). Several roles for each of these subsets are already identified in hematopoiesis 
(Winkler, Sims et al. 2010, Chow, Lucas et al. 2011, Chow, Huggins et al. 2013, Chang, 
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Sengupta et al. 2014, Jacobsen, Forristal et al. 2014, Dutta, Hoyer et al. 2015, McCabe, 
Zhang et al. 2015, Hur, Choi et al. 2016, Lu, Chen et al. 2016, Mohamad, Xu et al. 2017, 
Kaur, Raggatt et al. 2018). However, recently, multiple groups have identified several 
subtypes of BM Mφ and assigned to each individual subtype its own name or identity 
(Chow, Lucas et al. 2011, Chang, Sengupta et al. 2014, Jacobsen, Forristal et al. 2014, 
Hur, Choi et al. 2016, Mohamad, Xu et al. 2017, Kaur, Raggatt et al. 2018). This has led 
to confusion in the field with no generalized characterization of each of these subtypes. 
Below, I will describe the roles of each of the three broad subsets of macrophages and 
outline the dire need of a generalized, well characterized nomenclature system for these 
macrophages. 
1.3.3.1 Erythroblastic island macrophages (EIM) 
EIM are the central macrophages surrounded by erythroblasts in the erythroblastic islands 
which are essential for erythropoiesis (Bessis 1958). There are three main roles through 
which EIM support erythropoiesis. 1. Secretion of cytokines such as erythropoietin (EPO) 
without which erythropoiesis would fail (Rich, Vogt et al. 1988). 2. Recycling iron by 
incorporating it into ferritin which is essential for hemoglobin synthesis (Leimberg, Prus et 
al. 2008). 3. Phagocytosis of the nuclei which are extruded during the formation of 
reticulocytes (Toda, Segawa et al. 2014). Thus, EIM participate in the entire maturation 
process starting from the pro-erythroblast stage right up to their differentiation into mature 
enucleated erythrocytes. This was demonstrated by models involving depletion of EIM 
which led to total collapse of BM erythropoiesis (Jacobsen, Forristal et al. 2014). However, 
extramedullary erythropoiesis was capable of compensating for the loss in the number of 
erythrocytes; but it could not compensate for reduced hemoglobin levels indicating the 
importance of EIM in iron recycling (Ramos, Casu et al. 2013). 
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Phenotypic characterization of EIM identified that they express common macrophage 
markers such as F4/80, CD11b, Ly6G, VCAM-1 and CD169 (Jacobsen, Forristal et al. 
2014). However, what sets them apart from other subsets of macrophages is their 
expression of ER-HR3 (Sonoda and Sasaki 2008). Not much is known about the function 
of this antigen, nevertheless, it may play some role in macrophage maturity (de Jong, 
Leenen et al. 1994). 
EIM are particularly important during hematopoietic stress conditions. Loss of these 
macrophages before induced hemolytic anemia (Chow, Huggins et al. 2013) or 
administered exogenous EPO (Ramos, Casu et al. 2013) significantly impairs 
erythropoietic recovery. Also, depletion of these macrophages in polycythemia vera and 
β-thalassemia mouse models reduced impaired erythropoietic activity associated with 
these disease conditions (Ramos, Casu et al. 2013). This indicates that focusing on these 
macrophages could be an interesting futuristic therapeutic target for erythropoiesis related 
impairments. 
1.3.3.2 Osteomacs (OM) 
OM are bone resident macrophages, which form a canopy over the endosteal bone 
surface. They are currently characterized as CD45+F4/80+ cells which is the same 
definition as that of a BM Mφ (Chang, Raggatt et al. 2008). In fact, one of the differentiating 
characteristic between these two subsets is their location; BM Mφ are located towards the 
center of the bone marrow whereas OM are located at the endosteum (maximum of 2-3 
cells away from the bone surface) (Chang, Raggatt et al. 2008, Batoon, Millard et al. 2017). 
OM express several common macrophage markers including F4/80, CD11b, CD68, Gr-1 
and CSF1R. A similar CD68+ OM population has also been associated with human bone 
(Chang, Raggatt et al. 2008). Also, OM do not express tartrate resistant acid phosphatase 
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(TRAP) which is the identification marker of osteoclasts; which differentiate from 
macrophages and are separate from OM (Chang, Raggatt et al. 2008, Wu, Raggatt et al. 
2013, Sinder, Pettit et al. 2015). Recently, OM have even been shown to express CD169 
(Batoon, Millard et al. 2017, Mohamad, Xu et al. 2017) which to date has been associated 
with BM Mφ that are important for hematopoietic activity (Chow, Lucas et al. 2011, Chow, 
Huggins et al. 2013, Jacobsen, Forristal et al. 2014, Kaur, Raggatt et al. 2018). This 
phenotypic similarity drives the conundrum regarding which macrophage subset is 
important in the hematopoietic niche and increases the confusion in studies that affect 
many targets that are common to many macrophage types (such as CD169). This is 
especially important when CD169+ cells are depleted (Chow, Lucas et al. 2011, Chow, 
Huggins et al. 2013) thus attributing the function of CD169+ cells to macrophages in 
general and ignoring the fact that the described functions may be attributed to a certain 
subset of macrophages. These similarities between the two subsets will be further 
discussed in the next section. 
Functionally, OM are well defined for their role in bone morphogenesis. It was 
demonstrated that OM promote bone anabolism, remodeling, mineralization, repair and 
regeneration (Chang, Raggatt et al. 2008, Pettit, Chang et al. 2008, Alexander, Chang et 
al. 2011, Wu, Raggatt et al. 2013, Millard, Pettit et al. 2015, Sinder, Pettit et al. 2015, 
Alexander, Raggatt et al. 2017, Batoon, Millard et al. 2017, Batoon, Millard et al. 2017, 
Kaur, Raggatt et al. 2017). However, not much is known about its role in hematopoiesis. 
Winkler et. al have shown that G-CSF administration which mobilizes HSPC from the bone 
marrow to the peripheral blood also caused the depletion of OM. This depletion of OM 
occurred parallel to the suppression of osteoblasts and HSC mobilization; thus, suggesting 
that disruption of OM from the endosteal niche was linked to HSC mobilization (Winkler, 
Sims et al. 2010). My own work in tandem with the laboratory has demonstrated that OM 
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interact with osteoblasts and megakaryocytes to maintain hematopoietic activity both in 
vitro and in vivo; and that this activity cannot be substituted by BM Mφ (Mohamad, Xu et 
al. 2017). 
1.3.3.3 Bone marrow derived macrophages (BM Mφ) 
There is a considerable phenotypic heterogeneity amongst BM Mφ making their 
characterization extremely difficult. However, much is known about the role of these 
heterogenous populations in hematopoiesis. In 2011, Chow et. al used a CD169+ Mφ 
depletion model to indicate the importance of macrophages in hematopoiesis. They 
demonstrated that loss of these macrophages led to reduced expression of CXCL12, kit 
ligand, VCAM1 and angiopoietin-1 in BM stromal cells; with a concomitant increase in 
HSC egress (Chow, Lucas et al. 2011). They further characterized these macrophages as 
drivers of erythropoiesis under homeostatic and hematopoietic stress conditions (Chow, 
Huggins et al. 2013). Another group identified the importance of CD169+ Mφ in 
maintaining long-term reconstituting activity of HSC (Kaur, Raggatt et al. 2018). However, 
depletion of CD169+ Mφ also depletes EIM and blocks erythropoiesis (Jacobsen, Forristal 
et al. 2014). Similarly, OM also express CD169 (Batoon, Millard et al. 2017, Mohamad, Xu 
et al. 2017) and CD169+ Mφ depletion also leads to OM loss (Batoon, Millard et al. 2017). 
Thus, it is difficult to determine which subset of macrophages is responsible for 
maintaining the competence of the hematopoietic niche based on the CD169+ Mφ 
depletion model as described by Chow et al, Chow and Lucas, and Kaur and Raggatt. 
Moving away from CD169, Hur et. al, identified CD234/DARC+ macrophages to be 
important for hematopoiesis. LT-HSC express CD82 which is absent in other progenitors. 
Interactions between CD82 and CD234 cause the activation of TGF-β/SMAD-3 signaling 
pathways ultimately leading to cell-cycle inhibition and maintenance of quiescence in LT-
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HSC. 10% of DARC+ Mφ also expressed α-smooth muscle actin (α-SMA) and 
cyclooxygenase-2 (COX-2) (Hur, Choi et al. 2016). This subset of Mφ share a functional 
overlap with another subset described by Ludin et al. This rare subpopulation of Mφ is 
radiation resistant and found adjacent to HSPC (Ludin, Itkin et al. 2012). Under stress 
conditions, these Mφ upregulate COX-2 and in turn prostaglandin-E2, which restricts the 
production of reactive oxygen species (ROS) and maintains stem cell quiescence (Ludin, 
Itkin et al. 2012, Porter, Georger et al. 2013). This regulation of HSPC quiescence is 
especially important during stress conditions to prevent the exhaustion of the stem cell 
population. 
Circling back to interactions between different components of the niche, one such 
interaction exists between Mφ and osteoblasts. Using p62 deficient mice, Chang et. al 
discovered a loss in the repression of osteoblast mediated NF-κB signaling. This 
repression was based on direct cell-cell contact between Mφ and osteoblasts and was 
dependent on the presence of p62; a regulator of autophagy. P62 deficient mice lose bone 
as well as osteoblast C-C motif chemokine ligand-4 (CCL4) expression resulting in HSPC 
egress (Chang, Sengupta et al. 2014). 
Conversely, macrophages can even drive HSPC expansion and mobilization under 
stressful conditions. LECT-2 (Leukocyte Cell Derived Chemotaxin 2), a cytokine secreted 
by the liver into the blood is capable of binding to CD209a expressed by BM Mφ. This 
causes a reduction in the tumor necrosis factor (TNF) mediated CXCR4-CXCL12 
production causing HSPC mobilization (Lu, Chen et al. 2016). During hematopoietic stress 
caused by infection, a cytokine called Interferon-γ (IFN-γ) was also shown to act on Mφ to 
negatively regulate HSC numbers and function (McCabe, Zhang et al. 2015). Furthermore, 
recent data suggests that alternative polarized M2 Mφ promote, whereas, classical M1 
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Mφ inhibit the self-renewal and expansion of HSC from mouse bone marrow (Luo, Shao 
et al. 2018). These studies indicate the importance of the various roles played by 
macrophages in the hematopoietic niche. 
1.3.4 Other cellular components 
There are several other cell types participating in the hematopoietic niche to maintain HSC 
function. These cell types are both non-hematopoietic as well as hematopoietic in origin. 
Mesenchymal stromal cells (MSC) which can differentiate into osteoblasts, adipocytes and 
chondrocytes are one of the active non-hematopoietic resident in the niche. It was 
demonstrated that intra-femoral injections of these MSC co-transplanted with HSC 
increased HSC self-renewal (Ahn, Park et al. 2010). Besides, an MSC subset defined as 
CAR cells are deemed essential for efficient retention of HSPC in the bone marrow (Ding, 
Saunders et al. 2012, Greenbaum, Hsu et al. 2013). Adipocytes on the other hand, even 
though they are MSC progeny are negative regulators of the hematopoietic niche. This 
has been demonstrated using A-ZIP/F ‘fatless’ mice which are incapable of making 
adipocytes and have accelerated marrow engraftment post irradiation compared to wild 
type mice (Naveiras, Nardi et al. 2009). The balance between MSC undergoing 
osteoblastogenesis versus adipogenesis is key in determining the fate of the 
hematopoietic niche. 
Endothelial cells which are essential for vasculature are also an important part of the 
hematopoietic niche. They secrete paracrine factors such as stem cell factor (SCF) and 
CXCL12 to maintain hematopoiesis. Conditional depletion of these factors on Tie-2 
endothelial cells are shown to reduce endogenous HSC numbers (Ding, Saunders et al. 
2012, Greenbaum, Hsu et al. 2013). Additionally, in vivo ablation of endothelial cells 
disrupts thrombopoiesis (Avecilla, Hattori et al. 2004). On a different note, as described in 
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section 1.1, endothelial cell precursors play an important role in the ontogeny of HSC. 
Hemangioblasts, which are formed in the AGM have the capability to act as precursors for 
hemogenic endothelial cells. These cells are precursors for both HSC and endothelial 
cells. Hemogenic endothelial cells grow on the ventral wall of the aorta and bud off into 
HSC (North, De Bruijn et al. 2002, Lancrin, Sroczynska et al. 2009, Boisset and Robin 
2010). 
Neuronal and glial cells have also been implicated in stem cell maintenance via their 
impact on HSC mobilization. Convincing evidence exists regarding the sympathetic 
nervous system which controls the circadian rhythms of the body which in turn regulate 
CXCL12 production. This mechanism allows the nervous system to regulate HSC 
mobilization (Katayama, Battista et al. 2006, Mendez-Ferrer, Lucas et al. 2008). 
Furthermore, enzymatically truncated neurotransmitters such as neuropeptide Y are 
known to alter signaling in endothelial cells resulting in increased vascular permeability 
and HSPC egress (Singh, Hoggatt et al. 2017). Interestingly, non-myelinating Shwann 
cells are a major source of TGF-β in the bone marrow. Depletion of Shwann cells causes 
a loss in HSC quiescence and HSC numbers (Yamazaki, Ema et al. 2011). These data 
link the nervous system to HSC regulation in the bone marrow. 
On the hematopoietic front, neutrophils are suggested to play a role in G-CSF induced 
HSC mobilization via their production of proteinases such as matrix metalloproteinase-9 
(MMP9), neutrophil elastase and cathepsin G (Levesque, Takamatsu et al. 2001, Heissig, 
Hattori et al. 2002). It was hypothesized that neutrophil degranulation causes the release 
of these proteases which then cleaves stromal cells produced VCAM-1 and CXCL-12 
leading up to HSPC mobilization. However, there is contradictory evidence regarding the 
same. Protease deficient mice were used to demonstrate that lack of the proteases 
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mentioned above did not affect G-CSF induced HSPC mobilization (Levesque, Liu et al. 
2004). However, G-CSF does contribute to neutrophil expansion, which, through the 
increase of reactive oxygen species leads to the apoptosis of osteoblasts (Singh, Hu et 
al. 2012). Thus, G-CSF induced HSPC mobilization, neutrophil expansion and osteoblast 
apoptosis occur concomitantly, suggesting that neutrophils may have a protease 
independent role in G-CSF induced HSPC mobilization. Alternatively, neutrophil released 
proteases such as MMP9 are mechanistically involved in G-CSF independent HSPC 
mobilization induced by alternate mobilizers such as AMD3100 and GROβ (Hoggatt, 
Singh et al. 2018). Furthermore, there is evidence that IL-8 induced HSPC mobilization 
requires the activation of circulating neutrophils. This neutrophil regulation of HSPC 
mobilization is not dependent on degranulation and release of MMP9 (Pruijt, Verzaal et 
al. 2002). Other important players that are progeny of HSC are macrophages and 
megakaryocytes which have been discussed in the previous sections. 
1.4 CD166 as a regulator of the hematopoietic niche 
CD166 (ALCAM-Activated Leukocyte Cell Adhesion Molecule) is a transmembrane 
glycoprotein belonging to the immunoglobulin superfamily (Lehmann, Riethmuller et al. 
1989). It is expressed both by mice and humans; and between them, their amino acid 
sequence is conserved by 93% (Bowen, Bajorath et al. 1997). CD166 is capable of 
mediating both homophilic interactions as well as heterophilic interactions with CD6 
(Degen, van Kempen et al. 1998). It is found to be expressed on several hematopoietic 
cells including T cells (Zimmerman, Joosten et al. 2006), activated monocytes and 
macrophages (Masedunskas, King et al. 2006). It is even expressed on non-hematopoietic 
cells present in the niche such as osteoblasts, stromal cells and endothelial cells (Chitteti, 
Bethel et al. 2013). To date, this is the only marker which is identified to be expressed 
both on murine (Ohneda, Ohneda et al. 2001) and human HSC (Uchida, Yang et al. 1997); 
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bridging the gap between the two model systems (Chitteti, Cheng et al. 2010, Chitteti, 
Bethel et al. 2013, Chitteti, Kobayashi et al. 2014). In fact, using cell fractionation and 
CD166 knock out mice, it was demonstrated that the CD166+ fraction only, but not the 
CD166- fraction of murine HSC mediate robust engraftment in both primary and secondary 
transplants. The same results were observed while using the CD166+ fraction of human 
CD34+ cells, thus marking CD166 as an important molecular marker for HSC. Besides 
engraftment, CD166 is also demonstrated to play an important role during homing and 
recovery from hematopoietic stress (Chitteti, Kobayashi et al. 2014). This function is 
shown to be coupled with STAT3 activation. 
CD166 is also expressed on several cells residing in the stem cell niche. It was 
demonstrated that CD166 expression on osteoblasts is inversely proportional to its 
maturity. Immature osteoblasts expressing higher CD166 maintain maximum 
hematopoietic enhancing activity compared to differentiated osteoblasts expressing lower 
levels of CD166 (Chitteti, Cheng et al. 2010, Chitteti, Cheng et al. 2013). Furthermore, 
MSC which can give rise to several mesodermal tissues also express CD166. In fact, 
CD166 acts as an accelerant of bone morphogenesis when added to MSC undergoing 
osteogenic differentiation (Bruder, Ricalton et al. 1998). In 2001, Ohneda et. al 
demonstrated that stromal cells and yolk sac endothelial cells express CD166. He also 
went on to demonstrate the importance of the expression of this marker to mediate 
embryonic hematopoiesis and vasculogenesis (Ohneda, Ohneda et al. 2001). 
Normal expression of CD166 is important for the hematopoietic niche. However, aberrant 
expression of the same can give rise to osteosarcomas, melanomas, pancreatic cancers 
etc. (Degen, van Kempen et al. 1998, Kristiansen, Pilarsky et al. 2003, Federman, Chan 
et al. 2012). Even in the hematopoietic system, CD166 is overexpressed in B-lymphomas 
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(Zhang, Slaughter et al. 1995) and Hodgkin-lymphomas (Ma, Visser et al. 2008). Also, 
previous members in my laboratory have worked on the importance of CD166 expression 
for the prognosis of multiple myeloma. Osteolytic lesions indicate a poor prognosis of 
multiple myeloma. It was demonstrated that CD166+ myeloma cells alter bone remodeling 
by inhibiting osteoblastogenesis and increasing osteoclastogenesis. CD166 acts as a 
driver in homing of these multiple myeloma cells, thus guaranteeing its progression (Xu, 
Mohammad et al. 2016). These studies rationalize CD166 as an important therapeutic 
target for the possible treatment of multiple cancers. 
1.5 Embigin as a regulator of the hematopoietic niche 
Embigin is a transmembrane glycoprotein (gp70) belonging to the immunoglobulin 
superfamily (Huang, Ozawa et al. 1990, Huang, Ozawa et al. 1993). It is expressed on 
several hematopoietic cells including bone marrow progenitors, T cells and several 
myeloid cells; and is specifically repressed by Pax5 which is expressed on B cells 
(Pridans, Holmes et al. 2008). Functionally, embigin is essential for the expression of 
monocarboxylate transporter-2 on the plasma membrane. This transporter is important for 
the exchange of protons during anaerobic respiration in neurons (Wilson, Kraus et al. 
2013). In fact, embigin is shown to be involved in neuromuscular synapse formation (Lain, 
Carnejac et al. 2009). 
In a report by Silberstein et al., osteolineage cells proximal and distal to HSPC were 
isolated for further characterization of their mRNA profile. Proximal osteolineage cells 
were defined as the nearest cell within two cell diameters of HSPC; and were runx2+, 
osterix+, col1a+, osteopontin low and osteocalcin low. Distal osteolineage cells were 
defined as cells which were at least five cell diameters away from HSPC. Furthermore, 
proximal osteolineage cells had increased mRNA expression of embigin, angiogenin and 
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IL-18 compared to distal osteolineage cells. Silberstein et al. went on to demonstrate how 
angiogenin regulates LT-HSC quiescence, self-renewal and myeloid proliferation; 
whereas IL-18 regulates ST-HSPC quiescence. Blocking embigin in the hematopoietic 
niche results in loss of quiescence with a corresponding increase in the frequency of LT-
HSCs, ST-HSCs, as well as MPPs (Silberstein, Goncalves et al. 2016). Embigin, being a 
cell adhesion molecule (Huang, Ozawa et al. 1993), even causes a loss in HSPC 
localization (Silberstein, Goncalves et al. 2016). Overall, this was the first group implicating 
embigin as a regulator of hematopoiesis. However, the osteolineage cells in the 
hematopoietic niche responsible for these effects of embigin are still relatively unknown 
and were poorly defined in the studies of Silberstein et. al. (Silberstein, Goncalves et al. 
2016). 
1.6 Significance of the hematopoietic niche 
Networking between HSC and cells of the hematopoietic niche is critical for the 
maintenance of stem cell renewal and function. HSC maintenance in the hematopoietic 
niche is considered to be the product of intimate interactions between cellular and soluble 
elements of the niche and stem cells. Crosstalk between these niche elements; especially 
OM, osteoblasts and megakaryocytes is essential for the maintenance of the niche 
(Mohamad, Xu et al. 2017). If any of the niche components is functionally missing or 
cannot interact with other critically relevant components, it would hinder HSC from 
attaining maximal function and also compromise the hematopoietic niche (Visnjic, Kalajzic 
et al. 2004, Winkler, Sims et al. 2010, Chow, Huggins et al. 2013). Diabetes is an example 
of a disease which causes a major alteration in the hematopoietic niche. It affects BM 
architecture and function by altering both the endosteal and vascular niche. This leads to 
impaired HSPC mobilization and causes a decrease in the circulating pool of regenerative 
HSPC (Fadini, Ferraro et al. 2014). A compromised niche also results from diseased 
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conditions such as osteoporosis. Such alterations cause genetic mutations and reorganize 
the niche which could lead to malignancies and/or hematopoietic disorders. A befitting 
example of a genetic mutation disrupting the hematopoietic niche is that of mice deficient 
in the retinoblastoma gene or the retinoic acid receptor (Walkley, Olsen et al. 2007, 
Walkley, Shea et al. 2007). These genetic changes alter the BM microenvironment leading 
to myelodysplasia. Another example is the activation of β-catenin (Kode, Manavalan et al. 
2014) or PTH receptor (Krause, Fulzele et al. 2013) in osteoblasts which can induce acute 
myelogenous leukemia in mouse transplantation models. Alternatively, abnormal 
upregulation of CD166 in primary bone marrow cells is a hallmark of multiple myeloma. 
As mentioned before, CD166 upregulation in multiple myeloma cells promotes 
osteoclastogenesis and inhibits osteoblastogenesis thus disrupting the hematopoietic 
niche (Xu, Mohammad et al. 2016). Such examples dictate that the dysregulation of the 
hematopoietic niche could be devastating leading to malignancies such as leukemia and 
lymphomas amongst others. 
Another reason for a compromised niche is aging. With age, there is an increased number 
of phenotypically defined HSC both in human (Pang, Price et al. 2011) as well as C57BL/6 
mice (Rossi, Bryder et al. 2005). However, the increased number of HSC appear to be 
dysfunctional with reduced self-renewing capacity (Janzen, Forkert et al. 2006) and 
increased myeloid skewing (Gekas and Graf 2013). One of the reasons for this change 
are age-induced alterations in the hematopoietic niche. This includes decreased bone 
formation, increased adipogenesis and changes in the transcriptional regulation of HSC 
(Bethel, Chitteti et al. 2013, Latchney and Calvi 2016). Increased adipogenesis is inversely 
correlated with CXCL12 expression. Decreased CXCL12 expression causes increased 
mobilization of HSC to the peripheral blood (Tuljapurkar, McGuire et al. 2011). Changes 
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in the hematopoietic niche with age also promote progression of leukemias (Vas, 
Wandhoff et al. 2012). 
Another significant focus of hematopoietic niche research is bone marrow transplantation. 
Currently, bone marrow transplantation is used as a mode of treatment for several blood 
cancers and genetic disorders. My work involves identifying the molecular pathways 
through which OM maintain its function in the niche. The ultimate objective is to effectively 
use modulators to substitute for OM activity and enhance HSC function leading to 
increased efficiency of bone marrow transplantations. The premise that OM are important 
residents of the hematopoietic niche is important in understanding the crosstalk between 
cellular components within the niche; and is also an unexplored pathway critical to the 
maintenance of hematopoiesis.  
43 
CHAPTER TWO: Methods 
 
 
2.1 Mice 
C57BL/6J mice which were 2-3 day old in age were used to prepare neonatal calvarial 
cells (NCC) which consist of OM and osteoblasts. The long bones of the same mice were 
used to prepare neonatal bone marrow (NBM) from which bone marrow-derived 
macrophages (BM Mφ) were isolated. Certain experiments required the isolation of CD166 
knockout OM. CD166 KO mice on a C57BL/6 background were used to prepare the 
neonatal calvarial cells from which CD166 KO OM were isolated. All megakaryocytes were 
prepared from fetal livers. C57BL/6J mice which were 8-12 wk in age were used for the 
isolation of adult OM, BM Mφ and LSK cells. Competitive repopulation assays were 
performed using C57BL/6J mice as donors, BoyJ mice as competitors and C57BL/6J X 
BoyJ F1 mice as recipients. Fgd5 mice (8-12 wk in age) (courtesy of Dr. Louis Pelus, 
Indiana University) were used to perform 3D tissue cytometry. All mice were bred and 
housed at Indiana University School of Medicine. 
2.2 Cells 
Cells were prepared as described below. These protocols are available with more details 
in Methods in Molecular Biology (Ghosh, Mohamad et al. 2019).  
2.2.1 Preparation of fresh neonatal calvarial cells 
Calvariae from 2-3 day old pups were dissected and all associated soft tissues were 
removed. These calvariae were then pretreated with 4mM EDTA in phosphate buffer 
saline (PBS) for 10 mins at 37°C followed by a PBS wash. The pretreatment step was 
repeated twice. The pretreated calvariae were then digested using 5ml of collagenase, 
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type 2 (Worthington Biochemicals, Lakewood NJ). The first two digestions were performed 
for 10 mins at 37°C in a water bath shaker. The supernatant from both these digestions 
was discarded. The next three digestions were performed for 15 mins at 37°C in a water 
bath shaker. The supernatant from each of these digestions was transferred to a tube 
containing 25ml of complete α-MEM medium (α-MEM+ 10% fetal bovine serum +1% 
penicillin/streptomycin). At the end of the three digestions, the tube containing the 
digestion supernatant and complete α-MEM medium was centrifuged at 2000 rpm for 6 
mins at 4°C. The cells in the pellet are neonatal calvarial cells. The pellet was resuspended 
in 10ml of complete α-MEM medium and the cells were counted using a hemocytometer. 
These NCC are 90-95% osteoblasts or osteoblast precursors and ~5% OM. 
2.2.2 Preparation of fresh neonatal bone marrow 
The same 2-3 day old decapitated pups which were used to make NCC were also used 
to make NBM. The hind limbs from these pups were dissected and kept in Iscove’s 
Modified Dulbecco’s Medium (IMDM). Using sterile forceps, the skin was removed, and 
sterile gauze was used to manually separate muscle from bone. The bone, once 
separated from muscle, was cut into small pieces and transferred to a sterile mortar 
containing 2-3ml of IMDM. Next, a sterile pestle was used to gently crush the bone and 
release the marrow from within the bone. The supernatant accumulated in the mortar was 
transferred to a 50ml tube. Fresh 2-3ml IMDM was again added to the mortar and the 
bones were crushed gently once more to further release the marrow. The bones were 
crushed for a total of 3 rounds and the supernatant from each round was transferred to 
the same 50ml tube. The collected supernatant was centrifuged at 1800 rpm for 10 mins 
at 4°C. Once centrifuged, the supernatant was discarded, and the cell pellet was subjected 
to RBC lysis. 2ml of RBC lysis buffer (Invitrogen, Carlsbad, CA) was added to the cell 
pellet followed by incubation at room temperature for 3-4 mins. To stop the RBC lysis, 
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10ml of complete IMDM medium (IMDM+ 10% fetal bovine serum +1% 
penicillin/streptomycin +1% glutamax) was added to the cells. The tube was centrifuged, 
and the pellet was reconstituted in 10ml complete IMDM medium. Total cell counts were 
calculated using a hemocytometer. 
2.2.3 Preparation of fetal liver-derived megakaryocytes 
Megakaryocytes were prepared from murine fetal livers as previously described (Kacena, 
Shivdasani et al. 2004, Kacena, Eleniste et al. 2012). Fetuses were dissected from 
pregnant mice on E13-15. The livers were removed and made into a single cell suspension 
using first an 18 gauge followed by 20 and 23 gauge needles. Cells were washed for a 
total of two times using complete Dulbecco’s Modified Eagle Medium (DMEM) (DMEM+ 
10% fetal bovine serum +1% penicillin/streptomycin +1% murine thrombopoietin). 
Washed cells were cultured in complete DMEM medium in 10cm culture dishes (5 fetal 
livers/ dish). Cells became confluent within 3-5 days of culture. At this point albumin 
gradients were set up to separate megakaryocytes from lymphocytes and other cells. The 
bottom layer of the gradient consisted of 3% albumin in PBS (bovine albumin, protease-
free and fatty acid-poor, Serological Proteins Inc., Kankakee, IL); the middle layer was 
1.5% albumin in PBS, and the top layer was media containing the cells to be separated. 
The cells were sedimented through the layers at 1 x g for ~90 mins. The megakaryocyte 
rich fraction was sedimented to the bottom of the tube. These cells were collected and 
then used for tissue culture experiments. 
2.2.4 Preparation of 8-12 wk bone marrow 
To isolate bone marrow, hind limbs (2 femurs and 2 tibias) from 8-12 wk old C57BL/6J 
mice were dissected and stored in a sterile tissue culture plate containing 10ml IMDM. A 
pair of forceps and a sterile gauze were then used to strip the muscle off these bones. 
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The stripped bones were transferred to a new tissue culture plate containing IMDM. Using 
a 10ml syringe with a 25 gauge needle, complete IMDM medium was aspirated. This 
syringe containing IMDM was then inserted into the stripped bones to flush the bone 
marrow from within. The flushing process was repeated until all the bone marrow was 
released at which point the bone changed color from red to pale. The bone marrow was 
prepared into a single cell suspension by repeated aspiration, collected in 50ml tubes, and 
was centrifuged at 1800 rpm for 10 mins at 4°C. The supernatant was discarded, and the 
cell pellet was resuspended in 2ml of RBC lysis buffer which was incubated at room 
temperature for 3-4 mins. To stop the RBC lysis, 10ml of complete IMDM medium was 
added to the tube followed by centrifugation. The cell pellet was resuspended in 10ml of 
complete IMDM medium and counted using a hemocytometer. This bone marrow 
preparation was used to isolate bone marrow macrophages from adult and for flow 
cytometric analysis. 
Bone marrow was lineage depleted to isolate LSK cells for colony forming assays and 
competitive repopulation assays. MagCellectTM Mouse Hematopoietic Cell Lineage 
Depletion Kit from R&D Systems (Minneapolis, MN) was used to isolate lineage depleted 
cells. Briefly, 100 million RBC lysed bone marrow cells were resuspended in 5ml of 1X 
MagCellect Buffer. Then, 50μl of Blocking Reagent-1 was added to these cells followed 
by incubation at 4°C for 15 mins. After the blocking step, 100μl of Mouse Cell Lineage 
Depletion Biotinylated Antibody Cocktail was added and incubated at 4°C for 15 mins. 
Excess antibody was washed away by adding 10ml of 1X MagCellect Buffer followed by 
centrifugation. The supernatant was discarded and 150μl of Streptavidin Ferrofluid was 
added to the cell pellet which was again incubated at 4°C for 15 mins. At the end of the 
incubation period, the volume was brought up to 2ml and those 2ml were transferred to a 
5ml round bottom tube. The tube was placed in a magnet (Stemcell Technologies, 
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Vancouver, Canada) designed to accommodate 5ml tubes. Once in the magnet the tube 
was incubated at room temperature for 6 mins. Magnetically tagged lineage positive cells 
migrated towards the walls of the tube leaving the lineage negative cells in suspension in 
the supernatant. At the end of the 6 min incubation, the supernatant was carefully removed 
and transferred to a new tube. When required, a second magnetic separation was 
performed. Lineage depleted cells were counted using a hemocytometer and stained for 
flow cytometric sorting to isolate LSK cells. 
2.2.5 Preparation of 8-12 wk digested bone 
Long bones from 8-12 wk mice, which were previously flushed as described above, were 
used to obtain digested bone. Flushed bones were cut into small pieces approximately 
1mm long; and the cut pieces were transferred to a 15ml tube containing 5ml of sterile 
PBS. Bones from around 1-3 mice could be transferred to the same 15ml tube. The tube 
was thoroughly vortexed for 30 secs after which the PBS supernatant was discarded. The 
bones were then subjected to digestion by adding 2ml of collagenase for 15 mins at 37°C 
in a water bath shaker. For optimum results, the tube was vortexed every 5 mins. At the 
end of the first digestion, the supernatant was transferred to a 50ml tube through a 70μm 
cell strainer. To stop the digestion, 5ml of complete αMEM medium (αMEM +10% fetal 
bovine serum +1% penicillin/streptomycin +1% glutamax) was added and the tube was 
kept on ice. A total of 5 such digestions were performed. The combined supernatant from 
these 5 digestions was transferred to the same 50ml tube containing complete αMEM 
medium. At the end of the digestions, the 50ml tube was centrifuged at 1800 rpm for 10 
mins at 4°C.The supernatant was discarded, and the cells were resuspended in 10ml of 
complete αMEM medium. Total cell counts were calculated using a hemocytometer. 
Single cell preparation from digested bone was processed to obtain adult OM and 
osteoblasts by cell sorting and as described below. 
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2.3 Cell staining, flow cytometry and cell sorting 
Cells were washed with sterile cell stain wash (1% Bovine Serum in 1X PBS) at 1800 rpm 
for 10 mins at 4°C. Supernatant was discarded and the cell pellet was stained with the 
appropriate antibodies listed in Table 2.1. OM from NCC or 8 wk digested bone, as well 
as BM Mφ from NBM and 8 wk bone marrow were identified as CD45+F4/80+. Neonatal 
osteoblasts were identified as CD45-F4/80- whereas, 8 wk osteoblasts were lineage 
(Ter119, CD31, Sca-1)-CD45-F4/80-. Adult 8 wk bone marrow was also stained to sort for 
LSK cells which were Lin-Sca1+ckit+. The lineage cocktail for the LSK cells consisted of 
CD4, CD45R, CD3, Gr-1 and Ter-119. The other antibodies listed in Table 2.1 were all 
used for cell analysis. All antibodies were purchased from Biolegend (San Diego, CA) 
except for CD166 and Embigin which was purchased from eBiosciences (San Diego, CA) 
and CD110 from Immuno-Biological Laboratories, Japan. To stain for the respective 
experiments, 0.5-1μg of antibody was added per million cells. Cells were then incubated 
for 15 mins at 4°C after which they were washed with 2ml of cell stain wash. The 
supernatant was discarded, and the pellet was resuspended in stain wash as 10 million 
cells/ml. BD SORP Aria, Facs Aria and Facs Fusion were used to sort cells. LSR II, FACS 
Fortessa and FACS X20 were used for cell analysis.  
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Table 2.1 List of fluorophore conjugated antibodies used in this study. 
Antibody Fluorophore Clone 
CD45 FITC/ PE-Cy7/ Pacific Blue 30-F11 
F4/80 APC BM8 
CD11b PE/ APC-Cy7 M1/70 
CD14 PE rmC5-3 
CD31 PE/ FITC MEC 13.3 
CD150 PE TC15-12F12.2 
CD68 PE/ Percp-Cy5.5 FA-11 
CD34 PE MEC14.7 
CD169 BV605 3D6.112 
Ly6G PE-Texas Red 1A8 
Mac2 AF488 M3/38 
CD166 PE eBioALC48 
CSF1R PE-Cy7 AFS98 
CD110 Biotin AMM2 
Streptavidin Pacific Blue  
Lineage Cocktail (LSK) FITC/ PE  
Sca-1 FITC/ PE D7 
c-kit APC 2B8 
Ter-119 PE/ FITC TER-119 
CD41 FITC/ PE/ Biotin MWReg30 
CD45.1 FITC A20 
CD45.2 APC 104 
Embigin PE G7.43.1 
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2.4 Phagocytosis assay 
Phagocytosis assay was performed using pHrodo™ Red BioParticles® (Life 
Technologies, Carlsbad, CA). Briefly, digested bone and bone marrow were sorted using 
CD45 and F4/80 to isolate adult OM and BM Mφ respectively. These cells were 
resuspended as 75,000-100,000 cells per 100μl of complete αMEM medium (+10ng/ml of 
MCSF1). Cells were then cultured in a 96-well plate overnight at 37°C. This step was 
performed to let the macrophages adhere to the tissue culture plate. The next day, 
pHrodo™ Red BioParticles® were resuspended in 2ml of live imaging solution (Thermo 
Scientific, Waltham, MA). After resuspension, this solution contained 1mg/ml of lyophilized 
E. coli. The suspension was sonicated for 5 mins until all the fluorescent particles were 
homogenously dispersed. 
After the cells adhered to the tissue culture plate, supernatant media from each of the 
wells was removed. Three of the OM wells and three of the BM Mφ wells were 
supplemented with 100μl of complete αMEM medium and used as a negative control. The 
remaining three OM wells and three BM Mφ wells were supplemented with 100μl of the 
pHrodo Bioparticle solution. The culture plate was incubated at 37°C for 1–2 hours to allow 
phagocytosis and acidification to reach its maximum. Post incubation, cells were collected 
and analyzed using a flow cytometer. Red BioParticles were excited with 488nm and 
emission was collected at 575nm. Images of the same were collected using ImageStream 
(Amnis, Seattle, WA). 
2.5 Single cell qRT-PCR 
2.5.1 Data collection 
The procedure for data collection for single cell qRT-PCR has been previously described 
(Anjanappa, Cardoso et al. 2017). The C1 Single-Cell Auto prep System (Fluidigm, San 
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Francisco, CA) was used for capturing single cells and preparing cDNA followed by fast 
gene expression analysis using EvaGreen on the BioMark HD System (Fluidigm). 
Instructions for the same are provided online (PN 100-4904 I1). Briefly, a pool of 100μM 
primers (Fluidigm) were prepared, which was followed by preparation of the lysis final mix, 
reverse transcription final mix and preamp final mix. Each mix was prepared as per 
manufacturer’s instructions (Fluidigm). Next, the size of OM and BM Mφ was measured 
on an automated cell counter (Countess, Invitrogen) to determine the C1 chip needed to 
capture single cells. Based on the sizing, a C1 Integrated Fluidic Circuit chip (IFC) for 
PreAmp (10-17μm) for OM and a C1 IFC for PreAmp (5-10μm) for BM Mφ was primed. 
To prime the IFC chip, 200μl of the C1 harvest reagent was pipetted at the center of the 
IFC chip and 20μl of the same into each of the wells located to the sides. 20μl of the 
preloading reagent was added in the purple inlet, 15μl of blocking reagent in the white inlet 
and 20μl of cell wash buffer in the grey inlets followed by running it on the STA: Prime 
program on the C1. 
Simultaneously, cells were resuspended to a concentration of 200,000 cells/ml. These 
resuspended cells were mixed with the suspension reagent in a 3:2 ratio to prepare the 
final cell mix which was loaded onto the primed IFC. The IFC was placed onto the C1 and 
run using the STA: Cell Load script to capture single cells. The single cells were viewed 
under the microscope to identify and exclude capture sites which were empty, had 2 cells 
in 1 site or had debris. The IFC chip with the captured single cells was then loaded with 
7μl of lysis final mix, 7μl of RT final mix and 24μl of PreAmp final mix. This was again 
placed into the C1 system to run the STA: PreAmp script. At the end of this program, the 
mRNA from the single cells was reverse transcribed into cDNA and pre-amplified into the 
product that would finally be subjected to gene expression analysis. 
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The BioMark HD system (Fluidigm) (protocol 68000088 K1) was used to perform 90 
individual qRT-PCR reactions on the harvested product from every single cell captured on 
the IFC. A 96.96 dynamic array IFC was primed using the Prime (136X) script on the Juno 
system (Fluidigm). Next, the harvested product was combined with 2X SsoFast EvaGreen 
Supermix (Bio-Rad, Hercules, CA) and 20X DNA binding dye sample loading reagent 
(Fluidigm, #100-3738) to prepare the sample pre-mix. This pre-mix was then loaded on 
one side of the primed IFC BioMark chip. On the other side of the same chip, the assay 
mix which contained 2X loading reagent, 1X DNA suspension buffer and 100μM each of 
mixed forward and reverse primers was loaded. The Juno system was used to distribute 
the assay mix and the sample pre-mix into individual reaction chambers inside the IFC. 
The IFC was then transferred to the BioMark HD where individual gene expression was 
quantified at the single cell level. 
2.5.2 Data analysis of single cell qRT-PCR 
Singular Analysis Toolset available on the Fluidigm website was used to analyze the data 
files generated using the BioMark HD System. This toolset was only compatible when 
used with the software R (Version 3.0.2). Principal component analysis plots were used 
to determine outliers within the single cell OM group and single cell BM Mφ group. 
Differentially expressed genes were identified between OM and BM Mφ using one-way 
ANOVA. Violin plots and heat maps were created to further compare the two cell types. 
2.6 Single cell mRNA sequencing 
2.6.1 Data collection 
Single cell mRNA sequencing (scRNA-seq) was performed on OM cultured in the 
presence and absence of megakaryocytes. Briefly, 100,000 NCC (resuspended in 
complete αMEM) were cultured with or without 50,000 megakaryocytes for 16 hrs in a 12 
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well plate. After culture, the cells were trypsinized and stained for CD45 and F4/80. OM 
from each of these two groups were sorted out using flow cytometry (CD45+F4/80+) and 
these OM from NCC and NCC +megakaryocytes were analyzed for differential gene 
expression analysis. To do so, sorted cells from each group were suspended in PBS at a 
final cell density of 300,000 cells/ml. The cell suspension was then dispensed into 
individual medium sized IFC chips of the Fluidigm C1 Single-Cell Auto Prep System for 
scRNA-seq (Fluidigm Corporation) (Zhang, Ghosh et al. 2019). The principle and 
procedure for the single cell capture was almost the same as the one described above for 
the single cell qRT-PCR. mRNA was isolated from the single cells that were captured, 
which was followed by cDNA synthesis using the protocol for the Clontech SMART-Se v4 
Ultra Low Input RNA Kit for Fluidigm C1 System. Furthermore, cDNA was quantified using 
the PicoGreen Kit (Thermo Fisher); and up to 0.4ng of the quantified cDNA was used for 
library preparation and indexing using the Nextera XT DNA Library Prep Kit (Illumina, Inc., 
San Diego, CA). Quality of the libraries was assessed by the Qubit and Agilent Bioanalyzer 
after which 5μl of 4nM pooled libraries were used for 150b paired-end sequencing on 
NextSeq 500. 
2.6.2 scRNA-seq data analysis 
Raw fastq files of the scRNA-seq data were mapped to mm10 mouse genome by using 
STAR pipeline [23104886]. Cells with observed genes smaller than 500 and larger than 
8000, and cells with more than 10% reads mapped to mitochondrial genes were excluded 
from further analysis. 21 OM sorted from cultured NCC, and 24 OM sorted from cultured 
NCC+ megakaryocytes were retained. Cell type cluster analysis were conducted by using 
Seurat with default parameters [25867923]. Differential gene expression analysis were 
conducted by an in-house method LTMG-DGE [https://academic.oup.com/nar/advance-
article/doi/10.1093/nar/gkz655/5542876] with p<0.001 as significance cutoff. 
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2.7 Mass cytometry (CyTOF) 
2.7.1 Custom conjugation of CyTOF antibodies 
The antibodies used in this study, along with their clones are listed in Table 2.2. All pre-
conjugated antibodies and most custom conjugated antibodies were purchased from DVS 
sciences, Fluidigm. Certain antibodies (6 of the 30) were conjugated in house using the 
Maxpar Antibody Labeling kit (Fluidigm). The main components of the kit were the 
lanthanide solution which consisted of the metal that needed to be conjugated to the 
antibody; and the Maxpar Polymer which formed the link between the metal and the 
antibody. 
Step 1: The protocol began by resuspending the polymer with 95μl of L-buffer. Next, 5μl 
of lanthanide metal solution was added to the same tube; after which the tube was 
incubated at 37°C for 30-40 mins in a water bath. 
Step 2: Simultaneously, 100μg of the desired antibody was added in up to 400μl of R-
buffer to a 50kDa column filter. This was centrifuged at 12,000 x g for 10 mins at room 
temperature. The flow-through in the column was discarded and 100μl of 4mM TCEP-R-
buffer (Thermo Scientific) was added to the antibody in the filter. This was followed by 
incubating the tube at 37°C for 30 mins in a water bath (Do not exceed 30 mins!!) 
Step 3: Next, 200μl of L-buffer was added to a 3kDa filter. The tube from step 1 which 
contained the polymer and lanthanide solution was transferred to the same 3kDa filter. 
The tube was centrifuged at 12,000 x g for 25 mins at room temperature; and further 
washed with 400μl of C-buffer for 30 mins. 
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Step 4: The 50kDa filter containing the partially reduced antibody was retrieved and the 
filter was washed twice with 400μl of C-buffer at 12,000 x g for 10 mins at room 
temperature. 
It is imperative that step 3 and step 4 are completed at the same time.  
Step 5: The lanthanide loaded polymer was resuspended in 60μl of C-buffer and 
transferred to the 50kDa filter containing the partially reduced antibody. To let the 
conjugation occur, the filter was incubated at 37°C for 90 mins. 
Step 6: The conjugation mixture was washed for a total of 4 times using 400μl of W-buffer 
after which the yield of the conjugated antibody was determined using a nanodrop 
(Thermo Scientific). The antibody was resuspended at 0.5μg/μl in antibody stabilizer 
(CANDOR Bioscience, Germany) with 0.05% sodium azide. 
Each of the 30 antibodies was titrated to determine optimal concentration to label NCC 
and NBM.  
2.7.2 Staining protocol for cell surface and intracellular antibodies 
Four groups of cells were stained and analyzed for CyTOF. For the first two groups, freshly 
processed NCC and NBM were analyzed to phenotypically differentiate OM from BM Mφ. 
The second aim was to differentiate OM cultured in the presence and absence of 
megakaryocytes. To do this, 1 million NCC (resuspended in complete αMEM) were 
cultured per well in a 6 well plate. Half of these wells were cultured in the presence of 
500,000 megakaryocytes per well and the other half were cultured in the absence of 
megakaryocytes. Cells were cultured for a total of 2 days at 37°C. On the day of CyTOF 
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stain, fresh NCC and NBM were plated in a 6 well plate (2-3 million cells/well) and all 4 
groups were treated with 10ug/ml of Brefeldin A (Sigma-Aldrich, St. Louis, MO) in a 37°C 
incubator for 3 hrs to inhibit protein transport. Following stimulation with Brefeldin A, 3.5 
million cells were resuspended in 400μl of PBS and transferred to a 5ml round bottom 
tube. These cells were stained with 0.4μl of Cell-ID Cisplatin viability dye (DVS Sciences, 
Fluidigm) for 2 mins at room temperature. Cells were washed at 1800 rpm for 10 mins at 
4°C using 2ml of stain wash (0.1% BSA, 0.1% Na-Azide, 10nM EDTA in 1X PBS). The 
supernatant was discarded, and 1μl of Fc-Receptor blocking solution (Biolegend) was 
added to the cell pellet for 5 mins. Following the block, cells were stained with a master 
mix of primary fluorophore antibodies (refer Table 2.2) at 4°C for 20 mins. Cells were 
washed using stain wash and then stained with a master mix containing extracellular 
metal-labeled antibodies (refer Table 2.2) at 4°C for 30 mins. After surface staining, cells 
were washed using stain wash and then fixed with 1ml of 1.5% formaldehyde for 30 mins 
at room temperature. Two 10 min washes with Maxpar Perm-S Buffer (DVS Sciences, 
Fluidigm) were performed to permeabilize cells. Next, cells were stained with a master mix 
containing intracellular metal-labeled antibodies at 4°C for 30 mins. Following incubation, 
cells were washed using stain wash and incubated overnight in 1:1000 Cell-ID 
Intercalator-Ir diluted in Maxpar Fix and Perm buffer (DVS, Sciences, Fluidigm). The next 
day, the cells were washed once with stain wash and twice with Millipore water followed 
by resuspension in 1X EQ Calibration beads (DVS, Sciences, Fluidigm). Samples were 
acquired on a CyTOF 2 mass cytometer (DVS, Sciences, Fluidigm). The bead signature 
was used to normalize raw CyTOF data before analysis on Cytobank software. 
2.7.3 ViSNE analysis of normalized CyTOF events 
The exported files were gated on singlet viable cells based on DNA labeling with iridium 
(Ir191/193), event length and cisplatin (Pt195). NCC and NBM samples were then gated 
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on CD45+F4/80+ cells to identify OM and BM Mφ respectively. These gated 
CD45+F4/80+ cells were used to make viSNE plots and heatmaps on Cytobank software. 
Each antibody was further annotated on the viSNE plots to determine phenotypic 
differences between OM and BM-derived macrophages. The scale is the mean marker 
intensity of arcsinh transformed values. 
Table 2.2 List of metal conjugated CyTOF antibodies used in this study. 
Antibody Metal Extra/Intracellular Clone 
CD45 147Sm Extracellular 30-F11 
CD14 156Gd Extracellular Sa 14-2 
CD166 151Eu Extracellular eBioALC48 
CD11b 154Sm Extracellular M1/70 
CD169 170Er Extracellular 3D6.112 
CD206 173Yb Extracellular C068C2 
CD41 143Nd Extracellular MWReg30 
Mac2 153Eu Extracellular M3/38 
CD86 172Yb Extracellular GL1 
F4/80 146Nd Extracellular BM8 
Ly6G-FITC (Anti-
FITC metal) 
144Nd Extracellular 1A8 
Embigin-PE (Anti-
PE metal) 
145Nd Extracellular G7.43.1 
VCAM1-APC (Anti-
APC metal) 
176Yb Extracellular 429 (MVCAM.A) 
CSF1R 152Sm Extracellular AFS98 
VEGFR3 160Gd Extracellular Custom Clone 
CD130 166Er Extracellular 4H1B35 
CD143 155Gd Extracellular Custom Clone 
SDF1 165Ho Intracellular 79018 
PDGF-β 169Tm Intracellular Polyclonal 
MCP1 171Yb Intracellular 2H5 
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Antibody Metal Extra/Intracellular Clone 
TGF-β 164Dy Intracellular TW7-16B4 
FGF2 141Pr Intracellular MC-GF1 
IGF1 174Yb Intracellular Polyclonal 
IL-18 159Tb Intracellular 12E7.1 
TNF-α 162Dy Intracellular MP6-XT22 
pSTAT3 158Gd Intracellular 4/P-STAT3 
Ikzf1 175Lu Intracellular 2A9 
Lmo-2-Biotin (Anti-
Biotin metal) 
150Nd Intracellular aa35-84 
Fli-1 149Sm Intracellular Polyclonal 
PF-4 142Nd Intracellular RM0210-14M15 
 
2.8 Quantitative global proteomic comparison of protein levels in OM obtained 
from fresh NCC and NCC cultured in the absence and presence of megakaryocytes 
Three groups of cells were quantitatively compared for their protein levels using three 
biologically distinct replicate cell cultures for each group. Briefly, the groups are-1) fresh 
OM sorted from NCC (from now on will be referred to as “Fresh NCC”); 2) OM sorted from 
cultured NCC in the absence of megakaryocytes (from now on will be referred to as 
“NCC”); and 3) OM sorted from cultured NCC in the presence of megakaryocytes (from 
now on will be referred to as “NCC+MK”). Sample preparation, mass spectrometry 
analysis, bioinformatics and data evaluation were performed in collaboration with the 
Proteomics Core Facility at the Indiana University School of Medicine (IUSM), 635 Barnhill 
Drive, Medical Science Building 0034, Indianapolis, IN  46202-5122, U.S.A. Methods 
described below in brief were adaptations from literature reports published elsewhere 
(Mosley, Florens et al. 2009, Mosley, Sardiu et al. 2011, Smith-Kinnaman, Berna et al. 
2014, Wijeratne, Xiao et al. 2018, Yamamoto, Bone et al. 2019) and vendor provided 
protocols. 
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2.8.1 Cell lysis, protein assay and proteolytic digestion 
Pelleted cells mobilized in 8M urea in 100mM Tris.HCl (25μL) in 1.5mL Micro Tubes (TPX 
Plastic for Sonication from Diagende Inc.) were subjected to sonication using a Bioruptor® 
sonication system from Diagende Inc. USA, North America with 30 secs/30 secs on/off 
cycles for 15 mins in a cold water bath kept at 4oC. Protein concentrations of each sample 
was then determined using a Bradford protein assay (BioRad) and colorimeter-EPOCH|2 
(BioTek Instruments, Inc., Winooski, VT 05404-0998, U.S.A.) employing vendor provided 
protocols. Protein samples in equal amounts (2.5μg) were next subjected to reduction of 
Cys-Cys bonds of proteins with 5mM tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP), and alkylation with 10mM chloroacetamide (CAM) to protect the reduced Cys 
residues, followed by dilution of the solution to archive 2M urea concentration using 
100mM Tris.HCl. Overnight proteolytic digestion using 0.2μg Trypsin/Lys-C Mix Mass 
Spectrometry Grade for each sample (Promega Corporation, Madison, WI 53711-5399, 
U.S.A.) was then carried out as described (Mosley, Florens et al. 2009, Mosley, Sardiu et 
al. 2011, Smith-Kinnaman, Berna et al. 2014) to derive peptides. 
2.8.2 “De-salting” of peptides from other low molecular weight organic matter and 
salts 
Resulting peptides were “de-salted” using Sep-Pak® Vac 1cc C18 Cartridges, 50mg 
Sorbent per Cartridge, 55-105µm Particle Size (Waters Corporation Milford, MA 01757, 
U.S.A.) employing a vacuum manifold (Waters Corporation Milford, MA 01757, U.S.A.). 
Briefly, columns adapted onto the extraction manifold were first washed sequentially with 
(1) ACN (500μL)-two times, (2) ACN/H2O 70/30 (v/v; 0.1% FA; 200μL)-one time, and (3) 
MS-grade water (500μL)-two times. Peptides from each “digestion” solution were then 
subjected to immobilization on C18 material by a gentle application of vacuum into the 
extraction manifold vacuum chamber to move each solution three times by collecting the 
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“flow-through” fractions and running them again on to the same column. Next, the peptide-
bound C18 columns were washed with 500μL of MS-Grade H2O and then eluted by 
passing 150μL of ACN/H2O 70/30 (v/v; 0.1% FA) three times. All elution fractions were 
collected into 1.5mL eppendorf tubes and subjected to complete dryness using a speed 
vacuum system. 
2.8.3 Tandem Mass Tags (TMT) based peptide labelling, reaction quenching and 
mixing 
The respective dried samples were then subjected to TMT (Tandem Mass Tags) based 
labelling using a tenplex kit (TMT10plex™ Isobaric Label Reagent Set, 8 x 0.2mg; lot no. 
UC276347). The TMT channels-TMT126, TMT127N, TMT127C, and TMT128N, were 
employed for the labelling of four “NCC” samples; the TMT channels-TMT128C, 
TMT129N, and TMT129C were employed for the labelling of three “NCC+MK” samples 
and the TMT channels-TMT130N, TMT130C, and TMT131 were employed for the 
labelling of three “Fresh NCC” samples. Briefly, each dried sample was reconstituted in 
100μL of 50mM triethylammonium bicarbonate (TEAB) and dry labelling reagents were 
dissolved in 40μL of acetonitrile (ACN). Reconstituted peptide solution were then moved 
to the respective labelling reagent-vials and kept at room temperature for overnight to label 
the peptides. Labelling reaction was next quenched by adding 8μL of 5% hydroxylamine 
and keeping the reaction mixture at room temperature for more than 15 mins. Labelled 
peptide solutions were then mixed together and subjected to complete dryness in a speed 
vacuum system. 
2.8.4 “De-salting” of labelled peptide mixtures 
Dried labelled peptide mixture was reconstituted in 200μL of 0.1% FA (Formic Acid) and 
subjected to the above mentioned desalting procedure described in 2.8.2. The desalted, 
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eluted mixture that carries a higher percentage of acetonitrile was again subjected to 
complete dryness using a speed vacuum system prior to the below explained nano-LC-
MS/MS analysis. 
2.8.5 Nano-LC-MS/MS analysis 
Nano-LC-MS/MS analyses were performed on an Orbitrap Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific) coupled to an EASY-nLC HPLC system 
(Thermo Scientific). Labelled, mixed, and dried peptide samples were reconstituted in 
0.1% formic acid (12μL) and 5μL equivalent volume was loaded (i.e. two technical 
replicate analyses) onto a reversed phase PepMapTM RSLC C18 column (2μm, 100Å, 
75μm x 50cm) with Easy-Spray tip at 750 bar applied maximum pressure. The peptides 
were eluted using a varying mobile phase (MP) gradient from 94% phase A (FA/H2O 
0.1/99.9, v/v) to 28% phase B (FA/ACN 0.4/99.6, v/v) for 160 mins.; from 28% phase B to 
35% phase B for 5 mins; from 35% phase B to 50% phase B for 14 mins to ensure elution 
of all peptides; and bringing down the MP-composition to 10% phase B for 1 min. at 
400nL/min to bring the MP-composition to higher % of phase A. Nano-LC mobile phase 
was introduced into the mass spectrometer using an EASY-Spray™ Source (Thermo 
Scientific™). During peptide elution, the heated capillary temperature was kept at 275oC 
and ion spray voltage was kept at 2.5kV. The mass spectrometer method was operated 
in positive ion mode for 180 mins having a cycle time of 4 secs. MS data was acquired 
using a data-dependent acquisition method that was programmed to have 2 data 
dependent scan events following the first survey MS scan. During MSn level 1, using a 
wide quadrupole isolation, survey scans were obtained with an Orbitrap resolution of 60 k 
with vendor defined parameters―m/z scan range, 400-1500; maximum injection time, 50; 
AGC target, 4E5; micro scans, 1; RF Lens(%), 30; “DataType”, profile; Polarity, Positive 
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with no source fragmentation and to include charge states 2 to 6 for fragmentation. 
Dynamic exclusion for fragmentation was kept at 60 secs.  
During MSn level 2, following vendor defined parameters were assigned to isolate and 
fragment the selected precursor ions. Isolation mode = Quadrupole; Isolation Offset = Off; 
Isolation Window = 1; Multi-notch Isolation = False; Scan Range Mode = Auto Normal; 
First Mass = 100; Activation Type = HCD; Collision Energy Mode = Fixed; Collision Energy 
(%) = 36 for the 1st replicate and 37 for the second replicate MS analysis; Detector Type 
= Orbitrap; Orbitrap Resolution = 50k; Data type = Centroid; Polarity = Positive; Source 
Fragmentation = False. The data were recorded using Thermo Scientific Xcalibur 
(4.1.31.9) software (Copyright 2017 Thermo Fisher Scientific Inc.). 
2.8.6 Data analysis 
Resulting RAW files were analyzed using Proteome Discover 2.2 (Thermo Scientific). A 
specific TMT 10plex quantification method was formulated using the tools available in 
Proteome Discover 2.2 to account for isotopic impurity levels provided by vendor (lot no. 
UC276347). The MS/MS spectra were searched against in silico tryptic digest of a Mus 
musculus proteins database (FASTA format) downloaded from the UniProt sequence 
database (v. June 2017) using the SEQUEST HT search engine. In order to carry out the 
search, following specific search parameters were applied to vender provided “processing” 
and “consensus” workflow templates that correspond to Thermo “Fusion” instruments: 
Trypsin as the proteolytic enzyme; searched for peptides with a maximum number of 2 
missed cleavages; precursor mass tolerance of 10ppm; and a fragment mass tolerance 
of 0.6Da. Static modifications used for the search were, 1) carbamidomethylation on 
cysteine(C) residues; 2) TMT sixplex label on lysine (K) residues and the N-termini of 
peptides. Dynamic modifications used for the search were oxidation of methionines and 
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acetylation of N-termini. Percolator False Discovery Rate was set to a strict setting of 0.01 
and a relaxed setting of 0.05. Values from both unique and razor peptides were used for 
quantification. Peptides were normalized in Proteome Discover 2.2 (Thermo Scientific) 
using the “total peptide amount” option. Resulting “grouped” abundance values for each 
sample type; “abundance ratio” values; and respective “p-values (ANOVA)” from 
Proteome Discover were exported to Microsoft Excel and then to JMP® Pro 14.0.0 (64 
bit), Copyright © 2018 SAS Institute Inc. to construct “Distribution” plots and “Volcano 
Plots” to screen out statistically increased or decreased proteins for each global proteomic 
comparison performed. 
2.9 3D Tissue cytometry 
3D tissue cytometry was used to determine the spatial location of OM, osteoblasts and 
megakaryocytes in relation to HSC. Fgd5 mice (8-12 wk in age) (courtesy of Dr. Louis 
Pelus, Indiana University) which are GFP+ for HSC and endothelial cells were used. 
These mice were anesthetized and fixative perfused using 4% paraformaldehyde to clear 
the RBCs from the blood stream. Next, mice were sacked, and the femur and tibia were 
dissected. Muscle from the hind limbs was stripped after which the bones were fixed 
overnight in 10% neutral buffer formalin, then transferred to 70% ethyl alcohol. Bones 
were then placed in decalcification buffer (10% EDTA, pH7.4) for two weeks, after which 
they were paraffin embedded. A microtome was used to make 25 micron sections. These 
sections were then stained for imaging. 
To stain these sections, the paraffin embedding was first removed by incubating the 
sections in xylene (Honeywell Research Chemical, Mexico City, Mexico) for 10 mins at 
room temperature. This step was repeated thrice altogether and was followed by 5 mins 
incubation each in 100% ethyl alcohol, 95% ethyl alcohol, 75% ethyl alcohol, 50% ethyl 
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alcohol and 25% ethyl alcohol. The sections were washed twice in PBS for 5 mins at room 
temperature to get rid of the ethyl alcohol. Antigen retrieval was performed by incubating 
the sections in citrate buffer (10mM Citric Acid, 0.05% Tween-20, pH6.0) overnight in a 
60°C water bath. The next day, the sections were washed twice in PBS at room 
temperature for 10 mins; followed by blocking the tissue in blocking buffer (5-10% BSA, 
0.1% Tween-20 in PBS) at 4°C, overnight on a rotary shaker. On day 3, sections were 
incubated with F4/80 primary antibody at 4°C, overnight on a rotary shaker. The sections 
were washed with PBS (4 times for 30 mins at room temperature) and then incubated with 
AF647 anti-rat IgG (against F4/80) at 4°C, overnight on a rotary shaker. Next, the sections 
were incubated overnight with fluorophore conjugated antibodies CD45 AF594 and CD41 
AF405. All antibodies were used at a concentration of 1μg in 200μl blocking buffer. On the 
final day of staining, cells were washed four times in PBS (30 mins each, room 
temperature), incubated with DAPI at a ratio of 1:10,000 and finally mounted with a cover 
slip using an oil based mounting media. Images were captured using a confocal 
microscope (Leica) which included 2-photon mode. 
2.10 qRT-PCR 
qRT-PCR was performed to quantify the mRNA expression of several genes. To begin 
with, 100,000-200,000 cells were collected through cell sorting. These cells were 
subjected to an RNA extraction process using the RNeasy® Plus Micro Kit (Qiagen, 
Germany). Briefly, cells were lysed in 35μl of RLT buffer containing 10μl of β-
mercaptoethanol. The lysate was transferred to a QIAshredder spin column and 
centrifuged at full speed for 2 mins. The supernatant was then pipetted onto a gDNA 
Eliminator spin column and centrifuged at full speed for 30 secs. Next, 350μl of 70% 
ethanol was added to the flow through from the previous step and the entire volume was 
transferred to a RNeasy MinElute spin column which was centrifuged at full speed for 15 
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secs. The flow through was discarded and the column was washed with 700μl RW1 buffer 
followed by a wash using 500μl of RPE buffer. Finally, 500μl of 80% ethanol was added 
to the spin column and centrifuged at full speed for 2 mins. RNA was collected in 14μl of 
RNase-free water and the concentration was measured using a nanodrop (Thermo 
Scientific). 
Transcriptor First Strand cDNA Synthesis Kit (Version 6.0, Roche, Basel, Switzerland) 
was used to convert mRNA into cDNA. Briefly, 200ng of mRNA was added to a PCR tube 
along with 2μl of Random Hexamer Primer. Total volume was brought up to 13μl using 
PCR-grade water. The template-primer was denatured by heating the PCR tube for 10 
mins at 65°C in a thermocycler (Bio-Rad). The following was added to this tube: 4μl of 
reverse transcriptase reaction buffer, 0.5μl of RNase inhibitor, 2μl of deoxynucleotide mix 
and 0.5μl of reverse transcriptase. The reaction was run at 25°C for 10 mins followed by 
60 mins at 50°C. The enzyme was inactivated by heating the tube at 85°C for 5 mins, 
followed by cooling the tube at 4°C. The synthesized cDNA was diluted to a total volume 
of 100μl. 
To quantify the gene expression using qRT-PCR, a reaction tube was prepared containing 
12.5μl of 1X Power Sybr Green Master Mix (Applied Biosystems®, Foster City, CA), 1μl 
of 10μM forward primer, 1μl of 10μM reverse primer, 5.5μl of molecular biology grade 
water and 5μl of respective cDNA. The total volume for each reaction was 25μl. qRT-PCR 
was performed using an ABI Prism 7300 (Applied Biosystems). The machine was run 
using a standard protocol with 40 cycles. Each cDNA sample was run in triplicate. The 
average Ct value of the three replicates was calculated and normalized to GAPDH. The 
list of genes quantified, and their primers are given below in Table 2.3.  
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Table 2.3 List of qRT-PCR primers for genes investigated in this study. 
Gene Primers (5’-3’) 
PF4 
F- CTCATAGCCACCCTGAAGAATG 
R- AGGCAGCTGATACCTAACTCT 
Embigin 
F- ATCGCTTACGTGGGGGATTC 
R- AGCGTCAATGGGAACCTGTG 
Fli-1 
F- AGTTCACTGCTGGCCTATAAC 
R- TTATTGTTCCATGCTCCTCTCC 
Lmo-2 
F- CTACAAGCTGGGACGGAAAT 
R- CCCGCATCGTCATCTCATAG 
Ikzf1 
F- TTGTGGCCGGAGCTATAAAC 
R- TGCCATCTCGTTGTGGTTAG 
Runx2 
F- CGACAGTCCCAACTTCCTGT 
R- CGGTAACCACAGTCCCATCT 
Osterix 
F- CCCTTCTCAAGCACCAATGG 
R- AGGGTGGGTAGTCATTTGCATAG 
Col1a1 
F-CAGGGAAGCCTCTTTCTCCT  
R-ACGTCCTGGTGAAGTTGGTC 
Osteopontin 
F- ACTCCAATCGTCCCTACAGTCG 
R- TGAGGTCCTCATCTGTGGCAT 
Osteocalcin 
F - AAGCAGGAGGGCAATAAGGT 
R- TTTGTAGGCGGTCTTCAAGC 
Angiogenin 
F- AGCGAATGGAAGCCCTTACA 
R- CTCATCGAAGTGGACAGGCA 
IL-18 
F- ATGCTTTCTGGACTCCTGCC 
R- ATTGTTCCTGGGCCAAGAGG 
GAPDH 
F- CGTGGGGCTGCCCAGAACAT 
R- TCTCCAGGCGGCACGTCAGA 
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2.11 shRNA knockdown 
shRNAs were purchased and tested from Millipore-Sigma to achieve embigin lentiviral 
knockdown. Two of the 5 shRNA gave sufficient knockdowns. The first one was 
CCGGGCACAGAAGTAGCTTTATGAACTCGAGTTCATAAAGCTACTTCTGTGCTTTTT
G which targets the 3’UTR region of embigin; and the second one was 
CCGGCGGGTGACTTCAATACAACTACTCGAGTAGTTGTATTGAAGTCACCCGTTTTT
G which targets the coding region. All shRNAs were cloned into a pLKO.1-CMV-tGFP 
vector and were custom made by Sigma. HEK293T cells acquired by the American Type 
Culture Collection (ATCC) were used to make the virus. These cells were cultured in 10cm 
dishes containing 10ml of complete IMDM medium. Once the cells reached 70% 
confluency, they were ready for transfection. 5-8 million cells were transfected by a 
calcium phosphate-HEPES-buffered saline method (Layer, Alford et al. 2016). 1pmol 
pLKO.1-CMV-tGFP vector, 2pmol pMD-2, and 2pmol pSPAX2 (packaging plasmids 
courtesy of Dr. Justin Layer, Indiana University) plasmid constructs were used to derive 
virus. Following 12-18 hrs post transfection, medium was aspirated and replaced with 6ml 
of fresh complete IMDM. Virus was harvested at 24 hrs and 48 hrs. Virus titers were 
estimated by analyzing GFP from serially diluted virus used to transduce Jurkat cells. 
Spinfections were performed to transduce NCC with lentivirus. Briefly, NCC were 
resuspended in complete αMEM medium (750,000cells/ml) and then 1ml was plated per 
well in a 6 well plate. To achieve a multiplicity of infection of 1 to 2, either 500μl of shRNA 
containing lentivirus or empty vector lentivirus was added to each well. Around 2-3 wells 
were plated as no virus controls. Also, 4μg/ml of polybrene was added to the wells 
containing virus to increase the efficiency of transduction. These 6 well plates were 
centrifuged at 1800 rpm for 45 mins to perform the spinfection. Post spinfection, the 
medium containing virus was removed, and 1ml of fresh complete αMEM medium was 
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added. The cells were incubated at 37°C for 6 hrs followed by a 2nd spinfection. A total of 
4 spinfections were performed to transduce the cells with lentivirus. Post transduction, 
megakaryocytes were added to the NCC to help them recover and proliferate. These cells 
were cultured for 7 days at 37°C to achieve maximal knockdown. On day 7, cells were 
sorted for GFP+embigin- OM and osteoblasts (Knockdown cells), as well as 
GFP+embigin+ OM and osteoblasts (empty vector control). Transduction efficiency was 
~15-40% depending on the shRNA used. Of these transduced cells, 50-80% underwent 
embigin knockdown. These cells were used to perform colony forming assays. 
2.12 Colony forming assays 
Colony forming assays were performed to test the functionality of progenitor cells in vitro. 
Cultures were set up using 40,000 NCC cells/ well in a 12 well plate or 20,000 cells/ well 
in a 24 well plate. While using sorted neonatal OM and osteoblasts, cells were 
reconstituted based on the percentage of each group of cells on the day of the experiment. 
On an average, the cells were reconstituted as 3-5% OM and 95-97% osteoblasts. If adult 
cells, were used, OM and osteoblasts were reconstituted in a 1:1 ratio. When these assays 
were performed in the presence of megakaryocytes, 20,000 megakaryocytes were added 
per well in a 12 well plate or 10,000 cells/well in a 24 well plate. Cells were incubated at 
37°C in 500-750μl of complete αMEM medium. NCC were able to form a monolayer 
overnight; whereas adult OM and osteoblasts required incubation in 3% O2 for 1 week to 
form a monolayer. Once the monolayer was formed, each well was supplemented with 
1000 LSK cells in a 12 well plate or 500 LSK cells in a 24 well plate. To each well, 500-
750μl of complete IMDM medium was added supplemented with a cytokine cocktail 
containing 10ng/ml IL3, 10ng/ml SCF, 20ng/ml TPO, 25ng/ml Flt3, 25ng/ml IL-6 and 
25ng/ml IGF1. LSK cells were maintained for 1 week in culture alone or with other cell 
69 
types before being processed for colony forming assays or for competitive repopulation 
assays. 
For colony forming assays, cultured LSK cells were trypsinized and collected from each 
well. The cells were washed, the supernatant discarded, and the pellet resuspended in 
3ml of complete IMDM medium. Cells from each well were counted using a 
hemocytometer. 3500 cultured LSK cells from each group were replated in 3.5ml of 
methylcellulose (#GF M3434, Stemcell Technologies) contained in a 15ml tube. The tube 
was vigorously vortexed for approximately 30 secs to mix the cells and the 
methylcellulose; after which the tube was allowed to stand for 5-10 mins. Using an 18 
gauge needle and a 3ml syringe, 3ml of the concoction were aspirated and 1ml each was 
transferred in three 35mm tissue culture plates. The plates were incubated at 37°C for 1 
wk in a humidified environment after which number of colonies were counted using an 
inverted microscope. 
To better identify BFU-E and CFU-GEMM colonies, plates were stained with benzidine 
which stains hemoglobin blue. Briefly, 3μl of 50% hydrogen peroxide was added to 1ml of 
benzidine stain stock (0.2% benzidine dihydrochloride in 0.5M acetic acid). 0.5ml of this 
stain was immediately layered onto the methylcellulose dish. BFU-E and CFU-GEMM 
colonies which contain erythroid cells turn blue within 5 mins of incubation at room 
temperature. 
2.13 Competitive repopulating assays 
Competitive repopulating assays were performed to determine HSC functionality in vivo. 
Cultures were set up as described in the previous section. Donor LSK cells which were 
used fresh as well as cultured under different conditions were obtained from C57BL/6J 
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(CD45.2) mice; competitor bone marrow was obtained from BoyJ (CD45.1) mice and BoyJ 
X C57BL/6J F1 (CD45.1 and CD45.2) progeny were utilized as recipients. All procedures 
were approved by the Institutional Animal Care and Use Committee of the Indiana 
University School of Medicine and followed National Institutes of Health guidelines. 
Recipients received 1100cGy (750 and 350 cGy, split dose, 4hrs apart) before tail vein 
injection of test cells in 200μl of PBS. Freshly isolated 100,000 cells of BoyJ bone marrow 
was combined with either 1000 fresh LSK cells or progeny of cultured 1000 LSK cells 
(obtained from individual groups in the cultures mentioned above) as test cells. For test 
cells, all culture wells belonging to the same group were collected, mixed and then divided 
amongst recipients. Peripheral blood was assessed monthly to analyze percentage 
chimerism. Four months post primary transplantation, bone marrow from recipient mice 
was isolated and analyzed for percent engraftment via staining with CD45.1 and CD45.2. 
If secondary transplants were performed, half the bone marrow content of a femur from 
primary transplanted recipient was transplanted into lethally irradiated new F1 recipient 
mice. 
2.14 Recombinant, block and other proteins 
Several recombinant proteins were used to determine the molecular mediators through 
which OM enhance hematopoietic function. These recombinant proteins were 1μg/ml 
rmCD166 (R&D systems), 1μg/ml rmEmbigin (Cusabio Technology, Tokyo), 1μg/ml 
rmMac2 (In-house), 10ng/ml IL-10 (Biolegend), 25ng/ml IL-18 (R&D Systems), 25ng/ml 
Angiogenin (RayBiotech, GA), 10ng/ml MCSF (Pepro Tech Rocky Hill, NJ) and 25ng/ml 
Lcn2 (Biolegend). Surface proteins such as rmCD166, rmEmbigin and rmMac2 were 
reconstituted in PBS and coated on 24 well plates overnight at 4°C. The next day, the 
plates were washed with PBS and then coated with 2% low fat milk to prevent non-specific 
binding. Plates were incubated at room temperature for 30 mins after which they were 
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washed twice with PBS. Coated plates were used to perform certain colony forming 
experiments. 
For one of the colony forming experiments, an embigin blocking antibody provided by 
eBiosciences was used to block surface embigin on OM and osteoblasts. 
2.15 Statistical analysis 
Data has been presented as the mean ± standard deviation unless otherwise indicated. 
All experiments except the single cell genomics and competitive repopulating assays were 
repeated a minimum of 3 independent times. Statistical differences were determined using 
Student’s t-test or One-way Anova test followed by a Tukey Kramer post hoc analysis as 
indicated where appropriate. Significance was set at a p-value of 0.05. 
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CHAPTER THREE: Characterization of osteomacs and their phenotypic and 
functional differences from bone marrow derived macrophages 
 
 
3.1 Introduction 
Macrophages are phagocytic immune cells known for their heterogeneity amongst 
different tissues. Apart from the cartilage, resident macrophages in almost every tissue of 
the body have been phenotypically identified. Amongst these tissue resident 
macrophages are two subsets that normally reside in close proximity in the bone marrow 
microenvironment called osteomacs (OM) and bone marrow derived macrophages (BM 
Mφ). OM are bone resident macrophages, found lining the endosteal bone surface 
currently characterized as CD45+F4/80+ cells (Chang, Raggatt et al. 2008). Functionally, 
they are critical for promoting bone anabolism, remodeling, repair, and regeneration 
(Chang, Raggatt et al. 2008, Alexander, Chang et al. 2011, Guihard, Danger et al. 2012, 
Wu, Raggatt et al. 2013, Cho, Soki et al. 2014, Raggatt, Wullschleger et al. 2014, Sinder, 
Pettit et al. 2015, Vi, Baht et al. 2015, Alexander, Raggatt et al. 2017, Batoon, Millard et 
al. 2017, Batoon, Millard et al. 2017, Kaur, Raggatt et al. 2017). On the other hand, BM 
Mφ are found in the bone marrow cavity among other hematopoietic cells; and are similarly 
characterized as CD45+F4/80+ cells. Some subsets of macrophages have also been 
implicated in promoting erythropoiesis, HSC mobilization and HSC engraftment (Winkler, 
Sims et al. 2010, Chow, Lucas et al. 2011, Hoggatt and Pelus 2011, Ludin, Itkin et al. 
2012, Chow, Huggins et al. 2013, Chang, Sengupta et al. 2014, Heazlewood, Oteiza et 
al. 2014, Jacobsen, Forristal et al. 2014, Dutta, Hoyer et al. 2015, Jacobsen, Perkins et 
al. 2015, McCabe, Zhang et al. 2015, Hur, Choi et al. 2016, Qiao, Liu et al. 2018); whereas 
other subsets negatively regulate HSC numbers and function (McCabe, Zhang et al. 2015, 
Luo, Shao et al. 2018). Since both OM and BM Mφ are considered as residents of the 
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hematopoietic niche, it is difficult to attribute which macrophage subset is responsible for 
supporting hematopoietic function. In this chapter, calvariae-resident OM are defined and 
characterized; and distinguishing phenotypic and functional attributes between them and 
BM Mφ are demonstrated. 
3.2 Characterization of osteomac origin and phenotypic expression of surface 
markers 
Consistent with a previous study (Chang, Raggatt et al. 2008), the analysis of freshly 
isolated neonatal calvarial cells (NCC) led to the identification of a CD45+F4/80+ 
subpopulation of cells, that share multiple characteristics with OM. Further analysis of 
these cells revealed that they express classical macrophage markers such as CD11b, 
CD14 and CD68 (Figure 3.1, NCC). However, they do not express endothelial markers 
such as CD31; nor hematopoietic stem cell markers such as CD150 and CD34 (Figure 
3.1). Since megakaryocytes promote in vitro and in vivo osteoblast expansion (Kacena, 
Shivdasani et al. 2004, Kacena, Gundberg et al. 2005, Ciovacco, Goldberg et al. 2009, 
Ciovacco, Cheng et al. 2010, Kacena, Eleniste et al. 2012, Cheng, Hooker et al. 2013, 
Cheng, Streicher et al. 2015, Alvarez, Xu et al. 2018), the impact of megakaryocyte 
stimulation on NCC was examined. When cultured alone for 7 days, NCC increased in 
numbers but the percentage of OM remained relatively unchanged or declined (Figure 
3.1, middle panel). On the other hand, NCC cocultured with megakaryocytes displayed an 
almost 4-fold increase in the percentage of OM (Figure 3.1, right panel). This indicates 
that megakaryocytes promote OM proliferation in vitro.  
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Figure 3.1 Phenotypic characterization of fresh and cultured osteomacs. Representative 
flow cytometric data of freshly isolated NCC (left column), NCC cultured for 1 week in the 
absence (middle column) or presence (right column) of megakaryocytes (MK). N=3 
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Since OM are bone resident macrophages, the next focus was to determine whether they 
originate from progenitors produced during embryonic development or circulating 
monocytes derived from HSC (Yona, Kim et al. 2013, McGrath, Frame et al. 2015). To do 
so, a competitive repopulation assay was performed; where 1000 donor LSKs (C57BL/6J 
mice which are CD45.2+) and 100,000 competitor bone marrow cells (BoyJ mice which 
are CD45.1+) were co-transplanted into irradiated (900cGy) F1 recipients (Mice which are 
CD45.1+CD45.2+). A total of 18 F1 mice were transplanted. Every month, for a total of 4 
months, 4-5 mice were sacked and the hind limbs were dissected to obtain digested bones 
(previously flushed) which were analyzed for CD11b+F4/80+ macrophages (Figure 3.2A). 
These cells were then gated on CD45.1 and CD45.2 to obtain OM and determine their 
source of origin. Interestingly, it was observed that 5-30% of host OM (CD45.1+CD45.2+) 
survive irradiation (Figure 3.2B) right up to four months post transplantation. However, the 
data demonstrate that donor LSK cells could also differentiate into OM. It was observed 
that on an average 35-60% OM (CD45.2) originate from donor cells suggesting that OM 
are myeloid cells originating from HSC. These data and the design of the transplantation 
studies makes it difficult to reach a definitive answer concerning whether OM are totally 
HSC-derived or whether a subset is derived embryonically and cannot be replaced by 
transplantation.
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Figure 3.2 OM are radioresistant and are derived from HSC. 1000 LSK cells from C57BL/6 
(CD45.2) mice and 100,000 bone marrow cells from BoyJ (CD45.1) mice were co-transplanted 
in (900cGy) CD45.1/CD45.2 F1 recipients via tail vein injection. (A) Representative flow 
cytometry data from two mice outlining the gating were used to determine percent chimerism in 
CD11b+F4/80+ OM. (B) Monthly data demonstrating percent chimerism in OM post 
transplantation. *p < 0.05 1-way ANOVA. 
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3.3 CD166 and CSF1R co-expression distinguish between OM and BM Mφ from 
neonatal and adult donors 
Since OM and BM Mφ both are characterized as CD45+F4/80+ cells, the next goal was 
to examine phenotypic differences between OM contained in NCC and their CD45+F4/80+ 
BM Mφ from age matched counterparts collected from the long bones of neonatal pups. 
To identify possible developmental changes in the phenotypic makeup of BM Mφ, bone 
marrow (BM) cells collected from the long bones of 8 wk-old mice were analyzed. Also, to 
confirm that OM are osteolineage-associated macrophages (present in the bones of 
neonatal and adult mice) with a unique identity, digested bones (previously flushed) from 
8 wk-old mice were analyzed. The analysis showed that cells from all four sources 
demonstrate positive expression patterns for CD45, F4/80, CD169, CD11b, CD68, Ly6G 
and Mac-2 (Figure 3.3). However, only a subset of OM analyzed from NCC and 8 wk 
digested bone co-expressed CD166 and CSF1R. This co-expression was seen in the 
Ly6G+Mac-2+ as well Ly6G+Mac-2- subfractions of OM. BM Mφ from both NBM and 8 
wk flushed BM expressed CSF1R but not CD166. Interestingly, the expression of CD169, 
a known macrophage marker (Chow, Lucas et al. 2011, Chow, Huggins et al. 2013, 
Jacobsen, Forristal et al. 2014, Batoon, Millard et al. 2017) did not discriminate between 
OM and BM Mφ since both groups of cells expressed this marker (Figure 3.3). In fact, in 
the example shown in Figure 3.3, a higher percentage of neonatal OM expressed CD169 
than that detected among neonatal BM Mφ. However, the expression was similar on adult 
donor cells. CD169 macrophages have previously been implicated in promoting 
erythropoiesis and long-term hematopoietic stem cell engraftment (Chow, Lucas et al. 
2011, Chow, Huggins et al. 2013, Jacobsen, Forristal et al. 2014, Kaur, Raggatt et al. 
2018). This data indicates that irrespective of the developmental stage, a subfraction of 
OM both from neonatal and adult donors co-express CD166 and CSF1R; and this co-
expression is not detected on BM Mφ. 
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Figure 3.3 Phenotypic analysis of OM and BM Mφ derived from neonatal and adult donors. 
Nine color flow cytometric analysis of freshly isolated NCC and NBM; as well as 8 wk digested 
long bones (flushed then digested) and 8 wk flushed BM. All gates were based on fluorescence 
minus one (FMO) controls. Gating proceeded from top to bottom in each column. N=4-6 
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3.4 Single cell genomics identifies transcriptional changes between neonatal 
OM and BM Mφ 
The BioMark HD microfluidic platform was used to examine global differences between 
OM isolated from fresh NCC and their BM counterparts derived from neonatal long bones. 
First, 70 freshly isolated single OM and 96 single BM Mφ were captured using the C1 
integrated fluidic circuit. The cDNA from these cells was analyzed by qRT-PCR to quantify 
the expression of 90 genes. As observed in the violin plots (Figure 3.4A), 48 of the 90 total 
genes analyzed, were significantly different between the two cell types. The data indicated 
adiponectin (ADIPOQ) to be upregulated in BM Mφ with minimal mRNA expression in OM. 
On the other hand, the thrombopoietin receptor (CD110 or MPL) and bone morphogenetic 
protein-2 (BMP-2) were upregulated in OM with minimal to no mRNA expression in BM 
Mφ. Raw data for the significantly different genes has been shown in Figure 3.4B. To 
confirm these changes at the proteomic level, CD45+F4/80+ cells from both sources were 
gated and analyzed for the expression of CD110. Figure 3.4C demonstrates that CD110 
expression was unique to OM, indicating it to be a novel surface marker on neonatal OM. 
Due to the lack of a verified and dependable flow cytometry antibody, it was not possible 
to confirm the change in adiponectin and BMP-2 expression at the protein level. 
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Figure 3.4 CD110/MPL differentiates OM from BM Mφ in neonates. (A) Freshly isolated 70 
single OM and 96 single BM Mφ were captured using the C1 integrated fluidic circuit. The cDNA 
from these cells was analyzed by qPCR with the primers of 90 genes using the BioMark HD 
platform. Data have been represented using violin plots in (A). Blue asterix (*) indicates 
downregulation of that gene in OM whereas red asterix (*) indicates upregulation. p<0.05. Raw 
data for the 48 significantly different genes have been shown in (B). (C) Flow cytometric analysis 
(representative data) of freshly isolated neonatal cells (NCC) and freshly isolated neonatal bone 
marrow (NBM) using CD45, F4/80, and CD110 antibodies. N=3. 
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3.5 Single cell CyTOF analysis reveals a novel set of markers expressed on 
neonatal OM 
Single cell mass cytometry analysis (CyTOF) was used to further distinguish between 
neonatal OM and BM Mφ. The advantage of using CyTOF over flow cytometry were the 
absence of single color and FMO controls required to perform multi-color flow cytometric 
analysis; and the absence of compensation issues involved in flow cytometry. Also, 
CyTOF allows the use of complex algorithms such as ViSNE to understand the 
heterogeniety within populations in a more efficient manner. 
OM and BM Mφ were analyzed using simultaneously a panel of 17 surface and 13 
intracellular antibodies (Figure 3.5A). The panel of 30 antibodies was designed based on 
previous literature pertaining macrophage expression markers and regulators of 
hematopoiesis. The expression of several intracellular markers such as platelet factor-4 
(PF4), stromal derived factor-1 (SDF1), and platelet derived growth factor-β (PDGF-β) 
were upregulated in OM compared to BM Mφ (Figure 3.5B). Interestingly, these proteins 
were previously implicated in regulating hematopoiesis (Leveen, Pekny et al. 1994, Aiuti, 
Webb et al. 1997, Dominici, Rasini et al. 2009, Bruns, Lucas et al. 2014, Lim, Esain et al. 
2016). This indicates the possibility of different functional roles between OM and BM Mφ 
in the hematopoietic niche. To determine the individual functional roles of each of these 
cells in the hematopoietic niche is an important topic which will be covered in the next 
section. 
In my hands and with these two cell types, staining for intracellular markers reduced the 
expression of certain key surface markers such as CD166 and CD169. This reduction in 
expression of certain surface markers could be due to the permeabilization step involved 
in the staining of intracellular markers. Therefore, studies were performed on OM and BM 
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Mφ using a subgroup of 17 surface markers from the panel. Initial analysis of these data 
revealed the heterogeneity of OM and BM Mφ (Figure 3.6A). FlowSOM was used to 
identify unbiased subpopulations/clusters (7 in OM and 6 in BM Mφ) based on the 17 
surface antibodies. Each cluster was then phenotypically characterized based on the 
same panel of surface markers. Only 1 small cluster overlapped between OM and BM Mφ 
(group of cells designated teal in color in Figure 3.6A) indicating that these two cell sources 
are phenotypically very different. 
Consistent with previous characterization (Alexander, Chang et al. 2011), OM were Mac-
2 low and expressed macrophage markers such as CD11b, CD14, CSF1R and CD169 
(Figure 3.6B). In fact, expression of CD14 and CD169 was upregulated in OM compared 
to BM Mφ. CD166, a marker important for the hematopoietic niche (Chitteti, Cheng et al. 
2010, Chitteti, Bethel et al. 2013, Chitteti, Cheng et al. 2013, Chitteti, Kobayashi et al. 
2014) was also upregulated (Figure 3.6C). Also, the two cell sources were analyzed for 
expression of CD86 (M1 macrophage marker) and CD206 (M2 macrophage marker). 
Neonatal OM uniquely co-expressed CD86 and CD206 (Figure 3.4E), whereas BM Mφ 
expressed CD86 with low or undetectable expression of CD206. Altogether, the single cell 
data identified the unique expression of CD166, CD110 and CD206 on neonatal OM. 
Next, a four-color flow cytometry analysis was performed to identify the percentage of OM 
and BM Mφ which are CD206+CD80+. The analysis of CD80 was due to preliminary single 
cell RNA sequencing data performed in the laboratory using 8 wk OM and BM Mφ. As 
seen in Figure 3.7A, ~85-90% of neonatal OM co-express CD80 and CD206. However, a 
fraction of BM Mφ also expressed CD80, but not CD206. These data demonstrate that the 
unique expression of CD80 and CD206 on OM from neonatal pups can be used for future 
experiments to separate them from age matched contaminating BM Mφ. Interestingly, 
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these two surface markers lose expression during development. As seen in Figure 3.7B 
~45-55% of OM obtained from 3 wk calvarial cells and ~10-20% of OM obtained from 3 
wk digested bones co-express CD80 and CD206. Similarly, ~35-40% of OM obtained from 
8 wk calvarial cells and ~10-20% of OM obtained from 8 wk digested bones co-express 
CD80 and CD206 (Figure 3.7C), indicating the loss of co-expression of these markers on 
OM during aging or through development. 
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Figure 3.5 Differential expression patterns of surface and intracellular antigens on OM 
and BM Mφ from neonates. Single cell suspensions of NCC and NBM were analyzed using a 
panel of 30 surface and intracellular antibodies. Data were gated on CD45+F4/80+ cells to 
indicate OM in NCC (upper panel) and BM Mφ in NBM (lower panel). (A) Representative Heat 
map and (B) ViSNE plots indicating intracellular differences of several proteins between the two 
cell types. N=3-7 
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Figure 3.6 Multidimensional CyTOF analysis of OM and BM Mφ from neonates. Single cell 
suspensions of NCC and NBM were analyzed using a subpanel of 17 surface antibodies. Data 
were gated on CD45+F4/80+ cells to indicate OM in NCC (upper panel) and BM Mφ in NBM 
(lower panel). (A) Representation of the heterogeneity observed within subpopulations of OM 
and BM Mφ. Each subpopulation was characterized depending on their expression of the 
surface markers. (B) Heat map and (C) ViSNE plots indicating individual surface differences 
between OM and BM Mφ. N=3-6. 
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Figure 3.7 Developmental loss of CD206 expression on OM. Four color flow cytometric 
analysis of (A) freshly isolated NCC and NBM, (B) 3 wk digested calvarial cells (CC), digested 
long bones (flushed then digested) and bone marrow and (C) 8 wk digested CC, digested long 
bones (flushed then digested) and bone marrow. Cells were gated on CD45+F4/80+ 
macrophages which were further gates on CD80 and CD206. N=3 
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3.6 OM are a subset of macrophages that phagocytose and differentiate into 
osteoclasts 
Phagocytosis assays were performed to identify whether OM can phagocytose similar to 
other macrophage subtypes and might therefore possibly have an immune function. PE-
conjugated E.coli BioParticles were used to activate OM and induce phagocytosis. Flow 
cytometry results indicate that both OM and BM Mφ fluoresce in the PE channel illustrating 
that both cell types phagocytose (Figure 3.8A). Images of the same demonstrate that 
these BioParticles were intracellular in both OM and BM Mφ, indicating their engulfment 
(Figure 3.8B). These data show that OM can functionally phagocytose foreign particles 
similar to BM Mφ. 
Since macrophages act as osteoclast progenitors; and several phenotypic and functional 
similarities exist between OM and BM Mφ; the next goal was to determine if OM may also 
differentiate into osteoclasts. The data in Figure 3.9A (Mohamad, Xu et al. 2017) 
demonstrate that culturing OM with RANKL and M-CSF can induce their differentiation 
into multinucleated osteoclasts that express TRAP. In addition, these osteoclasts were 
functional since they were capable of resorbing dentin and forming resorption pits (Figure 
3.9B) (Mohamad, Xu et al. 2017). This suggests that contrary to previous published data 
(Chang, Raggatt et al. 2008), OM are osteoclast progenitors which can differentiate into 
functional osteoclasts.  
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Figure 3.8 OM perform phagocytosis comparable to BM Mφ. 8 wk digested long bones 
(flushed then digested) and 8 wk flushed BM were processed to isolate OM and BM Mφ, 
respectively, that were collected through flow sorting. 75,000 cells from each group were 
cultured per well in a 96-well plate for 24 hrs. The next day, cells were incubated with 100μL of 
PE conjugated E. coli BioParticles for 1 hr after which they were analyzed for phagocytosis. (A) 
Representative dot plots (N=3) and (B) images (N=2 independent experiments) indicating both 
OM and BM Mφ phagocytose PE conjugated E. coli. The top row in (B) are bright field (BF) 
images of cells whereas the bottom row represents cells that have engulfed the PE conjugated 
BioParticles. 
Control 
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Figure 3.9 OM can differentiate into functional osteoclasts. (A) CD45+F/480+ OM from 
NCCs or BM Mφ from NBM were cultured with RANKL and M-CSF to induce osteoclast 
formation. TRAP+ osteoclasts with less than or equal to 3 nuclei were quantified. *p>0.05. (B) 
Osteoclasts formed from the calvariae-derived (left panel) OMs were replated on dentin, and 
resorption pits were stained after 3 days (right panel). Representative images of TRAP1 
osteoclasts and resorption pits formed by these cells are shown. Slides were stained as 
described in (Mohamad, Xu et al. 2017). Scale bar indicates 50mm. 
A. 
B. 
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3.7 OM, osteoblast and megakaryocyte interactions are essential for 
maintaining murine hematopoietic stem cell function 
Since NCC mediate hematopoietic enhancing activity (Chitteti, Cheng et al. 2010), it was 
important to examine whether the OM and/or osteoblast subfraction of NCC were 
responsible for mediating this activity. As seen in Figure 3.10A, when OM were cultured 
with LSKs in the absence of osteoblasts, they were incapable of maintaining 
hematopoietic activity higher than the LSK control. On the other hand, osteoblasts alone 
were capable of expanding CFU fold change but not to the same level as that observed 
when osteoblast were mixed with OM. CFU fold change was significantly increased when 
both OM and osteoblasts were co-cultured; and this activity was further augmented by the 
addition of megakaryocytes to the mix. The CFU fold change of OM cultured with 
osteoblasts in the absence or presence of megakaryocytes was always higher compared 
to the CFU fold change of the LSK control. However, regardless of whether 
megakaryocytes were added to the co-cultures, BM Mφ were unable to substitute for OM 
to support hematopoiesis. These data demonstrate that while osteoblasts can mediate the 
previously reported hematopoiesis enhancing activity (Chitteti, Cheng et al. 2010), OM are 
required for maximal hematopoiesis enhancing activity promoted by NCC. Promotion of 
hematopoiesis enhancing activity was not restricted to OM isolated from neonatal 
calvariae since OM collected from long bones of adult mice mediated the same activity 
(Figure 3.10B). Together, the data indicate that OM, osteoblast and megakaryocyte 
interactions are important for maintaining hematopoietic stem cell activity and that OM 
cannot be substituted by BM Mφ to maintain this function in the hematopoietic niche. 
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Figure 3.10 OM are bone-resident macrophages that are functionally different from BM-
derived Mφ. (A) Co-cultures of NCC-derived osteoblasts (OB) mixed with either the original 
number of OM contained in freshly isolated NCC (OM+OB) or a complimentary number 
(equivalent to the original number of OM in NCC) of BM-derived CD45+F4/80+ macrophages 
(Mφ+OB) were established. LSK cells were added with (green bars) or without (red bars) 
megakaryocytes (labeled in this Figure as MK) and LSK progeny were assessed for CFU 
content on day 7. CFU fold-increase was calculated relative to that obtained from 250 fresh 
LSK. *p< 0.001 vs LSK, OM, Mφ, OB and Mφ+OB; +p<0.001 vs OM+OB, LSK+MK, OM+MK, 
Mφ+MK, OB+MK and Mφ+OB+MK, One-way Anova. (B) Long bones from adult mice were 
flushed, then digested with collagenase to obtain a cell population containing OM and 
osteoblasts (OB). OM and OB were purified by sorting. Sorted cells were cultured alone or co-
cultured in a 1:1 ratio for 7 days. These cultures were then seeded with LSK and assayed 7 
days later for their CFU content. CFU fold increase was calculated relative to that obtained from 
250 fresh LSK cells. *p< 0.01 compared to LSK, 8w OM and 8w OB, One-way Anova. 
B. 
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3.8 Discussion 
In this chapter, calvariae-resident macrophages called OM were characterized and shown 
to be phenotypically and functionally different from BM Mφ. OM, which were first defined 
in 2008 (Chang, Raggatt et al. 2008), are identified as F4/80+ macrophages that line the 
endosteum. Through the work in this chapter, OM were further characterized; and it was 
shown that in addition to F4/80, they express other classical macrophage markers such 
as CD11b, CD14, CD68 and Mac-2 (Figure 3.1 and Figure 3.3). Interestingly, all these 
markers are common between OM and BM Mφ which are also defined as CD45+F4/80+ 
cells. Similar to BM Mφ, OM possess the functional capability of phagocytosis, marking 
them as part of the immune system (Figure 3.8). Although no previous data demonstrated 
that OM phagocytose, there have been instances of correlation between OM and 
efferocytosis of apoptotic cells within the bone (Cho, Soki et al. 2014, Sinder, Zweifler et 
al. 2017). Data in Figure 3.8 further strengthen this analogy and identify OM as possessing 
the most classical function of macrophages, which is phagocytosis. 
Another important function of BM Mφ is their ability to differentiate into osteoclasts. 
However, previous reports have mentioned that OM do not act as osteoclast precursors 
(Chang, Raggatt et al. 2008). Contrary to these data, it was demonstrated that OM are 
able to differentiate into TRAP+ osteoclasts when cultured in the presence of MCSF-1 and 
RANKL (Figure 3.9A) (Mohamad, Xu et al. 2017). Furthermore, these osteoclasts 
resorbed dentin (Figure 3.9B). Although it remains possible that different OM 
subpopulations were used by the independent laboratories, carefully controlled and 
optimized culture conditions are also necessary to induce osteoclast differentiation, which 
could possibly explain the differing results. Whether only a subpopulation of OM 
differentiated into osteoclasts is also not defined at present. Interestingly, OM but not BM 
Mφ differentiated into osteoclasts in the absence of MCSF-1 (Data not shown). These 
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findings correlate with the single cell qPCR data where it was demonstrated that OM 
express significantly higher MCSF-1 mRNA compared to BM Mφ (Figure 3.4A and B). 
In the past decade, several groups have demonstrated various tissue resident 
macrophages including BM Mφ as being resistant to radioablation (Haniffa, Ginhoux et al. 
2009, Hashimoto, Chow et al. 2011, Winkler, Pettit et al. 2012, Kaur, Raggatt et al. 2018). 
In this study, the CD45.1/CD45.2 system was used, where donor cells express the CD45.2 
allele, and recipients express both CD45.1 and CD45.2. The transplant data demonstrate 
that a percentage of OM in recipient mice survive post irradiation. However, this 
radioresistant population eventually depletes and is replaced by donor OM derived from 
HSC (Figure 3.2). This answers a second question regarding OM origin. Several reports 
have identified that fetal-derived macrophage progenitors are responsible for maintaining 
several tissue resident macrophages in adult hematopoiesis (Schulz, Perdiguero et al. 
2012, Yona, Kim et al. 2013). The transplant data in Figure 3.2 demonstrate that OM are 
radioresistant myeloid cells which can originate from HSC. 
All characteristics discussed above, are phenotypic and functional similarities between 
OM and BM Mφ. The similarities as well as the differences between neonatal and adult 
OM and BM Mφ are summarized in Table 3.1. Next, a series of experiments were 
designed, which included multi-color flow cytometry, single cell genomics and single cell 
proteomics, to determine phenotypic differences between the two neonatal subsets. Each 
of these experiments was designed to include maximum novel expression markers which 
could help characterize OM and distinguish them from BM Mφ. Through these studies, a 
subfraction of neonatal OM was identified which was CD166 and CSF1-R positive (Figure 
3.3) and was phenotypicallly distinct from neonatal BM Mφ. Interestingly, the same 
subfraction of OM was present not only in neonatal calvariae, but also in the long bones 
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of adult mice. This indicates that OM are not a developmentally unique cell type present 
only in neonatal calvariae. In fact, OM from both neonates and adults are also functionally 
similar in that they interact with osteoblasts to enhance hematopoietic activity (Figure 
3.10). This hematopoietic activity of OM could not be substituted by BM Mφ. It was 
previously demonstrated that CD166 is a critical mediator of the hematopoietic niche 
(Chitteti, Cheng et al. 2010, Chitteti, Cheng et al. 2010, Chitteti, Bethel et al. 2013, Chitteti, 
Cheng et al. 2013, Chitteti, Kobayashi et al. 2014). Since this marker is present on OM 
and not on BM Mφ, it is possible to hypothesize that CD166 may be one of the molecular 
mediators through which OM enhance hematopoietic function. This premise will be 
covered in the upcoming chapters. 
Through the multi-color flow cytometry studies and CyTOF, it was also shown that 
neonatal OM express CD169 at a higher level than their bone marrow counterpart; 
whereas adult OM and BM Mφ express similar levels of CD169 (Figure 3.3, Figure 3.6). 
This illustrates that CD169 is not a distinguishing marker between various subsets of 
macrophages. However, CD169 has been implicated as an important identifying marker 
for BM Mφ resident in the hematopoietic niche (Chow, Lucas et al. 2011, Chow, Huggins 
et al. 2013). Furthermore, depletion of CD169+ macrophages causes loss of both OM 
lining the endosteum and BM Mφ lodged within the center of the bone marrow (Batoon, 
Millard et al. 2017). This makes it difficult to determine which subset of macrophages is 
essential for hematopoietic function. Hence, it is important to identify a novel marker 
distinguishing adult OM from BM Mφ. Current studies have identified CD166 as a 
distinguishing marker between adult OM and BM Mφ, but it only expressed on a small 
subset of OM. 
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Single cell studies have further helped identify several phenotypic differences between 
neonatal OM and BM Mφ including expression of CD110, CD206, CD86 and CD80 (Figure 
3.4, 3.5, 3.6, 3.7). Interestingly, previous data bifurcate CD86 macrophages as M1 
subtype and CD206 macrophages as M2 (Hume 2015, Huang, Feng et al. 2019). 
However, OM are unique since they co-express both CD86 and CD206 on their surface 
(Figure 3.6). There is a possibility that these macrophages are at an earlier phase of 
differentiation and lose expression of either CD86 or CD206 with development. This 
finding was not further explored. Also, OM express CD80 which is an important co-
stimulatory marker on T cells (Sabzevari, Kantor et al. 2001). It was demonstrated that 
almost all CD80+CD206+ cells in neonatal calvarial cells are CD45+F/480+ (Figure 3.7A). 
For future studies, CD206 and CD80 could be used as two distinct markers that 
discriminate OM from contaminating macrophages within the neonatal calvariae. 
Interestingly, CD80 and CD206 expression patterns of OM in 3 wk and 8 wk old mice was 
also analyzed (Figure 3.7B and C). A decline in the expression pattern of both CD206 and 
CD80 on OM was observed with age. Furthermore, the decline was faster in OM isolated 
from long bones as compared to OM obtained from calvarial cells. On the other hand, BM 
Mφ gain expression of CD80 with development. CD80 being a marker of T-cells and in 
turn the immune system (Sabzevari, Kantor et al. 2001), there is the possibility that as the 
immune system is exposed to various foreign antigens and develops, immune cells such 
as BM Mφ, these gain CD80 expression with time. This is an interesting avenue which 
could be explored in future research. Nonetheless, CD206 and CD80 which are excellent 
distinguishing markers between neonatal OM and BM Mφ, are only expressed on a subset 
of OM in adults. It is critical to identify a distinguishing marker between adult OM and BM 
Mφ so that genetic models can be used to define their individual function in vivo in the 
hematopoietic niche. 
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Overall, these studies suggest that even though OM phagocytose (Figure 3.8) and act as 
osteoclast progenitors (Figure 3.9) (Mohamad, Xu et al. 2017) similar to BM Mφ; they are 
phenotypically and functionally very distinct from their BM counterparts (Table 3.1). These 
investigations extend the definition of OM and describe novel surface markers such as 
CD166, CD110, CD206 and CD80 which distinguish neonatal OM from BM Mφ. 
Furthermore, the importance of networking between OM, osteoblasts and 
megakaryocytes in enhancing hematopoietic function is described. Detailed analysis of 
the crosstalk between these cells and the molecular mediators through which OM maintain 
hematopoiesis will be covered in the upcoming chapters. 
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Table 3.1 Summary of similarities and differences between OM and BM Mφ. 
Characteristic 
Neonatal 
OM 
Neonatal 
BM Mφ 
Adult 
OM 
Adult 
BM Mφ 
Expression of surface markers: 
• CD45 
• F4/80 
• CD11b 
• CD68 
• Ly6G 
• Mac-2 
• CSF-1R 
• CD14 
• CD169 
• CD166 
• CD110 
• CD206 
• CD86 
• CD80 
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++ 
++ 
++ 
- 
- 
- 
+ 
++ 
 
++ 
++ 
+++ 
+ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
N/D 
+ 
+ 
++ 
 
++ 
++ 
+++ 
+ 
+++ 
++ 
+++ 
++ 
++ 
+ 
N/D 
- 
+ 
+++ 
Expression of intracellular markers: 
• SDF-1 
• PF-4 
• PDGF-β 
• MCP-1 
• TNF-α 
 
+++ 
+++ 
+++ 
+++ 
+ 
 
+ 
+ 
+ 
- 
++ 
 
N/D 
N/D 
N/D 
N/D 
N/D 
 
N/D 
N/D 
N/D 
N/D 
N/D 
Resistance to radioablation N/D N/D Yes Yes 
Megakaryocyte induced proliferation Yes No Yes N/D 
Phagocytic Capability Yes Yes Yes Yes 
Precursor for osteoclast differentiation Yes Yes Yes Yes 
Size 
~10-15 
micron 
~8-10 
micron 
N/D N/D 
Interacts with osteoblasts and megakaryocytes 
to enhance hematopoietic activity 
Yes No Yes No 
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CHAPTER FOUR: Megakaryocytes interact with osteomacs and osteoblasts 
to regulate murine hematopoiesis 
 
 
4.1 Introduction 
Megakaryocytes are hematopoietic myeloid cells whose primary function is to produce 
platelets that are critical for blood clotting. Megakaryocytes are also known to play key 
roles in skeletal homeostasis and hematopoiesis. In skeletal homeostasis, they regulate 
osteoblast proliferation and suppress osteoblast differentiation (Kacena, Shivdasani et al. 
2004, Kacena, Gundberg et al. 2005, Ciovacco, Goldberg et al. 2009, Bethel, Srour et al. 
2011, Cheng, Hooker et al. 2013, Cheng, Streicher et al. 2015, Alvarez, Xu et al. 2018). It 
was previously demonstrated that megakaryocytes increase OM numbers that are 
contained within NCC (Mohamad, Xu et al. 2017) (Figure 3.1). Also, OM, osteoblasts and 
megakaryocytes are all part of the hematopoietic niche. However, the relative location of 
these cells with respect to each other and also in relation to HSC is not clear. Several 
groups have indicated that quiescent HSC are found near the endosteum; and localize 
adjacent to megakaryocytes in a non-random manner (Nilsson, Johnston et al. 2001, 
Heazlewood, Neaves et al. 2013). Detailed multi-dimensional imaging studies combining 
existing data with additional niche participants are warranted. 
Maintenance of HSC function is an orchestrated event between multiple cell types. 
Crosstalk between these cell types is an essential part of HSC regulation. Previous data 
has demonstrated the importance of NCC, which consist of OM and osteoblasts, in 
maintaining hematopoietic function (Chitteti, Cheng et al. 2010). Also, in chapter three, it 
was demonstrated that the hematopoietic enhancing function of NCC is further augmented 
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in the presence of megakaryocytes (Mohamad, Xu et al. 2017). This is not the first instance 
where megakaryocytes have been implicated in hematopoiesis. In 2009, Dominici et al. 
illustrated that megakaryocytes migrate to the endosteum post lethal radioablation. Once 
at the endosteum, they release growth factors such as PDGF-β and FGF-2 which 
accelerate osteoblast proliferation and in turn enhance hematopoietic function (Dominici, 
Rasini et al. 2009, Olson, Caselli et al. 2013). Interestingly, megakaryocytes can also 
directly regulate HSC pool size via direct secretion of factors such as CXCL4 and IGF-1 
(Heazlewood, Neaves et al. 2013, Bruns, Lucas et al. 2014). 
This chapter is focused on understanding the relative location of HSC, OM, osteoblasts 
and megakaryocytes within the hematopoietic niche. Previously, the importance of 
crosstalk between OM, osteoblasts and megakaryocytes in maintaining hematopoietic 
function was established. In this chapter, the essential role of megakaryocytes in 
maintaining hematopoiesis is discussed; and the importance of physical interactions 
between OM, osteoblasts and megakaryocytes in maintaining hematopoietic function is 
determined. 
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4.2 Crosstalk between OM, osteoblasts and megakaryocytes is essential to 
maintain murine hematopoiesis 
It was previously established that immature osteoblasts support the most robust 
hematopoietic activity (Cheng, Chitteti et al. 2011, Chitteti, Cheng et al. 2013) and that 
osteoblasts lose this potential as they differentiate in culture (Chitteti, Cheng et al. 2010, 
Cheng, Chitteti et al. 2011, Chitteti, Cheng et al. 2013). Also, megakaryocytes have the 
potential to suppress osteoblast differentiation (Ciovacco, Cheng et al. 2010). Hence, the 
next study was to examine if megakaryocytes can augment osteoblast-mediated 
hematopoiesis enhancing activity via their interactions with OM. Unsorted NCC, sorted 
osteoblasts (CD45-F4/80-), or OM from C57BL/6 mice (CD45.2) were used for these 
assays. NCC were cultured fresh (NCC) or were maintained for 1 wk without (1 wk NCC) 
or with megakaryocytes (1 wk NCC+MK) prior to their use in culture (Figure 4.1A). The 
hypothesis being that cultured 1 wk NCC would have a higher number of differentiated 
osteoblasts; whereas the presence of megakaryocytes with NCC (1 wk NCC+MK) would 
suppress osteoblast differentiation and thus 1 wk NCC+MK will enhance hematopoiesis 
at the same level as fresh NCC. Similarly, cultures of osteoblasts (designated in Figure 
4.1A as OB) and OM with megakaryocytes (1 wk OB+MK and 1 wk OM+MK, respectively) 
were established. At the 1 wk time point, cultures were seeded with freshly sorted BoyJ-
derived (CD45.1) LSK cells. Cells were harvested 7 days later and assayed for CFU 
(Figure 4.1A). Consistent with previous findings, NCC maintained in culture for 1 wk (1 wk 
NCC) provided a significantly decreased level of hematopoiesis enhancing activity relative 
to fresh NCC. Megakaryocytes promoted the hematopoiesis enhancing activity of 1 wk 
NCC (1 wk NCC+MK) as evidenced by similar CFU counts compared to fresh NCC 
cultures. Interestingly, the megakaryocyte-enhanced activity was lost when OM were 
removed from NCC by cell sorting (1 wk OB+MK), suggesting that osteoblasts, OM, and 
megakaryocytes cooperate to promote hematopoietic progenitor and HSC function and 
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that megakaryocytes can delay or suppress osteoblast differentiation thus preserving their 
hematopoiesis enhancing potential. Data depicting the breakdown of the CFU subtypes 
based on lineage in these clonogenic assays are shown in Figure 4.1 B, C and D. The 
multi-lineage data suggests that crosstalk between OM, osteoblasts and megakaryocytes 
affect the CFU fold change at the granulocyte-monocyte level. 
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Figure 4.1 Effect of megakaryocytes on OM and osteoblast function. Neonatal OM and OB 
were co-cultured for 1 week in the absence (red bars) or presence (green bars) of MK. At the 
end of the week, additional control groups of fresh OM+OB and fresh NCC were plated. LSK 
cells were added to each of these groups and progenitor assays were performed on day 7 (14 
days total after the establishment of the first series of cultures). CFU fold change was 
determined relative to 250 fresh LSK cells. Multilineage analysis was performed to identify the 
distribution of GM (B), GEMM (C) and BFU-E (D) colonies. N=One of three independent 
experiments performed in triplicates. NOTE: Each graph has been set with a different scale on 
the y-axis. *p< 0.05 vs LSK, OM and OB, +p< 0.005 vs LSK+MK, OM+MK, OB+MK, #p< 0.05 
vs OM+OB, ^p< 0.05 vs MK, OM+MK, OM+OB; One Way Anova. 
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In vitro observations were validated in competitive repopulation assays (Mohamad, Xu et 
al. 2017). Culture conditions were maintained similar to the previous CFU experiment. 
LSK cells (CD45.2) from each culture condition along with competitor cells (CD45.1) were 
co-transplanted into lethally irradiated F1 mice (CD45.1/CD45.2). Kinetics of chimerism in 
primary recipients over a period of 4 months are shown in Figure 4.2. LSK cells maintained 
for 1 wk in NCC+MK cultures retained the highest level of repopulating activity relative to 
fresh LSK cells (Figure 4.2A) suggesting that megakaryocytes were able to relatively 
reverse the decline in the hematopoiesis enhancing activity of NCC cultured alone without 
megakaryocytes (1 wk NCC). Secondary transplantation data (Figure 4.2B) demonstrated 
again that 1 wk NCC cultured with megakaryocytes (1 wk NCC+MK) retained a robust 
hematopoiesis enhancing activity relative to LSK cells cultured with NCC maintained alone 
for 1 wk. Neither osteoblasts nor OM alone sustained the marrow repopulating potential 
of LSK cells suggesting that the previously documented hematopoiesis enhancing activity 
of NCC (Chitteti, Cheng et al. 2010) is synergistically mediated by osteoblasts and OM. 
Overall, these data establish the importance of crosstalk between OM, osteoblasts and 
megakaryocytes to form a novel network in supporting HSC function. 
  
108 
  
Figure 4.2 In vivo assays of cells maintained in vitro with NCC or sorted fractions of NCC. 
Progeny of 1000 LSK cells from C57BL/6 (CD45.2) mice, which were cocultured for 5 days with 
each group of cells identified in Figure 4.1A, were transplanted in a competitive repopulation 
assay with 100,000 BoyJ (CD45.1) cells via tail vein injection in lethally irradiated (split dose of 
650 and 350 cGy) CD45.1/CD45.2 F1 recipients. Freshly isolated LSK cells from BoyJ mice 
were used as control. (A) Chimerism in the BM of primary recipients at 4 months post 
transplantation. (B) At 4 months post–primary transplantation, halves of femurs from primary 
recipients were transplanted into lethally irradiated secondary recipients. Chimerism in 
secondary recipients at 3 months post transplantation is shown in (B). *p < 0.05 vs LSK group, 
+p < 0.05 vs 1w NCC+MK group, 1-way ANOVA (Mohamad, Xu et al. 2017) 
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4.3 Early stage megakaryocytes are functionally important for OM proliferation 
The evolution of megakaryocytes begins with a megakaryocyte progenitor which 
differentiates into a megakaryoblast (CD41-CD61+). These megakaryoblasts act as 
precursors for immature megakaryocytes (CD41+CD49d+) which then differentiate into 
mature megakaryocytes (CD41+CD49b+). Mature megakaryocytes are the cells that 
ultimately differentiate into platelets (Ciovacco, Cheng et al. 2010). Based on this process, 
the goal was to determine whether megakaryocytes at a particular stage of differentiation 
are responsible for OM proliferation. To do so, whole fraction megakaryocytes were flow 
sorted to isolate megakaryoblasts, immature megakaryocytes and mature 
megakaryocytes. Each of these three groups was then cultured with NCC in a 1:2 ratio. 
On day 6 of culture, cells were analyzed for OM expansion. As expected from earlier 
results (Figure 3.1), an increase in OM numbers and percentage was observed when NCC 
were cultured in the presence of unsorted megakaryocytes (Figure 4.3, top panel). The 
data consistently demonstrated that megakaryoblasts increase or maintain OM numbers 
in culture, whereas, OM numbers decline when cultured with mature megakaryocytes 
(Figure 4.3, bottom panel). These data indicate that most likely OM expand in numbers 
when cultured with immature megakaryocytes (megakaryoblasts and immature 
megakaryocytes). Furthermore, it suggests that mature megakaryocytes fail to sustain OM 
expansion. 
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Figure 4.3 Early stage megakaryocytes promote OM proliferation in vitro. (Top Panel) NCC 
were cultured for 6 days in the absence or presence of megakaryocytes (MK). (Bottom Panel) 
Megakaryocytes were sorted into CD61+CD41- megakaryoblasts, CD41+CD49d+ immature 
MK and CD41+CD49b+ mature MK. NCC were cultured for 6 days with each of these sub-
groups of MK. On day 6, cells were stained with CD45 and F4/80 to identify % increase in OM. 
N=3 
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4.4 Direct interactions between OM, osteoblasts and megakaryocytes are 
essential for maintaining hematopoiesis 
Next, to determine the importance of direct contact between OM, osteoblasts and 
megakaryocytes in maintaining OM proliferation, NCC were cultured in the absence or 
presence of megakaryocytes for 4-6 days. To eliminate contact between NCC and 
megakaryocytes, 1-micron transwell system was used to separate the two types of 
cultured cells. The small pore size of the transwell even prevented platelets which are a 
maximum of 2-3 microns in size (Krishnegowda and Rajashekaraiah 2015) from coming 
into direct contact with NCC. On analyzing the data, OM failed to expand in numbers when 
NCC were physically separated from megakaryocytes (Figure 4.4). This indicates that OM 
need to be in direct contact with megakaryocytes for them to increase in numbers.  
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Figure 4.4 Direct interaction is required for megakaryocytes to enhance OM numbers. 
NCC were cultured for 6 days in the absence or presence of megakaryocytes (MK). An 
additional culture condition was maintained wherein a 1-micron transwell was placed above 
NCC creating a barrier between NCC and MK. On day 6 of culture, cells were collected and 
stained for CD45 and F4/80 to identify % increase in OM. N=2 
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Furthermore, these studies were expanded to determine whether direct contact between 
the three cell types is essential to maintain hematopoiesis. Sorted OM and osteoblasts 
(labeled as OB in Figure 4.5) were reconstituted and cultured in the absence (OM+OB) or 
presence (OM+OB+MK) of megakaryocytes, with a 0.4-micron transwell placed above 
OM+OB cultures to prevent direct contact with megakaryocytes. The next day, cultures 
were seeded with freshly sorted LSK cells that were placed in the lower chamber in direct 
contact with OM+OB but not with megakaryocytes in the upper chamber. Cells were 
harvested 7 days later and assayed for CFU. As seen in Figure 4.5, in the absence of a 
transwell, OM+OB maintained hematopoietic enhancing activity; and this activity was 
augmented when megakaryocytes were added in culture. However, when a transwell 
membrane separated megakaryocytes from OM+OB, the latter failed to augment the CFU 
fold change beyond what was observed with OM+OB cultured in the absence of 
megakaryocytes. Interestingly, placing a transwell above OM+OB+MK cultures wherein 
all the cells were in direct contact (OM+OB+MK (T)), also caused a decline in CFU activity. 
These data suggest, that this decline in CFU fold change might be due to alterations in 
oxygen exchange and/or changes in cellular waste in the medium due to the placement 
of the membrane in the transwell system.  
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Figure 4.5 Direct interactions between OM, osteoblasts and megakaryocytes are 
important to maintain hematopoietic enhancing activity. Neonatal OM and osteoblasts (OB) 
were co-cultured for 1 day in the absence (red bars) or presence (green bars) of 
megakaryocytes (MK). In the groups labeled (T), a 0.4-micron transwell was added above the 
cultures. In the group labeled (T+MK), MK were added on the transwell separating them from 
OM and OB. LSK cells were added below the transwell to each of these groups and progenitor 
assays were performed on day 7. CFU fold change was determined relative to 250 fresh LSK 
cells. N=One of three independent experiments performed in triplicates. *p< 0.05 for 
OM+OB+MK vs all other groups, One Way Anova. 
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4.5 3D tissue cytometry helps define the spatial localization of OM, osteoblasts 
and megakaryocytes relative to HSC in the hematopoietic niche 
The previous data (Figure 4.4 and 4.5) indicate that direct contact is required between 
OM, osteoblasts and megakaryocytes to maintain hematopoiesis. Therefore, the next goal 
was to understand the spatial relationship of these three cell types with respect to HSC in 
the hematopoietic niche. The use of confocal microscopy allows for the collection of large 
3D datasets which preserve the spatial relationship between cells and allows for the 
quantitation of various cell types within this spatially conserved intact tissue. This process 
is referred to as 3D tissue cytometry. It has been successfully developed and used in the 
field of immunology, for example, to measure distances between various immune cells in 
intact kidney tissue (Winfree, Khan et al. 2017) and recently in the bone marrow (Coutu, 
Kokkaliaris et al. 2017). Therefore, 3D tissue cytometry was performed to understand the 
spatial location of HSC, OM, osteoblasts and megakaryocytes in the hematopoietic niche. 
Fgd5 reporter mice were used to identify GFP+ HSC and GFP+ vasculature. 
Cells were stained with anti-F4/80 antibody to identify macrophages in the bone marrow. 
Based on the anatomic location of F4/80+ macrophages, OM were identified as F4/80+ 
macrophages located at or near the endosteum (maximum of 2-3 cells away); whereas, 
BM Mφ were F4/80+ macrophages located towards the center of the marrow away from 
the endosteum. Megakaryocytes were stained with an anti-CD41+ antibody. However, the 
CD41 antibody was conjugated to the AF405 fluorophore which was detected in the same 
channel as DAPI (a nuclear stain). A nuclear stain is always required in the 3D cytometry 
setting to identify all the cells observed in a given field of observation. Hence 
megakaryocytes were recognized partly based on their CD41 staining; and partly on their 
unique multi-lobulated nucleus which was easily identifiable. Finally, a 2 photon 
microscope was used to image the bone and ultimately identify osteoblasts. 
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As expected, majority of GFP+ HSC were located within the growth plate (Ellis, Grassinger 
et al. 2011). Interestingly, in the epiphysis as well as the diaphysis, multiple fields were 
observed wherein all four cell types were in close proximity to each other. Representative 
images are shown in Figure 4.6 B and C. Also, a mosaic encompassing the entire 25 
micron section of the femur was captured (Figure 4.6A). Ongoing studies using the 
mosaic, involve determining the number of HSC, OM, osteoblasts and megakaryocytes 
within the whole volume of the unperturbed bone marrow; and using those data to 
compare the relative number and location of cells in a stressed or aged bone marrow. 
Altogether, these initial data suggest intimate spatial interactions between HSC, OM, 
osteoblasts and megakaryocytes in the unperturbed bone marrow. 
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Figure 4.6 Use of 3D cytometry to determine localization of hematopoietic niche 
residents. 25-micron sections of Fgd5 mice were used to stain for 3D tissue cytometry. HSC 
(yellow arrow) were GFP+, OM (red arrow) and BM Mφ (white arrow) were F4/80+ (AF647), 
megakaryocytes (purple arrow) were multi-lobulated and CD41+ (AF405). Osteoblasts (blue 
arrow) were imaged using the second harmonic signal (SHG). (A) Mosaic of the entire femur. 
(B) (C) 3D z-stack images of 25-micron sections. 
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4.6 Discussion 
In this chapter, the importance of megakaryocytes in the hematopoietic niche was 
demonstrated. To begin with, the spatial localization of HSC, OM, osteoblasts and 
megakaryocytes was identified. HSC are known to localize adjacent to megakaryocytes 
in a non-random fashion (Heazlewood, Neaves et al. 2013). Also, HSC have the tendency 
to migrate to the endosteum to retain their quiescence (Nilsson, Johnston et al. 2001, 
Zhang, Niu et al. 2003, Xie, Yin et al. 2009). Previous studies illustrating HSC localization 
have always been focused on its location near the endosteum or the vasculature (Aiuti, 
Webb et al. 1997, Nilsson, Johnston et al. 2001, Zhang, Niu et al. 2003, Kiel, Yilmaz et al. 
2005, Sugiyama, Kohara et al. 2006, Xie, Yin et al. 2009, Kunisaki, Bruns et al. 2013, 
Nombela-Arrieta, Pivarnik et al. 2013). The 3D tissue cytometry data in Figure 4.6 support 
these concepts, and furthermore provide additional information regarding the proximity of 
OM relative to the cell types mentioned above. Through ongoing studies, it was observed 
that HSC, OM, osteoblasts and megakaryocytes tend to co-localize in close proximity 
within the hematopoietic niche (Figure 4.6). However, these studies are at early stages. 
One of the technical difficulties in these studies include getting sections with bone marrow 
intact and attached to bone. This is because bone marrow easily sloughs off, giving 
cracked sections. Also, the current sections are only 25 microns in width. To truly 
understand the complexity of the niche, imaging whole femurs will be necessary. 
Furthermore, an additional technical problem to overcome is due to autofluorescence of 
bone. To overcome this obstacle, clearing the bone will be required to better visualize 
bone marrow architecture; a concept recently developed for other tissues (Li, Germain et 
al. 2017). Though these studies are incomplete, future studies will establish relative 
numbers of these four cell types in whole unperturbed bone marrow. The use of 3D 
technology to establish such correlations between cells has previously been developed at 
Indiana University (Winfree, Khan et al. 2017). Once complete, the changes in localization 
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that occur within a stressed hematopoietic niche will be determined. It is well established 
that age stresses the hematopoietic niche and slows down hematopoiesis (Rossi, Bryder 
et al. 2005, Janzen, Forkert et al. 2006, Gekas and Graf 2013). It will be interesting to 
determine whether changes in localization, occur with age correlating to loss in 
hematopoietic function. 
However, HSC are dynamic in nature. Hence, the close proximity of HSC to OM, 
osteoblasts and megakaryocytes is not sufficient to suggest functional correlation. To that 
end, in vitro and in vivo data was established to determine the importance of crosstalk 
between OM, osteoblasts and megakaryocytes in maintaining hematopoietic function. 
These data demonstrate that OM and osteoblasts enhance hematopoietic activity, and 
megakaryocytes further augment this function (Figure 3.9A). Since immature osteoblasts 
best support hematopoietic enhancing activity (Chitteti, Cheng et al. 2010, Cheng, Chitteti 
et al. 2011, Chitteti, Cheng et al. 2013), this suggests the possibility that megakaryocytes 
might be suppressing osteoblast differentiation to maintain hematopoiesis. This is 
supported by the data in Figure 4.1 and 4.2, which show that fresh NCC, which consist of 
immature osteoblasts, maintain hematopoiesis similar to NCC cultured in the presence of 
megakaryocytes. Furthermore, megakaryocytes might also be supporting hematopoiesis 
through pathways involving OM. Since megakaryocytes increase OM numbers in NCC 
cultures, there is a possibility that they may also regulate expression of certain molecules 
on OM which in turn maintain hematopoietic function. This topic will be covered in more 
detail in the next chapter. 
The next important question that was addressed was whether direct interactions are 
required between HSC, OM, osteoblasts and megakaryocytes or whether 
megakaryocytes might be working in a paracrine fashion to release cytokines or growth 
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factors that help OM and osteoblasts maintain hematopoiesis. Previous studies have 
demonstrated that megakaryocytes release growth factors such as FGF2 and PDGF-β to 
increase osteoblast proliferation post hematopoietic stress (Dominici, Rasini et al. 2009, 
Olson, Caselli et al. 2013). Also, previous reports have demonstrated that megakaryocytes 
themselves release several cytokines which directly regulate HSC pool size and 
quiescence (Heazlewood, Neaves et al. 2013, Bruns, Lucas et al. 2014, Nakamura-Ishizu, 
Takubo et al. 2014, Zhao, Perry et al. 2014). Therefore, it is important to understand 
whether megakaryocytes require direct physical contact with OM and OB to mediate 
hematopoietic function. The studies in Figure 4.4 illustrate, that OM also require physical 
contact with megakaryocytes to increase their proliferation. The observed increase in OM 
numbers was more robust when it was induced by megakaryocytes that are at early stages 
of differentiation (Figure 4.3). Furthermore, direct contact is also essential for 
megakaryocytes to augment OM and osteoblast mediated hematopoiesis (Figure 4.5). 
This is different from previous reports that demonstrate the importance of megakaryocyte 
secreted cytokines in direct regulation of HSC pool size and quiescence (Heazlewood, 
Neaves et al. 2013, Bruns, Lucas et al. 2014, Nakamura-Ishizu, Takubo et al. 2014, Zhao, 
Perry et al. 2014). This difference could be due to the different experimental procedures 
employed by different laboratories. For example, the report described by Dominici et al., 
is based on the migration of megakaryocytes to the endosteum post radioablation and the 
release of growth factors that catalyze osteoblast proliferation (Dominici, Rasini et al. 
2009, Olson, Caselli et al. 2013). Since the megakaryocytes release the growth factors 
only after migrating to the endosteum, there is a possibility that direct contact between 
osteoblasts and megakaryocytes is necessary for the regulation of osteoblast proliferation. 
Also, Bruns et al., demonstrated the role of megakaryocytes in regulating HSC quiescence 
through CXCL4 secretion (Bruns, Lucas et al. 2014). They used two main pieces of data 
to verify this hypothesis. The first was depletion of megakaryocytes which resulted in loss 
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of HSC function. This fits with the data in Figure 4.1 and 4.2 where it was demonstrated 
that maximal hematopoietic enhancing activity is achieved only in the presence of 
megakaryocytes which interact with OM and osteoblasts. The second result was that 
megakaryocytes secrete CXCL4 and that CXCL4-/- mice exhibit decreased HSC 
quiescence. The catalyst which activates the megakaryocyte secretion of CXCL4 is still 
unknown. Therefore, the possibility remains that direct interactions between OM, 
osteoblasts and megakaryocytes may be required to induce the secretion of CXCL4 by 
megakaryocytes. 
Studies in this chapter demonstrate the importance of direct interactions between OM, 
osteoblasts and megakaryocytes to mediate hematopoietic function and maintain the 
competence of the hematopoietic niche. These findings help establish correlations 
between hematopoietic function and the close proximity of these cell types. These data 
suggest that hematopoiesis is best maintained when the four cell types interact as shown 
in Figure 4.7. It is postulated that as these cells ‘age’ or are compromised upon stress, 
their interactions are disrupted, and HSC begin to lose function leading to a compromised 
niche (Figure 4.7). Further detailed analyses are required to molecularly define how these 
cell types interact together.  
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Figure 4.7 Model depicting functional interaction between OM, osteoblasts and 
megakaryocytes. Crosstalk between OM, osteoblasts and megakaryocytes are essential to 
maintain maximal hematopoietic function (left). Disruption in the functional interaction between 
these three cell types leads to a compromised hematopoietic niche (right). 
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CHAPTER FIVE: CD166 and embigin are molecular mediators through 
which OM maintain hematopoietic function 
 
 
5.1 Introduction 
Networking between HSC and cells of the hematopoietic niche is important to maintain 
hematopoiesis. Amongst the cell groups of the niche involved in this process are a group 
of bone-resident macrophages known as osteomacs (OM). Previously, it was 
demonstrated that OM and osteoblasts contained within NCC are critical to maintain 
hematopoietic function (Chitteti, Cheng et al. 2010, Mohamad, Xu et al. 2017). 
Additionally, interactions between NCC and megakaryocytes further enhance this 
hematopoietic activity (Figure 4.1, 4.2). However, the molecular pathways through which 
this crosstalk occurs and in turn enhances hematopoietic activity are still unknown. 
CD166 (ALCAM-Activated Leukocyte Cell Adhesion Molecule) is a transmembrane 
glycoprotein belonging to the immunoglobulin superfamily (Lehmann, Riethmuller et al. 
1989). It is capable of mediating both CD166-CD166 homophilic interactions as well as 
heterophilic interactions with CD6 (Degen, van Kempen et al. 1998). Recently, CD85k has 
been identified as a ligand which binds to CD166 and in turn blocks tumor growth in 
CD166+ tumor cell lines (Xu, Chang et al. 2018). In hematopoiesis, CD166 is an important 
functional marker of HSC and is critical for the competence of the niche (Chitteti, Cheng 
et al. 2010, Chitteti, Bethel et al. 2013, Chitteti, Cheng et al. 2013, Chitteti, Kobayashi et 
al. 2014). Previous work in my laboratory demonstrated that CD166 expression on 
osteoblasts is inversely proportional to their maturity (Chitteti, Cheng et al. 2010, Chitteti, 
Cheng et al. 2013). Immature osteoblasts expressing higher CD166 maintain maximum 
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hematopoietic enhancing activity compared to differentiated osteoblasts expressing lower 
CD166. Furthermore, CD166 through a mechanism likely involving STAT3 activation, 
plays an important role in homing and recovery from hematopoietic stress (Chitteti, 
Kobayashi et al. 2014). Besides HSC and osteoblasts, CD166 is also expressed on 
several other niche residents such as mesenchymal stem cells, endothelial cells and OM 
(Chitteti, Bethel et al. 2013, Mohamad, Xu et al. 2017). 
Expression of embigin on hematopoietic cells such as bone marrow progenitors, T cells, 
B cells and several myeloid cells has been previously reported (Pridans, Holmes et al. 
2008). Embigin, which is a transmembrane glycoprotein belonging to the immunoglobulin 
superfamily (Huang, Ozawa et al. 1990, Huang, Ozawa et al. 1993) is an ion transporter 
essential for the exchange of protons during anaerobic expression in neurons (Wilson, 
Kraus et al. 2013). Recently, it was reported that blocking embigin in the hematopoietic 
niche resulted in loss of quiescence with a corresponding increase in the frequency of LT-
HSCs, ST-HSCs, as well as MPPs (Silberstein, Goncalves et al. 2016). Embigin, being a 
cell adhesion molecule (Huang, Ozawa et al. 1993), even caused a loss in HSPC 
localization (Silberstein, Goncalves et al. 2016). However, the cellular elements in the 
niche responsible for this hematopoietic function are still unknown. 
In this chapter, it is demonstrated that crosstalk between OM, osteoblasts and 
megakaryocytes is required for the upregulation of CD166 and embigin expression on OM. 
Once activated, these molecular mediators are partially responsible for OM arbitrated 
maintenance of hematopoietic function. Moreover, recombinant CD166 and embigin can 
be used to partially substitute for OM activity in vitro. Together, the data once again 
demonstrate the importance of CD166 for the hematopoietic niche; and introduce embigin 
expression on OM as a regulator of hematopoietic function. 
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5.2 Single cell mRNA sequencing identified several targets through which OM 
potentially maintain hematopoietic function 
Single cell mRNA sequencing was performed to identify the molecular pathways through 
which OM interact with osteoblasts and megakaryocytes to maintain hematopoietic 
function. These single cells studies are highly beneficial over bulk genomics wherein 
quantification of target genes is averaged; and heterogeneity within populations is left 
unaccounted. Briefly, 100,000 NCC which consist of OM (~5%) and osteoblasts were 
cultured for 16 hrs in the absence or presence of 50,000 megakaryocytes. OM from these 
groups were sorted at the end of the 16 hrs incubation and subjected to single cell mRNA 
sequencing. Depending on the group from which the OM were sorted, data in the figures 
have been labeled as NCC or NCC+MK. From each group, 24 cells were sequenced and 
analyzed. 21 OM from NCC and 24 OM from NCC+MK passed quality check and were 
used for differentially expressed gene analysis. Comparisons identified 1008 genes as 
significantly expressed between the two groups. Multidimensional scaling (MDS) plot of 
top-2 principal components (PCs) of significantly expressed genes suggest a difference 
between OM obtained from NCC and NCC+MK (Figure 5.1A). Next, a heat map was 
plotted to identify target genes potentially implicated in the hematopoiesis enhancing 
activity of OM (NCC+MK) (Figure 5.1B). A total of 299 genes were upregulated in OM 
obtained from NCC+MK compared to those obtained from NCC, whereas, 709 genes were 
downregulated. Of note, embigin and PF-4, both of which have been implicated in 
hematopoiesis (Bruns, Lucas et al. 2014, Silberstein, Goncalves et al. 2016), were 
upregulated when OM were cultured with megakaryocytes. Lmo-2, Fli-1 and Ikzf-1 which 
are part of the HSC differentiation pathway (Zhu, Traver et al. 2005, Ferreiros-Vidal, 
Carroll et al. 2013, Malinge, Thiollier et al. 2013, Smeets, Chan et al. 2013, Pimkin, 
Kossenkov et al. 2014) were also upregulated. Single cell mRNA sequencing results were 
validated via qPCR (Figure 5.1C). These single cell genomics data demonstrate the 
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upregulation of genes such as embigin, PF-4, Fli-1, Lmo-2 and Ikzf-1 when OM contained 
within NCC were cultured in the presence of megakaryocytes. These targets could act as 
molecular mediators through which OM maintain HSC function. 
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Figure 5.1 Single cell mRNA sequencing of OM sorted from NCC and NCC+MK. Neonatal 
calvarial cells (NCC) were cultured for 16 hrs in the absence (NCC) or presence of 
megakaryocytes (NCC+MK). OM were sorted from these two groups and then subjected to 
single cell capture. From each NCC and NCC+MK 24 OM underwent single cell mRNA 
sequencing. (A) PCA plot and (B) heat map of the differentially expressed genes in OM obtained 
from NCC and NCC+MK. (C) qPCR of target genes to validate single cell mRNA sequencing. 
N=3; p>0.05, One Way Anova. 
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5.3 Quantitative comparison of protein levels using TMT based peptide labeling 
and LC-MS/MS 
To determine whether target genes which were identified via mRNA sequencing were also 
differentially expressed at the translational level, the focus was shifted to proteomics. 
Overnight cultures were established with NCC in the absence or presence of 
megakaryocytes. Next, both these groups were seeded with LSK cells and cultured for an 
additional two days after which OM contained within both NCC and NCC+MK were sorted 
using flow cytometry. Additionally, OM from fresh NCC were sorted as a control. OM from 
these three groups were labeled with TMTs and analyzed by mass spectrometry (LC-
MS/MS). A total of 1548 proteins were identified of which 1359 proteins were quantified. 
The list of proteins which were upregulated and downregulated in OM contained within 
NCC+MK in comparison to OM contained within NCC is provided in Table 5.1 and 5.2 
respectively. One of the top targets which was significantly upregulated in OM contained 
within NCC+MK was embigin. As can be seen in the volcano plots in Figure 5.2A embigin 
(highlighted black dot) was upregulated in OM contained within NCC+MK compared to 
both OM contained within cultured NCC, as well as fresh NCC (middle and right plot in 
Figure 5.2A). Also, there was no difference in the expression levels of embigin between 
OM contained within cultured NCC and fresh NCC (left plot). Thus, embigin, a protein 
which has previously been implicated in hematopoiesis (Silberstein, Goncalves et al. 
2016), was upregulated due to crosstalk between OM, osteoblasts and megakaryocytes 
both at the transcriptional and translational level (Figure 5.1 and 5.2). None of the other 
targets which were more abundant or had a higher p-value than embigin had been 
previously implicated in hematopoiesis.  
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Table 5.1 List of proteins upregulated in NCC+MK in comparison to NCC. 
Description 
Abundance 
Ratio 
(log2) 
Abundance 
Ratio -log10 
P-Value 
Solute carrier family 2, facilitated glucose transporter 
member 3 1.070 3.100 
MCG130182, isoform CRA 1.190 3.015 
Arginase-1 1.060 3.013 
Protein S100-A4 1.010 3.010 
Stefin-1 0.960 2.947 
Protein FAM162A 1.480 2.772 
Embigin 1.580 2.686 
Ribosomal protein 1.120 2.538 
Protein S100-A11 1.230 2.536 
Alpha-enolase 0.870 2.513 
Histone H1.1 1.130 2.342 
Histone H1.3 0.990 2.249 
Histone H1.4 0.880 2.239 
Myosin regulatory light chain 12B 1.440 2.233 
Myosin light polypeptide 6 1.100 2.228 
Glyceraldehyde-3-phosphate dehydrogenase 0.880 2.165 
Non-histone chromosomal protein HMG-17 (Fragment) 2.220 2.156 
Protein S100-A9 0.960 2.068 
Succinate dehydrogenase assembly factor 2, 
mitochondrial 1.210 1.990 
Golgi-associated plant pathogenesis-related protein 1 0.970 1.972 
Chromobox protein homolog 3 1.000 1.837 
Myosin-9 0.920 1.807 
Histone H1.5 1.580 1.629 
High mobility group protein HMG-I/HMG-Y 2.210 1.620 
Cytochrome b-245 heavy chain 1.380 1.591 
Mast cell-expressed membrane protein 1 0.910 1.544 
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Description 
Abundance 
Ratio 
(log2) 
Abundance 
Ratio -log10 
P-Value 
Histone H4 0.880 1.543 
High mobility group protein B2 1.200 1.476 
Cytochrome c oxidase subunit 7A2, mitochondrial 0.840 1.473 
Three-prime repair exonuclease 1 1.320 1.408 
Bridging integrator 2 0.830 1.368 
Lysophosphatidylcholine acyltransferase 2 0.930 1.318 
 
Table 5.2 List of proteins downregulated in NCC+MK in comparison to NCC. 
Description 
Abundance 
Ratio (log2) 
Abundance 
Ratio -log10 
P-Value 
Platelet glycoprotein 4 -1.760 3.865 
Protein Ahnak2 (Fragment) -1.080 3.142 
Myelin protein P0 -0.880 3.045 
Fatty acid-binding protein, adipocyte -0.870 2.767 
Switch-associated protein 70 -1.160 2.622 
Peroxiredoxin-1 -0.990 2.319 
Fatty acid-binding protein, epidermal -0.940 2.220 
Translin-associated factor X-interacting protein 1 -1.360 2.189 
Gamma-enolase -2.300 2.143 
Low affinity immunoglobulin gamma Fc receptor III -0.910 2.132 
Synaptic vesicle membrane protein VAT-1 homolog -1.000 2.039 
Protein ATP1B4 -0.930 2.003 
Heat shock 70 kDa protein 1B -0.940 1.985 
Thioredoxin domain-containing protein 12 -0.900 1.805 
Serpin H1 -1.230 1.429 
Macrosialin -1.050 1.392 
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Figure 5.2 Quantitative analysis of OM protein levels using LC-MS/MS. NCC were co-
cultured overnight in the absence (NCC) or presence (NCC+MK) of megakaryocytes. Each 
group was then seeded with LSK cells for 2 days followed by OM isolation through flow 
cytometry. OM from fresh NCC were sorted as a control. OM from each group were subjected 
to TMT based peptide labeling and LC-MS/MS. A total of 1548 proteins were identified, of which 
1359 proteins were quantified. (A) Volcano plots comparing the protein expression of OM 
contained within NCC and fresh NCC (left), NCC+MK and fresh NCC (middle), and NCC+MK 
and NCC (right). The highlighted dot (black arrow) is the expression level of embigin in all three 
plots. The orange horizontal line is the p-value cut-off which was set at 0.05. (B) Average 
grouped abundance of embigin which was upregulated in OM contained within NCC+MK 
compared to the other two groups. Statistical accuracy was estimated using standard error. 
N=3-4. 
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5.4 Single cell CyTOF analysis identified CD166 and embigin as potential 
mediators through which OM maintain hematopoietic function 
The LC-MS/MS data were unable to identify all the target genes that were detected 
through single cell-mRNA sequencing. Hence, single cell CyTOF was performed to 
validate the mRNA sequencing data. A panel of 17 surface and 13 intracellular antibodies 
was designed based on the sequencing data in Figure 5.1, as well as based on 
hypothetical molecular mediators through which OM might maintain hematopoietic 
function. The complete list of antibodies is provided in Table 2.2. Briefly, NCC were 
cultured for 2 days in the absence or presence of megakaryocytes; after which cells were 
stained and analyzed for CyTOF. It was hypothesized that 48 hrs of culture is long enough 
for protein expression on these cells but most likely not long enough for expression to 
wane and become undetectable by immunostaining. To maintain conditions similar to 
single cell mRNA sequencing, LSK cells were not included in culture. Also, CyTOF allows 
limited number of sample collection per day. Adding LSK cells in culture would vastly 
reduce the relative number of OM that could be collected and analyzed. 
Both groups were first gated on CD45 and F4/80 to identify OM contained within NCC and 
NCC+MK. After this initial gating, OM from both groups were analyzed in a couple of 
different ways. ViSNE plots were generated to convert the high dimensional data into 
simple 2-D plots (Figure 5.3C). Also, a FlowSOM analysis was performed on these ViSNE 
plots to determine unbiased phenotypic heterogeneity between OM contained within both 
groups. As can be seen in Figure 5.3A, 8 metaclusters were observed within OM contained 
in NCC and 4 metaclusters were observed within OM contained in NCC+MK. 2 
metaclusters (Metaclusters 2 and 3) overlapped between the two groups. Each of the 
metaclusters were characterized using the 17 surface antibodies. Interestingly, CD166 
and embigin (designated as Emb in Figure 5.3A) which were upregulated in OM contained 
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within NCC+MK (Figure 5.3C) were found within metacluster 1, 2 and 5. Of these three 
clusters, metacluster 1 was unique as it expressed the highest level of embigin and CD166 
antigens and was absent in OM contained within NCC. 
Heat maps and ViSNE plots were generated to analyze differential protein expression 
between the two groups (Figure 5.2B and C). Several surface proteins such as Mac-2 and 
CD14 were upregulated on OM within NCC+MK as compared to OM within NCC. CD166, 
an important functional marker of the hematopoietic niche (Chitteti, Cheng et al. 2010, 
Cheng, Chitteti et al. 2011, Chitteti, Bethel et al. 2013, Chitteti, Cheng et al. 2013, Chitteti, 
Kobayashi et al. 2014) was upregulated when OM were cultured with megakaryocytes. 
Interestingly, out of the five target genes identified in the single cell mRNA sequencing 
data (embigin, PF-4, Lmo-2, Fli-1 and Ikzf1), only embigin was upregulated on OM due to 
crosstalk between NCC and megakaryocytes. Lmo-2 and Fli-1 remain unchanged 
between the two groups; whereas PF-4 and Ikzf1 were downregulated in OM contained 
within NCC+MK (Figure 5.3B and C). Combined, the single cell genomics and proteomics 
data suggest that CD166 and embigin which are upregulated on OM due to crosstalk 
between NCC and megakaryocytes; might act as potential mediators through which OM 
maintain hematopoietic function. Also, both these groups were highest in expression in 
metacluster 1, indicating the possibility that the highest functionality of OM might be 
contained within this population.  
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  Figure 5.3 Multidimensional CyTOF analysis of OM contained within NCC cultured in the 
absence and presence of megakaryocytes. Single cell suspensions of NCC were cultured 
for 2 days in the absence or presence of megakaryocytes (MK) and then analyzed using a panel 
of 30 surface and intracellular antibodies. Data were gated on CD45+F4/80+ cells to indicate 
OM in NCC and NCC+MK. (A) Representation of the heterogeneity observed within 
subpopulations of OM from NCC and NCC+MK. Each subpopulation has been characterized 
depending on their expression of 17 surface markers. (B) Heat maps and (C) ViSNE plots 
indicating individual differences between OM obtained from NCC and NCC+MK. N=3. 
140 
5.5 Characterization of OM as potential osteolineage cells proximal to HSC 
Recently, in a publication by Silberstein et. al., it was demonstrated that osteolineage cells 
proximal to HSPC (maximum of two cell diameters away) had increased mRNA 
expression of embigin, angiogenin and IL-18 compared to distal osteolineage cells 
(maximum of five cell diameters away) (Silberstein, Goncalves et al. 2016). Additionally, 
each of these three genes were shown to have an important role in maintaining 
hematopoiesis. These proximal osteolineage cells were defined as runx2+, osterix+, 
col1a+, osteopontinlow and osteocalcinlow when compared to distal osteolineage cells. A 
summary of the characterization of these proximal osteolineage cells is given in Figure 
5.4A. Based on these studies, the next focus was to determine whether OM are similarly 
characterized as proximal osteolineage cells defined by Silberstein et. al and understand 
whether embigin, IL-18 and/or angiogenin were the molecular mediators through which 
OM maintained hematopoiesis. 
To characterize OM, the mRNA gene expression profile of runx2, osterix, collagen 1a, 
osteopontin and osteocalcin was analyzed. As seen in Figure 5.4B, OM but not 
osteoblasts possessed an mRNA gene expression profile similar to proximal osteolineage 
cells (Silberstein, Goncalves et al. 2016). Flow cytometry and CyTOF analysis 
demonstrated that OM express high levels of VCAM-1 and SDF-1 further increasing the 
similarities between proximal osteolineage cells and OM (Figure 5.4 C and D). Since it 
was concluded that proximal osteolineage cells express higher levels of embigin, IL-18 
and angiogenin mRNA, the mRNA levels of these genes between OM and osteoblasts 
was quantified. As seen in Figure 5.4E, OM also expressed higher mRNA levels of 
embigin, IL-18 and angiogenin compared to osteoblasts. Moreover, it was already 
demonstrated in Figure 5.3C that embigin protein expression is upregulated on OM due 
to crosstalk between OM, osteoblasts and megakaryocytes. IL-18 expression was present 
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on OM, but downregulated (Figure 5.3B); whereas, angiogenin was not included in the 
CyTOF panel. 
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Figure 5.4 Characterization of OM in relation to proximal osteolineage cells. (A) Summary 
illustrating side by side comparison of proximal osteolineage cells (POC) and OM. (B) OM and 
osteoblasts (OB) were sorted from fresh NCC followed by qPCR quantitation of runx2, osterix, 
col1a, osteopontin, osteocalcin, N=3. (C) Flow cytometric analysis of VCAM-1 expression on 
OM (CD45+F4/80+) contained within NCC. N=3. (D) CyTOF analysis shown in Figure 3.5B. 
ViSNE plot for SDF-1 expression on NCC gated on CD45+F4/80+ OM. (E) qPCR quantitation 
of embigin, angiogenin and IL-18 on OM and OB, N=3. 
143 
5.6 Recombinant CD166 and embigin partially substitute OM mediated 
hematopoietic function 
Colony forming assays were performed to determine whether recombinant CD166 and 
embigin could substitute for OM activity in vitro. Briefly, rCD166 and recombinant embigin 
(rEmb) were coated onto tissue culture plates. These coated plates were then used to 
culture osteoblasts (sorted from NCC and labeled as OB in Figure 5.5) in the absence or 
presence of megakaryocytes. BSA coated plates were used to set up cultures as one set 
of controls. OM were also cultured with osteoblasts in the absence or presence of 
megakaryocytes on non-coated tissue culture plates as a second set of controls. After one 
day of culture, LSK cells were seeded onto each of these groups. 7 days post LSK culture, 
a colony forming assay was set up to determine CFU fold change of cultured LSK progeny 
relative to 250 fresh LSK cells. No difference was observed in CFU fold change between 
OM+OB, rCD166+OB, rEmb+OB and rCD166+rEmb+OB (highlighted in the purple 
rectangle) indicating that rCD166 and rEmb could partially substitute for OM-mediated 
hematopoietic activity in vitro (Figure 5.5A). As expected, all four groups were significantly 
upregulated compared to osteoblasts cultured on BSA coated plates. In every experiment 
that was performed (N=3), the same non-significant trend was observed wherein 
rCD166+rEmb+OB was slightly upregulated compared to rCD166+OB and rEmb+OB 
suggesting that the combination of recombinant proteins might have an additive effect on 
hematopoiesis as compared to each individual protein alone. Of note, a further increase 
in the CFU fold change of these groups was expected when cultured in the presence of 
megakaryocytes. However, addition of megakaryocytes to these cultures did not further 
augment CFU fold change suggesting that the levels of endogenous factors added to the 
cultures may have exceeded the physiologic increase in those factors induced by 
megakaryocytes. Data depicting the breakdown of the CFU subtypes in these cultures are 
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shown in Figure 5.5 B, C and D. Overall, the data demonstrate that CD166 and embigin 
partially substitute for OM-mediated hematopoietic activity in vitro. 
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Figure 5.5 CD166 and embigin are potential mediators through which OM maintain 
hematopoietic function. Recombinant CD166 and embigin (as a substitute for OM) were 
coated on tissue culture plates. These plates were used to culture osteoblasts (OB) sorted from 
NCC in the absence (red bars) or presence (green bars) of megakaryocytes (MK). LSK cells 
were cultured for one week with each of these groups. CFU assays were set up to determine 
CFU fold change of cultured LSK progeny relative to 250 fresh LSK cells. Multilineage analysis 
was performed to identify the distribution of (B) GM, (C) GEMM and (D) BFU-E colonies. One 
of three independent experiments performed in triplicates. *p<0.05, ^p<0.05 vs OM+OB, 
rCD166+OB, rEmb+OB and rCD166+rEmb+OB, #p<0.05 vs OM+OB, BSA+OB+MK, 
rCD166+OB+MK, rEmb+OB+MK, rCD166+rEmb+OB+MK, One Way Anova. 
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5.7 CD166 as a molecular mediator through which OM maintain the 
hematopoietic function of osteoblasts 
Since recombinant CD166 could partially substitute for OM activity in vitro, the next goal 
was to validate these results and determine whether the CD166+ fraction of OM was 
functionally more relevant than the CD166- fraction. To do this, OM processed from NCC 
were flow sorted into CD166+ and CD166- fractions. These fractions were individually 
cultured with osteoblasts (cultures labeled as CD166+OM +OB and CD166-OM +OB in 
Figure 5.6) also obtained from NCC. The cultures were maintained overnight and the next 
day were seeded with LSK cells. 7 days post LSK culture, a colony forming assay was set 
up to determine CFU fold change of cultured LSK progeny relative to 250 fresh LSK cells. 
The data demonstrated that the CFU fold change of CD166+OM +OB was statistically not 
significant compared to OM+OB (Figure 5.6). Interestingly, CD166-OM +OB had a 
significantly lower CFU fold change compared to the two groups mentioned above. This 
indicates that the CD166+ fraction of OM is functionally important to mediate 
hematopoiesis. 
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Figure 5.6 The CD166+ fraction of OM mediates the hematopoietic enhancing activity of 
osteoblasts. NCC were first fractionated into CD166+OM, CD166-OM and osteoblasts (OB). 
These CD166+ and CD166- OM were plated with OB and subsequently seeded with LSK for 7 
days. CFU assays were set up to determine CFU fold change of cultured LSK progeny relative 
to 250 fresh LSKs. One of three independent experiments performed in triplicates, *p<0.05 vs 
all controls besides CD166+OM +OB. One Way Anova. 
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Subsequently, CD166 knockout mice were utilized to better understand whether CD166 
null OM support hematopoiesis. CD166 knockout OM (labeled as KO OM in Figure 5.7) 
or wild type OM (labeled as OM in Figure 5.7) were cultured with osteoblasts in the 
absence or presence of megakaryocytes. KO OM were collected from CD166 knockout 
NCC, whereas OM and osteoblasts were collected from wild type NCC. Megakaryocytes 
were obtained from fetal liver of wild type mice. Similar number of wild type and knockout 
OM were used to set up these cultures. 7 days post culture, flow cytometry was used to 
analyze cells for proliferation. As expected, wild type OM increased in numbers when 
cultured in the presence of osteoblasts and megakaryocytes (Figure 5.7A). Interestingly, 
CD166 KO OM also increased in numbers when cultured in the presence of osteoblasts 
and megakaryocytes indicating that presence of CD166 is not important for OM 
proliferation. 
Next, colony forming assays were performed using CD166 knockout OM. Overnight 
cultures were set up using wild type or knockout OM along with wild type osteoblasts in 
the absence or presence of wild type megakaryocytes. 24 hrs later, LSK cells from wild 
type mice were added to all culture groups. 7 days post LSK culture, colony forming 
assays were set up to determine CFU fold change. As expected, an increased CFU fold 
change was observed when LSK cells were cultured with wild type OM and osteoblasts, 
which was further augmented with the addition of megakaryocytes (Figure 5.7B). 
However, CD166 knockout OM were unable to mediate the same hematopoiesis 
enhancing activity regardless of whether megakaryocytes were present in the co-culture 
or not. Data depicting the breakdown of the CFU subtypes in these cultures are shown in 
Figure 5.7 C, D and E. Overall, the data demonstrate that the absence of CD166 does not 
affect OM proliferation, but it does affect OM-mediated hematopoietic enhancing activity 
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suggesting that OM proliferation is disconnected from their ability to augment 
hematopoiesis.  
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Figure 5.7 CD166 is one of the molecular mediators through which OM maintain 
hematopoietic function of osteoblasts. Co-cultures of NCC-derived osteoblasts (OB) mixed 
with either the original number of OM contained in freshly isolated NCC (OM+OB) or a 
complimentary number (equivalent to the original number of OM in NCC) of CD166 knockout 
OM (KO OM +OB) were established in the absence (red bars) or presence (green bars) of 
megakaryocytes (MK). (A) Flow cytometry at D7 of culture. (B) Overnight cultures were seeded 
with LSK cells and further cultured for one week with each of the groups mentioned above. 
CFU assays were set up to determine CFU fold change of cultured LSK progeny relative to 
250 fresh LSKs. Multilineage analysis was performed to identify the distribution of (C) GM, (D) 
GEMM and (E) BFU-E colonies. One of three independent experiments performed in 
triplicates. *p<0.05 vs controls without megakaryocytes, ^p<0.05 vs controls with 
megakaryocytes, #p<0.05; One-way Anova. 
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5.8 Embigin as a molecular mediator through which OM maintain hematopoietic 
function of osteoblasts 
To determine the importance of embigin expression on OM in mediating hematopoietic 
function, OM and osteoblasts were cultured for 7 days in the absence or presence of 
megakaryocytes. An embigin blocking antibody (1μg per well) was added on day 0, day 3 
and day 6 of culture. Cultures without the embigin blocking antibody were used as controls. 
On day 7, excess antibody was washed away, and the groups were seeded with LSK 
cells. Through this approach, embigin was temporarily blocked on OM, osteoblasts and 
megakaryocytes, but not on LSK cells which also express embigin on their surface. All 
groups were cultured with LSK cells for an additional 7 days, after which LSK progeny 
were plated in methylcellulose to perform colony forming assays. It was observed that 
blocking embigin in culture caused a decline in CFU fold activity when compared to 
controls (Figure 5.8). Furthermore, this decline in CFU fold change was observed 
irrespective of the absence or presence of megakaryocytes in culture. This indicates that 
blocking embigin on OM and osteoblasts causes a decline in hematopoietic activity. 
Subsequently, the next study was to determine whether blocking embigin on OM is 
sufficient to cause the decline in hematopoietic activity. Due to the absence of embigin 
knockout mice, a shRNA mediated embigin knockdown was performed on OM obtained 
from NCC. Briefly, NCC were infected either with one of two shRNAs against embigin or 
with a virus containing an empty vector. One plate of NCC culture was left uninfected as 
a control. Post spinfection, megakaryocytes were added to the NCC cultures to promote 
increase in cell numbers. These cultures were maintained for 7 days, after which shRNA 
knocked down OM, empty vector OM, uninfected OM and uninfected osteoblasts were 
sorted via flow cytometry. The gating strategy is shown in Figure 5.9A and OM shown in 
the right most column were sorted out for CFU assays. shRNA knocked down OM 
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(GFP+Emb-) or empty vector OM (GFP+Emb+) or uninfected OM were cultured with 
osteoblasts for 1 day, after which all groups were seeded with LSK cells. Cultures were 
maintained for an additional 7 days, after which the progeny of LSK cells were plated onto 
methylcellulose to perform colony forming assays. No significant difference was observed 
in CFU fold change between the groups which contained LSK cells cultured with 
uninfected OM and osteoblasts (labeled as OM+OB in Figure 5.9B) and empty virus 
infected OM and osteoblasts (labeled as OM (EV) +OB in Figure 5.9B). However, a decline 
in CFU fold change was observed when OM knocked down for embigin were present in 
culture (labeled as OM (Emb KD1) +OB and OM (Emb KD2) +OB in Figure 5.9B) with 
osteoblast and LSK cells. These data indicate that loss of embigin expression on OM 
affects its hematopoietic enhancing activity. Data depicting the breakdown of the CFU 
subtypes in these cultures are shown in Figure 5.9 C, D and E. At present, it is not 
understood why the shRNA system is more consistent with previous findings than the anti-
embigin antibody. Speculations suggest that the antibody used may not be fully 
neutralizing. 
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Figure 5.8 Blocking embigin expression on NCC causes a decline in hematopoietic 
activity. Osteoblasts (OB) were co-cultured with OM both of which are contained in freshly 
isolated NCC. Co-cultures were set up in the absence (red bars) or presence (green bars) of 
megakaryocytes (MK). An embigin blocking antibody was added to 3 wells containing OM+OB 
and 3 wells containing OM+OB+MK on D0, D3 and D6 of culture. On D7, excess antibody was 
washed away and LSK cells were cultured for 1 wk with each of these groups. CFU assays 
were set up to determine CFU fold change of cultured LSK progeny relative to 250 fresh LSKs. 
One of three independent experiments performed in triplicates. *p<0.05 vs LSK, OM, OB, >Emb 
OM+OB; ^p<0.05 vs LSK+MK, OM+MK, OB+MK, >Emb OM+OB+MK, #p<0.05; One-way 
Anova. 
155 
 
  
F4/80 
C
D
4
5
 
Emb 
S
S
C
 
GFP 
S
S
C
 
EV NCC 
Emb KD1 
NCC 
Emb KD2 
NCC 
NCC 
74% 
62% 
66% 
72.3
29% 
35.5
33.5
22% 
4.5% 
8% 
5% 
A. 
156 
 
  
0
10
20
30
40
50
60
70
C
F
U
 F
o
ld
 C
h
a
n
g
e
* 
* 
* 
B. 
Figure 5.9 Embigin is one of the molecular mediators through which OM maintain 
hematopoietic function of osteoblasts. NCC were subjected to four spinfections over a span 
of two days to infect them with GFP+ virus containing shRNA against embigin or an empty 
vector. At the end of the fourth spinfection, megakaryocytes were cultured for 1 wk with each of 
these groups. On D7, OM which were GFP+Emb- (labeled as OM (Emb KD1/2)) and 
GFP+Emb+ (labeled as OM (EV)) were sorted out. (A) Gating strategy for the virus infected OM 
sort from left to right. Uninfected OM and osteoblasts (OB) were also sorted to set up controls. 
(B) Overnight co-cultures were set up with virus infected OM and uninfected OB. Uninfected 
OM+OB were cultured as a control. The next day, LSK cells were cultured for 1 wk with each of 
these groups. CFU assays were set up to determine CFU fold change of cultured LSK progeny 
relative to 250 fresh LSKs. Multilineage analysis was performed to identify the distribution of (C) 
GM, (D) GEMM and (E) BFU-E colonies. One of three independent experiments performed in 
triplicates. *p<0.05; One-way Anova. 
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5.9 Discussion 
Networking between HSC and cells of the hematopoietic niche is critical for the 
maintenance of stem cell renewal and function. Amongst the most characterized resident 
cells of the niche are osteoblasts. Their importance in the regulation of the hematopoietic 
niche has been well established (Calvi, Adams et al. 2003, Zhang, Niu et al. 2003, Chitteti, 
Cheng et al. 2010, Cheng, Chitteti et al. 2011, Cheng, Streicher et al. 2015, Alvarez, Xu 
et al. 2018). Moreover, not much is known about interactions between OM, osteoblasts 
and megakaryocyte and how together they regulate hematopoiesis. In fact, even though 
OM are a resident of the hematopoietic niche, more is known about their function in bone 
modeling (Chang, Raggatt et al. 2008, Alexander, Chang et al. 2011, Guihard, Danger et 
al. 2012, Wu, Raggatt et al. 2013, Cho, Soki et al. 2014, Raggatt, Wullschleger et al. 2014, 
Sinder, Pettit et al. 2015, Vi, Baht et al. 2015, Alexander, Raggatt et al. 2017, Batoon, 
Millard et al. 2017, Batoon, Millard et al. 2017, Kaur, Raggatt et al. 2017). than their role 
in hematopoiesis. However, in 2010, Winkler et. al. established that loss of OM caused a 
concurrent disruption of the endosteal niche and mobilization of HSPCs from the bone 
marrow to the peripheral blood (Winkler, Sims et al. 2010). Also, in the previous chapter, 
the importance of crosstalk between OM, osteoblasts and megakaryocytes to regulate 
hematopoietic function was demonstrated (Mohamad, Xu et al. 2017). In this chapter, the 
focus was to determine the molecular mediators which are triggered due to crosstalk 
between OM, osteoblasts and megakaryocytes and, ultimately how these molecular 
mediators support hematopoietic enhancing activity. Since much is known about 
interactions of osteoblasts and megakaryocytes within the hematopoietic niche, focus was 
shifted to the role of OM in these dynamics. 
Single cell studies helped narrow down targets which could act as potential mediators 
through which OM functionally enhance hematopoiesis. Of interest, an upregulation in the 
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expression of embigin and CD166 on OM was observed when they interacted with 
osteoblasts and megakaryocytes (Figure 5.1, 2 and 3). Embigin, a molecule which has 
previously been implicated in hematopoiesis (Silberstein, Goncalves et al. 2016), was 
upregulated both at the single cell mRNA level, as well as the translational level. In fact, it 
was one of the top targets in the mass spectrometry data (Figure 5.2) in which the only 
targets above it were a glucose transporter member, arginase and some undefined 
proteins (Table 5.1). These targets could be potentially investigated in the future. On the 
other hand, CD166 which is a critical molecule for the hematopoietic niche (Chitteti, Cheng 
et al. 2010, Cheng, Chitteti et al. 2011, Chitteti, Bethel et al. 2013, Chitteti, Cheng et al. 
2013, Chitteti, Kobayashi et al. 2014) was not upregulated on OM at the single cell mRNA 
level as a result of the crosstalk between OM, osteoblasts and megakaryocytes. However, 
the CyTOF data demonstrated an upregulation of CD166 (Figure 5.3C) at the single cell 
protein level indicating possible regulation at the translational level. The reason for this 
discrepancy between CyTOF and single cell mRNA sequencing is not known at this point. 
Also, CD166 was not a candidate protein in the mass spectrometry data. However, the 
culture conditions for both the proteomics experiments were different. Data for the mass 
spectrometry experiment was obtained from OM cultured with LSK cells unlike the single 
cell CyTOF analysis data which were collected from OM cultured without LSK. Since 
CD166-CD166 homophilic interactions are expected in the hematopoietic niche, there is 
a possibility that CD166 expressed by OM in the mass spectrometry experiment was 
bound to LSK cells and was lost in the cell processing methods. This limitation might be 
the reason CD166 was not identified in this experiment. Interestingly, unlike CD166 which 
was upregulated at the translational level, there were several targets such as PF-4, Lmo-
2, Fli-1 and Ikzf1 which were upregulated at the mRNA level (Figure 5.1B) but remained 
unchanged at the protein level (Figure 5.3C). This points out one of the biggest 
shortcomings of single cell genomics, where genes which are regulated at the 
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transcriptional level may not necessarily behave the same way at the translational level. 
These shortcomings have already been pointed out in previous publications (Chitteti, Liu 
et al. 2011). 
The next question was whether CD166 and embigin act as molecular mediators through 
which OM mediate hematopoietic function. Previous investigations have established that 
osteolineage cells proximal to HSC express embigin and are involved in maintenance of 
hematopoiesis (Silberstein, Goncalves et al. 2016). This was the first instance where 
embigin had been identified as a regulator of hematopoiesis. The studies in this chapter, 
have expanded on these previous data and have hypothesized that these proximal 
osteolineage cells mentioned by Silberstein et. al. might be OM. To give support to this 
hypothesis, several experiments were performed including qPCR, flow cytometry and 
CyTOF which identified similarities between the published proximal osteolineage cells and 
OM. Furthermore, in vitro progenitor assays establish the importance of embigin as a 
molecule which regulates OM-mediated hematopoietic function (Figure 5.8 and 5.9). 
However, due to lack of an embigin knockout model, knockdown studies were used to 
determine the effects of loss of embigin expression on OM. Even though knocked down 
OM were sorted out for the experiments, shRNA studies are generally unstable, and the 
use of embigin knockout OM would be preferred. Making an embigin knockout mouse 
model is currently underway, and future studies would include moving this project to an in 
vivo setting. Moreover, recombinant studies were performed which conclude that both 
embigin and CD166 are molecular mediators which can partially substitute for OM activity 
in vitro (Figure 5.5). 
CD166 studies were more expansive due to prior laboratory investigations into its role in 
the hematopoietic niche and availability of CD166 KO mice (Chitteti, Cheng et al. 2010, 
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Chitteti, Cheng et al. 2010, Cheng, Chitteti et al. 2011, Chitteti, Bethel et al. 2013, Chitteti, 
Cheng et al. 2013, Chitteti, Kobayashi et al. 2014, Xu, Mohammad et al. 2016). Using 
CD166 knockout mice, it was demonstrated that CD166 knockout OM have reduced 
function and cannot maintain hematopoiesis in vitro (Figure 5.6, 5.7). CD166 expression 
on OM is upregulated due to the crosstalk between OM, osteoblasts and megakaryocytes 
and its absence affects hematopoietic activity which is at its maximum when LSK cells co-
cultured with wild type OM, osteoblasts and megakaryocytes are transplanted (Figure 4.3). 
It was previously established that LSK cells co-cultured with CD166 knockout NCC 
demonstrate reduced engraftment potential (Chitteti, Kobayashi et al. 2014). The next step 
is to transplant LSK cells co-cultured with knockout OM, wild type osteoblasts and wild 
type megakaryocytes to validate these in vitro results in vivo. Transplant studies are 
currently underway and are very early to yield meaningful conclusions. Interestingly, 
through the CyTOF data it was observed that the same metacluster of OM (Metacluster 
1) showed high expression of CD166 and embigin due to interactions between OM, 
osteoblasts and megakaryocytes (Figure 5.3A and C). This leads to another important 
unanswered question whether CD166 and embigin act through the same pathway or 
employ different pathways to maintain OM-mediated hematopoietic activity. Double 
knockout studies would be an important tool to answer this question in the future. 
Overall, previous and current data corroborate the importance of crosstalk between OM, 
osteoblasts and megakaryocytes to maintain hematopoietic enhancing activity. As seen 
in Figure 5.10 (left to the axis), previous studies demonstrate that megakaryocytes 
suppress osteoblast differentiation; and immature osteoblasts which express high levels 
of CD166 best maintain HSC function (Chitteti, Cheng et al. 2010, Cheng, Chitteti et al. 
2011, Chitteti, Cheng et al. 2013). HSC also express CD166 (transcriptional activation via 
STAT3 binding to promoter region) through which they possibly interact with osteoblasts 
162 
through CD166-CD166 homophilic interactions. CD166 expression on HSC is important 
for both homing and engraftment (Chitteti, Kobayashi et al. 2014). On the other hand, 
current studies (Figure 5.10, right to the axis) indicate that interaction with osteoblasts and 
megakaryocytes causes enhanced OM proliferation (Mohamad, Xu et al. 2017) and 
upregulation of CD166 and embigin expression on OM. Since STAT3 binds to the CD166 
promoter causing its regulation in HSC, one could hypothesize that the same mechanism 
might be responsible for upregulating CD166 expression on OM. Both CD166 and embigin 
act as molecular mediators through which OM maintain hematopoietic function when they 
interact with osteoblasts and megakaryocytes. 
 
  
Figure 5.10 Summary of previous and current studies. Figure depicting the crosstalk 
between OM, osteoblasts and megakaryocytes in the hematopoietic niche. 
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CHAPTER SIX: Future Directions 
 
 
6.1 The requirement of a phenotypic marker distinguishing adult OM from BM Mφ 
Currently, three in vivo macrophage depletion models have been reported: 1) Mafia 
transgenic mice through which a drug-induced Fas suicide gene can cause the apoptosis 
of a broad spectrum range of macrophages present in several tissues (Chang, Raggatt et 
al. 2008, Winkler, Sims et al. 2010); 2) Clodronate liposomes, which use the phagocytic 
capability of macrophages and osteoclasts to deplete them (van Rooijen and Hendrikx 
2010); and 3) CD169-diptheria toxin receptor mouse which, via the activation of the 
diphtheria toxin depletes CD169+ cells including macrophages in vivo (Chow, Lucas et al. 
2011). This CD169+ macrophage depletion model is currently the most commonly used 
model to understand the role of macrophages resident in the hematopoietic niche (Chow, 
Lucas et al. 2011, Chow, Huggins et al. 2013, Jacobsen, Forristal et al. 2014, Batoon, 
Millard et al. 2017). This model targets HSC niche resident BM Mφ, OM and EIM. As 
discussed in chapter 3, CD169 is not a distinguishing marker between OM and BM Mφ 
(Figure 3.3 and 3.6). In fact, a higher percentage of neonatal OM expressed CD169 than 
that detected amongst neonatal BM Mφ; and its expression on both cell types becomes 
similar with development. This makes it difficult to determine which subset of 
macrophages is responsible for maintaining the competence of the hematopoietic niche 
based on the CD169+ Mφ depletion model as described by Chow et al, Chow and Lucas, 
and Kaur and Raggatt. 
The lack of an OM specific depletion model is a setback for in vivo studies and something 
that needs to be discussed. My work in the laboratory was aimed to identify a 
distinguishing marker between OM and BM Mφ which can potentially be used to make an 
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OM depletion mouse model. The results in this thesis successfully demonstrate 
phenotypic markers such as CD166, CD206 and CD110 which differentiate OM from BM 
Mφ in neonates (Figure 3.3, 3.4 and 3.6). However, the expression of CD166 is limited to 
a subset of OM in adults and CD206 expression on OM is reduced with age (Figure 3.7). 
Hence, there is an urgent need to identify a phenotypic marker which distinguishes adult 
OM from BM Mφ if genetic models are to be used in future investigations. Since CD110 
expression has not been checked on adult OM, the search for a unique marker can begin 
by analyzing CD110 expression on OM in adults by flow cytometry. However, although 
CD110 might be a useful distinguishing surface marker between adult OM and BM Mφ, 
this surface marker cannot be used for an OM depletion model due to its expression on 
megakaryocytes (Kacena, Gundberg et al. 2006, Bethel, Barnes et al. 2015). Other 
possible experiments could include single cell mRNA sequencing (10X genomics) which 
would help identify distinguishing markers between adult OM and BM Mφ; and mass 
spectrometry as performed in Figure 5.2. Once a novel marker is identified, it would help 
in the formation of an in vivo mouse model to specifically deplete OM similar to the CD169+ 
depletion model. This new model would be very useful in fully understanding the role of 
OM in the hematopoietic niche. 
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6.2 To identify the localization of OM, osteoblasts and megakaryocytes with 
respect to HSPCs in stressed and aged mice 
The current work in 3D tissue cytometry is very encouraging. Paraffin embedded murine 
long bones were successfully stained and imaged for OM and megakaryocytes using a 
confocal microscope. Since the model is a Fgd5 mouse, HSC and vessels are GFP+ 
making it easy to identify them. Finally, the use of 2-photon imaging allows the user to 
visualize osteoblasts. Through concentrated efforts multiple fields were obtained wherein 
all four cell types were in close proximity to each other (Figure 4.6). However, a number 
of obstacles were encountered reaching this point. For example, it was difficult to attain 
several sections where the bone marrow was intact and attached to the bone. This was 
because the bone marrow easily sloughed off giving cracked sections. Also, the current 
sections are only 25 microns in depth which is not sufficient to fully understand the 
complexity of the hematopoietic niche. Finally, the bone is a highly auto fluorescent organ 
adding to these difficulties. To overcome these issues, and move this project to the next 
level, the following has been planned: 
• The next step is to use whole bone rather than 25 micron sections. This will help 
image greater depths (minimum of 100 microns) of bone through confocal 
microscopy. Also, the use of whole bone will help overcome the issue of cracked 
sections. However, using whole bone would make staining more difficult. Hence, 
it would be simpler to make frozen sections instead of paraffininzing the bone. 
Frozen sections are known to be much easier to stain and image compared to 
paraffinized sections. Also, to reduce autofluorescence and make staining whole 
bone possible, a protocol which includes clearing the bone has been adapted. This 
is a protocol that was recently developed (Li, Germain et al. 2017) and attains 
excellent tissue transparency for most organs including bone. 
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• Once cleared, this new system will be used to quantitate the number of OM, 
osteoblasts, megakaryocytes and HSC in whole bone. The algorithm to quantitate 
cells in z-stacks was developed at Indiana University and has successfully been 
implemented in the kidney (Winfree, Khan et al. 2017). This quantitation will help 
understand the number of each cell type in unperturbed bone marrow. Moreover, 
this technology can be used to quantitate the number of each cell type in the 
epiphysis versus the diaphysis. Previous studies have demonstrated that most 
HSC reside within the growth plate of the bone (Ellis, Grassinger et al. 2011). 
Current studies can help corroborate this data and additionally understand the 
differences in the niche within the growth plate versus the rest of the bone. 
• Finally, there is ample evidence indicating that the hematopoietic niche alters with 
age (Rossi, Bryder et al. 2005, Janzen, Forkert et al. 2006, Gekas and Graf 2013) 
and stress (Severe, Karabacak et al. 2019). For example, there are data 
demonstrating that megakaryocytes number increase with age (Rundberg Nilsson, 
Soneji et al. 2016). Similarly, flow cytometry data demonstrate that OM numbers 
decrease with age (Figure 6.1). This indicates the possibility of change in crosstalk 
between cells in aged bone marrow. Likewise, hematopoietic stress such as 
irradiation also changes the co-localization and crosstalk between different 
resident cells in the hematopoietic niche (Dominici, Rasini et al. 2009, Olson, 
Caselli et al. 2013). The ultimate goal is to understand and quantitate the 
differences in co-localization and number of OM, osteoblasts, megakaryocytes and 
HSC in hematopoietic stressed and aged bone marrow compared to unperturbed 
bone marrow. This is a novel and unique aspect of this research which might help 
understand the functional loss of HSC with age. 
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Figure 6.1 Phenotypic characterization of young and old osteomacs. (A) Representative 
flow cytometric data of freshly isolated digested bone from 8 wk young (top row) and 24 months 
old (bottom row) mice.  (B) Combined average of percent young and old OM, p<0.001, N=8. 
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6.3 To determine the molecular mediators through which OM maintain 
hematopoietic activity in vivo 
The work centered on CD166 and embigin as molecular mediators through which OM 
maintain hematopoietic function has mainly been focused on the use of in vitro 
experiments (Figure 5.5-5.9). However, the relevance of this work is based on translating 
the in vitro studies in vivo. For this, the next step would be to transplant LSK cells co-
cultured with CD166 knockout OM, wild type osteoblasts and wild type megakaryocytes 
to validate these results in vivo. The transplant studies are currently underway and are 
very early to yield meaningful conclusions. Also, the embigin studies are based on a 
lentiviral knockdown system which is considered to be unstable. Ideally, for the embigin 
studies, it would be preferred to use an embigin knockout mouse to obtain embigin 
knockout OM for the co-cultures with osteoblasts, megakaryocytes and HSC which would 
culminate in progenitor and competitive transplantation assays. Since embigin knockout 
mice are currently unavailable, embigin flox/flox mice (Originally made by Dr. Jyrki Heino, 
Finland) will be obtained which can be used to make embigin global knockout mice or 
embigin conditional knockout mice. 
The data using simultaneously a combination of recombinant CD166 and embigin proteins 
to substitute for OM functionality showed a trend towards non-significant increase in CFU 
fold change compared to individual recombinant protein data (Figure 5.5). These findings 
suggest that CD166 and embigin may work through the same pathway or mechanism. 
Following up on this observation, there is the possibility to potentially knockdown embigin 
using the lentivirus system in CD166 knockout OM. In this way, OM devoid of both CD166 
and embigin expression could be isolated. This could help understand whether CD166 
and embigin work separately or together to maintain OM-mediated hematopoietic 
enhancing activity. 
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It is unlikely that CD166 and embigin are the only two mediators through which OM 
mediate their hematopoiesis enhancing activity. Therefore, another avenue to explore 
would be to identify other molecular mediators (besides embigin and CD166) through 
which OM maintain hematopoiesis. Single cell mRNA sequencing data demonstrated the 
upregulation of over 200 genes in OM which were co-cultured with osteoblasts and 
megakaryocytes (Figure 5.1). Similarly, the mass spectrometry data identified 32 proteins 
which were upregulated on OM isolated from NCC+MK (Figure 5.2). These data could be 
used to test other mediators through which OM could potentially augment hematopoietic 
activity. One of the proteins from the mass spectrometry data that was upregulated on OM 
was arginase. Recent findings suggest that M2 Mφ through the expression of arginase 
promote the self-renewal and expansion of HSC (Luo, Shao et al. 2018). Investigating 
arginase as a potential mediator of OM-mediated hematopoiesis is another avenue left 
unexplored. 
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